 | Harry Roger BüllerDepartment of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands | From KU Leuven Department of Cardiovascular ... |
Kol Lebenslauf für Harry Roger Büller (pulmonary embolism, disease, embolism, pulmonary heart disease, pulmonary embolism, pulmonary, heart)
| Year | |
|---|---|
| 2022 | Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands |
| 2021 | From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.). Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands (H.R.B.). |
| 2020 | From the Faculty of Medical Sciences, State University of Groningen, Groningen, the Netherlands (M.O.); Department of Vascular Medicine, Amsterdam University Medical Centre, Amsterdam, the Netherlands (H.R.B., N.V.Es.); Department of Radiology, Haaglanden Medical Centre, The Hague, the Netherlands (D.K.); Department of Radiology, Nederlands Kanker Instituut, Amsterdam, the Netherlands (S.F.O.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, U.S.A. (T.M.); Department of Intensive Care Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands (D.G.); 7. National Institute of Public Health, Ministry of Health, Bilthoven, the Netherlands (J.V.D.); Department of Vascular Medicine, Maastricht University, Maastricht, the Netherlands (H.T.C.); Edinburgh Imaging, Queens Medical Research Institute, University of Edinburgh, Edinburgh, U.K.(E.J.R.V.B.) Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands |
| 2019 | Department of Vascular Medicine, Academic Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands. Dept of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands |
| 2018 | Department of Vascular Medicine, Academic Medical Centre Amsterdam, University of Amsterdam, Amsterdam, Netherlands |
| 2017 | Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, AZ, Amsterdam, The Netherlands. From Academic Medical Center and Slotervaartziekenhuis, Amsterdam, the Netherlands; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Université de Bretagne Occidentale, Brest, France; Hospital of Padua, Padua, Italy; Clinica Universidad de Navarra, Pamplona, Spain; Virgen del Rocio Hospital, Seville, Spain; Karolinska Institutet, Stockholm, Sweden; Warsaw Medical University, Warsaw, Poland; Centre Hospitalo-Universitaire Estaing, Clermont-Ferrand, France; University of Utah, Salt Lake City, Utah; University Hospital Leuven, Leuven, Belgium; and University G. D'Annunzio, Chieti-Pescara, Italy. |
| 2016 | Center for Experimental and Molecular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands |
| 2015 | Academic Medical Center University of Amsterdam Department of Vascular Medicine Amsterdam the Netherlands |
| 2014 | From the College of Public Health, University of Oklahoma Health Sciences Center (G.E.R., M.M., A.W.); Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (P.A.); División Hemostasia, Academia Nacional de Medicina, Buenos Aires, Argentina (A.N.B.); Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (H.B.); SA Pathology–Department of Hematology, Flinders Medical Center, Adelaide, South Australia, Australia (A.G.); Thrombosis and Thrombophilia Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom (B.J.H.); Boston University School of Medicine, MA (E.M.H.); Thrombosis Research Institute, London, United Kingdom (A.K.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University, Mainz, Germany (S.V.K.); Department of Laboratory Medicine, University of Yamanashi, Tamaho, Yamanashi, Japan (Y.O.); and McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.I.W.). Department of General Practice, Academic Medical Centre, University of Amsterdam, Amsterdam and |
| 2013 | Department of Vascular Medicine, F4-140, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands Academic Medical Center, Amsterdam (H.R.B.) |
| 2012 | Academic Medical Center, Department of Vascular Medicine, Amsterdam (H.R.B.) Vascular Medicine, AMC, Amsterdam, the Netherlands |
| 2011 | Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, From the Academic Medical Center and Slotervaart Hospital, Amsterdam |
Prominent publications by Harry Roger Büller
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
[ PUBLICATION ]
BACKGROUND: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide.
OBJECTIVES: To establish a common international consensus addressing practical, clinically relevant questions in this setting.
METHODS: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system.
RESULTS: For the ...
| Bekannt für Vte Patients | Venous Thromboembolism | Prophylaxis Lmwh | 3 Months | Practice Guidelines |
KOL Index score: 20177
OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.
BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...
| Bekannt für Atrial Fibrillation | Bled Bleeding | Hemorr2hages Atria | Intracranial Hemorrhage | Topic Risk |
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
[ PUBLICATION ]
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key ...
| Bekannt für Antithrombotic Therapy | Grade 1a | Venous Thromboembolic Disease | Vka Lmwh | Inr Range |
KOL Index score: 16684
PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major ...
| Bekannt für Venous Thromboembolism | Bleeding Complications | Patients Malignancy | Retrospective Analysis | International Normalized |
KOL Index score: 16378
BACKGROUND: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with ...
| Bekannt für Venous Thromboembolism | Patients Cancer | Hazard Ratio | Clinically Relevant Bleeding | Factor Inhibitors |
KOL Index score: 15975
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.
METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), ...
| Bekannt für Warfarin Patients | Hazard Ratio | Venous Thromboembolism | Pulmonary Embolism | Primary Efficacy Outcome |
ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer
[ PUBLICATION ]
ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.
BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which ...
| Bekannt für Willebrand Factor | Venous Thromboembolism | Vte Cancer | Vwf Adamts13 | Khorana Score |
KOL Index score: 15571
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.
METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or ...
| Bekannt für Oral Rivaroxaban | Venous Thromboembolism | Vitamin Antagonist | Continued Treatment | Hazard Ratio |
KOL Index score: 15512
BACKGROUND: After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.
METHODS: In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after ...
| Bekannt für Hip Replacement | Dabigatran Enoxaparin | Venous Thromboembolism | Etexilate Versus | Primary Efficacy Outcome |
KOL Index score: 15505
CONTEXT: Previous studies have evaluated the safety of relatively complex combinations of clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.
OBJECTIVE: To assess the clinical effectiveness of a simplified algorithm using a dichotomized clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with suspected pulmonary embolism.
DESIGN, SETTING, AND PATIENTS: Prospective cohort study of consecutive patients with clinically ...
| Bekannt für Pulmonary Embolism | Computed Tomography | Dimer Testing | Patients Suspected | 3 Months |
KOL Index score: 15415
BACKGROUND: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery.
METHODS: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) ...
| Bekannt für Total Hip | Dabigatran Etexilate | Thromboembolic Events | Knee Replacement | Vte Patients |
KOL Index score: 14849
BACKGROUND: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery.
METHODS: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1-4 hours after surgery, or subcutaneous enoxaparin ...
| Bekannt für Subcutaneous Enoxaparin | Oral Dabigatran | Total Knee Replacement | Venous Thromboembolism | Prevention Vte |
Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism
[ PUBLICATION ]
BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization.
METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. ...
| Bekannt für Unfractionated Heparin | Pulmonary Embolism | Initial Treatment | Subcutaneous Fondaparinux | Intravenous Injections |
KOL Index score: 14727
OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).
STUDY SELECTION: Randomised controlled trials and prospective cohort ...
| Bekannt für Anticoagulant Treatment | Recurrent Vte | Unprovoked Venous | 10 Years | 95 Confidence Interval |
Harry Roger Büller: Einflussstatistik
Bericht ausführen
| Concept | World rank |
|---|---|
| acquired atiii deficiency | #1 |
| current practise | #1 |
| lmwhs 95 | #1 |
| patients treatment duration | #1 |
| strategy abdominal pelvic | #1 |
| safety idraparinux | #1 |
| variable d‐dimer thresholds | #1 |
| long haul flights | #1 |
| rfviia fondaparinux | #1 |
| uesvt | #1 |
| quantitative dimer | #1 |
| platelets iqr | #1 |
| 2630 pilots | #1 |
| patients idraparinux | #1 |
| elevated levels fviii | #1 |
| compression ultrasonography | #1 |
| cancer 145 patients | #1 |
| 0·2 3633 patients | #1 |
| cancer patients uedvt | #1 |
| ddimer levels cdr | #1 |
| fetal loss stillbirth | #1 |
| aged nadroparin | #1 |
| extended anticoagulation apixaban | #1 |
| recurrence major bleeding | #1 |
| heparins inhibition | #1 |
| leg ultrasonography patients | #1 |
| previous surveys netherlands | #1 |
| oral rivaroxaban treatment | #1 |
| clinical probability exclusion | #1 |
| management study | #1 |
| recurrent thromboembolism enoxaparin | #1 |
| heparin survival | #1 |
| vte trial | #1 |
| ambulatory computers | #1 |
| presentation major | #1 |
| abelacimab | #1 |
| method factor | #1 |
| individualized duration | #1 |
| clinical probability risk | #1 |
| fxainhibitors | #1 |
| suspected symptomatic | #1 |
| subcutaneous length life | #1 |
| ft4 level patients | #1 |
| randomized studies efficacy | #1 |
| ivte | #1 |
| pvo qscan | #1 |
| nondiagnostic lung scan | #1 |
| clinical probability patients | #1 |
| calfvein thrombi | #1 |
| easier monitoring | #1 |
| einsteindvt | #1 |
| symptomatic legs dvt | #1 |
| normal levels fviii | #1 |
| 2 diagnostic management | #1 |
| 3633 patients edoxabantreated | #1 |
| wellsrule | #1 |
| vte procoagulant activity | #1 |
| studies ttr | #1 |
| wound haematoma | #1 |
| xainhibitors | #1 |
| normotensive patients studies | #1 |
| 560 pharmacies | #1 |
| carriers pulmonary embolism | #1 |
| subcutaneous idraparinux | #1 |
| 5 years lmwh | #1 |
| mortality postthrombotic symptoms | #1 |
| dalteparin major bleeding | #1 |
| safety outcome | #1 |
| pulmonary embolism studies | #1 |
| association travel | #1 |
| increasing levels ft4 | #1 |
| standard treatment idraparinux | #1 |
| patients acute recurrent | #1 |
| duration heparin treatment | #1 |
| ufh grade | #1 |
| progression svt | #1 |
| thromboembolism treated | #1 |
| heparin org 10172 | #1 |
| subcutaneous nadroparin placebo | #1 |
| proximal location ipe | #1 |
| pulmonary embolism tests | #1 |
| acenocoumarol efficacy | #1 |
| age recurrent vte | #1 |
| smoking patency | #1 |
| 12 months edoxaban | #1 |
| predefined outcomes | #1 |
| scan pulmonary embolism | #1 |
| risk homozygous women | #1 |
| international thrombosis experts | #1 |
| noacs prevention | #1 |
| apixaban randomized patients | #1 |
| combined training gps | #1 |
| treatment experimental thrombosis | #1 |
| treatment idraparinux | #1 |
| noncarriers annual incidence | #1 |
| preferred oral anticoagulant | #1 |
| obese hemophilic patients | #1 |
| venography tests | #1 |
| abdominal pelvic strategies | #1 |
| pulmonary embolism idraparinux | #1 |
| ddimer test | #1 |
| hokusai vte cancer | #1 |
| lowmolecularweight heparin treatment | #1 |
| absolute thrombotic risk | #1 |
| prescriptionbased | #1 |
| efficacy heparin therapy | #1 |
| guidelines abi | #1 |
| embolism randomized | #1 |
| flebography | #1 |
| proximal extent ipe | #1 |
| probability ventilation | #1 |
| oral administration bsf | #1 |
| failure diagnostic management | #1 |
| vitamin antagonists treatment | #1 |
| perelated death category | #1 |
| safety 60 dose | #1 |
| consensus strategy strategy | #1 |
| cart lower levels | #1 |
| heparins data | #1 |
| messages justification | #1 |
| 7268 patients | #1 |
| united states rnapc2 | #1 |
| suspected perfusion scan | #1 |
| 25mg apixaban | #1 |
| obstetric complications relatives | #1 |
| ddimer test result | #1 |
| elevated biomarkers hospital | #1 |
| proportion 75 years | #1 |
| leg veins patients | #1 |
| ldf cus | #1 |
| beneficial lmwh | #1 |
| 00515 | #1 |
| ultrasonography dvt | #1 |
| rate recurrent | #1 |
| clinical decision rule | #1 |
| heparin initial | #1 |
| ecq ankle brachial | #1 |
| elevated fviii patients | #1 |
| scenarioanalysis | #1 |
| patency smokers | #1 |
| dalteparin vte treatment | #1 |
| heparin initial treatment | #1 |
| 3633 patients edoxaban | #1 |
| relevant major | #1 |
| anticoagulant treatment vte | #1 |
| cdrs patients | #1 |
| wells rules | #1 |
| followup overt cancer | #1 |
| hokusai‐vte cancer study | #1 |
| popliteal veins sensitivity | #1 |
| diagnostic strategies patients | #1 |
| clinically relevant disease | #1 |
| smoking graft patency | #1 |
| initial treatment dvt | #1 |
| prophylaxis idraparinux | #1 |
| pulmonary embolism cdr | #1 |
| uesvt mortality | #1 |
| rtap lmwh | #1 |
| patients wells rule | #1 |
| simplified geneva score | #1 |
| 5 avidin infusion | #1 |
| —brachial | #1 |
| dose daily edoxaban | #1 |
| probability normal | #1 |
| levonorgestrel desogestrelcontaining | #1 |
| safety clinical utility | #1 |
| chest perfusion scan | #1 |
| doubleheterozygotes | #1 |
| revascularisation procedures patients | #1 |
| org aptt | #1 |
| rabinov | #1 |
| thrombosis vte | #1 |
| rule exclusion | #1 |
| evaluable patients apixaban | #1 |
| patients advanced prostate | #1 |
| 9 incidence | #1 |
| idraparinux placebo | #1 |
| hokusaivte trial patients | #1 |
| fviii hyperhomocysteinemia | #1 |
| lmwh immobilization | #1 |
| reduceddose noacs stroke | #1 |
| bleeding clinically | #1 |
| procoagulant factors levels | #1 |
| upper extremity uedvt | #1 |
| unexplained dvt patients | #1 |
| loss subsequent pregnancy | #1 |
| matisse clinical trials | #1 |
| 95ci tb402 | #1 |
| prothrombin 20210a mutation | #1 |
| carriers recurrence | #1 |
| lmwh delivery | #1 |
| molecular weight fondaparinux | #1 |
| 0·2 edoxabantreated | #1 |
| asymptomatic extension | #1 |
| rfviia 3 | #1 |
| total vte patients | #1 |
| normal dimer | #1 |
| unexplained dvt | #1 |
| qscan | #1 |
| idraparinux 6 months | #1 |
| systematic search cteph | #1 |
| dvt symptomatic | #1 |
| org heparin | #1 |
| vka recipients | #1 |
| venous thrombosis vwf | #1 |
| ldfr symptomatic legs | #1 |
| treatment venous | #1 |
| cancer patients ufh | #1 |
| relatives tafi levels | #1 |
| baseline pvo | #1 |
| tests venography | #1 |
| thiazoles venous | #1 |
| conventional therapy enoxaparin | #1 |
| clinically suspected cancer | #1 |
| rivaroxaban dvt treatment | #1 |
| p0001 saline | #1 |
| enoxaparin vkas | #1 |
| ventricular dysfunction edoxaban | #1 |
| idraparinux months | #1 |
| doac recipients | #1 |
| deficiency proteins | #1 |
| vte airline pilots | #1 |
| major bleeds vka | #1 |
| clinically suspected dvt | #1 |
| abnormal vaginal bleeding | #1 |
| tb402 12 kg1 | #1 |
| gastrointestinal cancer edoxaban | #1 |
| segmental subsegmental | #1 |
| 7268 patients suspected | #1 |
| year prophylaxis | #1 |
| hellp syndrome mutations | #1 |
| category perelated death | #1 |
| test venography | #1 |
| oral edoxaban dose | #1 |
| patients artificial graft | #1 |
| rnapc2 groups placebo | #1 |
| symptomatic recurrent vte | #1 |
| relatives elevated levels | #1 |
| vte arterial | #1 |
| idraparinux vte | #1 |
| patients advanced malignancy | #1 |
| poc test patients | #1 |
| activecontrol placebo | #1 |
| patients retropubic prostatectomy | #1 |
| 023 relatives | #1 |
| polyethylenglycolhirudin | #1 |
| ufh grade 1a | #1 |
| control anticardiolipin antibodies | #1 |
| fviii normal levels | #1 |
| hokusaivte study | #1 |
| alternative diagnoses patients | #1 |
| fondaparinux rfviia injection | #1 |
| prediction models recurrence | #1 |
| simple diagnostic strategy | #1 |
| ctscan qscan | #1 |
| ddimer result | #1 |
| ultrasonography leg veins | #1 |
| rnapc2 patients | #1 |
| 53 amputations | #1 |
| pulmonary embolism | #1 |
| venous thrombosis hyperglycemia | #1 |
| role exclusion | #1 |
| patients enoxaparin vkas | #1 |
| relatives normal fviii | #1 |
| preference doacs | #1 |
| respondents lmwh | #1 |
| 65±9years | #1 |
| elevated cardiac troponins | #1 |
| embolism sensitivity | #1 |
| association protein levels | #1 |
| presentation 1 week | #1 |
| 50 years combination | #1 |
| efficiency subgroups | #1 |
| relevant bleeding | #1 |
| coagulationinhibiting | #1 |
| embolism wells | #1 |
| wells rule primary | #1 |
| inr range ttr | #1 |
| gentamicin patients netilmicin | #1 |
| s1p1activation | #1 |
| acenocoumarol therapy acenocoumarol | #1 |
| normal ddimer concentration | #1 |
| cstatistic major bleeding | #1 |
| rule dimer | #1 |
| desogestrelcontaining coagulation factors | #1 |
| heparins cancer patients | #1 |
| travel venous thromboembolism | #1 |
| pulmonary angiography strategies | #1 |
| pulmonary angiography study | #1 |
| lmwh users incidence | #1 |
| beta thromboglobulin org | #1 |
| pulmonary embolism fondaparinux | #1 |
| netherlands vka | #1 |
| patients khorana | #1 |
| clinical uedvt | #1 |
| relative risks carriers | #1 |
| original wells | #1 |
| death category | #1 |
| dvt 69 | #1 |
| probabilityscan | #1 |
| uesvt recurrent vte | #1 |
| ankle brachial prevalence | #1 |
| fxainhibitors vka recipients | #1 |
| simplified wells rule | #1 |
| studies doac treatment | #1 |
| lmwh edoxaban | #1 |
| age multiple comorbidities | #1 |
| rabinovpaulin | #1 |
| incidental symptomatic vte | #1 |
| exclusion pulmonary | #1 |
| falsenormal | #1 |
| relatives normal levels | #1 |
| p0424 | #1 |
| probability categories | #1 |
| mdct expert radiologist | #1 |
| standardintensity vkas doacs | #1 |
| wells clinical | #1 |
| khorana | #1 |
| patients uedvt uesvt | #1 |
| enoxaparin warfarin antiplatelet | #1 |
| apc resistance tests | #1 |
| patients protein deficiencies | #1 |
| 20210a mutation | #1 |
| levels procoagulant factors | #1 |
| vka treatment treatment | #1 |
| daily dalteparin treatment | #1 |
| wells cdr | #1 |
| bleeding einstein | #1 |
| ml1 ctpa | #1 |
| proportion pulmonary embolism | #1 |
| incidence venous | #1 |
| venous thromboembolism edoxaban | #1 |
| double heterozygous carriers | #1 |
| scores riete score | #1 |
| coagulation clinical | #1 |
| treatment cumulative incidence | #1 |
| level loss patency | #1 |
| bleeding rates quality | #1 |
| doacs initial heparin | #1 |
| compression ultrasonography patients | #1 |
| presentation category | #1 |
| thrombosis vitamin | #1 |
| vte day | #1 |
| ili score | #1 |
| suspected deep | #1 |
| fibrinolysis levels | #1 |
| lmwh rtap | #1 |
| graft patency patency | #1 |
| strategies ultrasonography | #1 |
| extended anticoagulation doacs | #1 |
| coagulation fibrinolytic proteins | #1 |
| studies 3 months | #1 |
| patients initial heparin | #1 |
| false normal | #1 |
| hokusaivte trial | #1 |
| prevention topic guidelines | #1 |
| tests prevalence abi | #1 |
| recurrence bleeding risk | #1 |
| dose response apixaban | #1 |
| intravenous unfractionated | #1 |
| netherlands lmwh | #1 |
| recommendations dvt | #1 |
| thrice daily gentamicin | #1 |
| timerequirement | #1 |
| intestinal microbiota coagulation | #1 |
| combination cdrscore | #1 |
| d‐dimer test | #1 |
| sustained antithrombotic effects | #1 |
| oral apixaban treatment | #1 |
| diagnostic strategy primary | #1 |
| 500 org | #1 |
| months standard therapy | #1 |
| subsequent symptomatic cancer | #1 |
| edoxaban east asian | #1 |
| heparin acenocoumarol | #1 |
| amplify trial apixaban | #1 |
| prolactin venous thrombosis | #1 |
| apixaban conventional therapy | #1 |
| cstatistic model discrimination | #1 |
| edoxaban risk factors | #1 |
| intravenous injections lmwh | #1 |
| questionnaires thrombosis | #1 |
| presence venous thrombosis | #1 |
| cdr physicians | #1 |
| matisse trials | #1 |
| heparinoid | #1 |
| avidin placebo | #1 |
| evaluable patients 95 | #1 |
| qscan 3 weeks | #1 |
| antithrombotic prescriptions adherence | #1 |
| combination cdr | #1 |
| aptt org | #1 |
| comparison vidas assay | #1 |
| embolism radionuclide | #1 |
| vte addition | #1 |
| departments orthopedic surgery | #1 |
| edoxaban warfarin groups | #1 |
| cip diagnostic management | #1 |
| positive vte | #1 |
| sspe proximal | #1 |
| ldf diagnosis | #1 |
| patients reduceddose noacs | #1 |
| somittrial | #1 |
| vte risk coc | #1 |
| travellers thrombosis | #1 |
| incidence ctni | #1 |
| strategies abdominal pelvic | #1 |
| lowmolecularweight heparin 95 | #1 |
| 8h flight | #1 |
| venous thrombosis mutations | #1 |
| prophylaxis crt | #1 |
| initial heparin edoxaban | #1 |
| cancer cdr | #1 |
| frequency venous thromboembolism | #1 |
| combination cdrs | #1 |
| nadroparin patients | #1 |
| lmwhmediated | #1 |
| cus strategies | #1 |
| severity clinical presentation | #1 |
| deep vein thrombosis | #1 |
| avidin idrabiotaparinux | #1 |
| vte difference | #1 |
| compression ultrasound dvt | #1 |
| cdr normal | #1 |
| reocclusion antithrombotic drug | #1 |
| treat thrombosis | #1 |
| symptomatic venous | #1 |
| patients clinical probability | #1 |
| embolism suspected | #1 |
| 5395 patients | #1 |
| thrombo‐embolic events | #1 |
| doacs factor | #1 |
| rivaroxaban replacement | #1 |
| pulmonary embolism basis | #1 |
| patients ivte | #1 |
| cdr ddimer levels | #1 |
| enoxaparin tb402 | #1 |
| sensitivity 100 percent | #1 |
| echocardiography normotensive patients | #1 |
| normohomocysteinemic relatives hyperhomocysteinaemia | #1 |
| crt cvc | #1 |
| lmwh venous thrombosis | #1 |
| death venous thromboembolism | #1 |
| risk pulmonary embolism | #1 |
| included patients study | #1 |
| patients malignancy | #1 |
| 3 idraparinux | #1 |
| relatives mutation | #1 |
| anticoagulant fondaparinux | #1 |
| calf dvt ultrasound | #1 |
| acute treatment lmwh | #1 |
| uedvt terms | #1 |
| uesvt patients | #1 |
| anticoagulants double | #1 |
| severe presentation patients | #1 |
| rnapc2 groups | #1 |
| coagulation factors markers | #1 |
| anticoagulants probability | #1 |
| pharmacological methods prophylaxis | #1 |
| venous thrombus growth | #1 |
| bleeding risk treatment | #1 |
| protein resistance control | #1 |
| double reports | #1 |
| tests pulmonary embolism | #1 |
| recurrent dvt dvt | #1 |
| death vte studies | #1 |
| edoxaban dalteparin | #1 |
| enoxaparin heparin treatment | #1 |
| dimer test | #1 |
| screening carriers | #1 |
| oral anticoagulants phase | #1 |
| dvt 3 | #1 |
| protein mortality | #1 |
| selective ddimer thresholds | #1 |
| synthetic selective factor | #1 |
| older patients cdr | #1 |
| combination ddimer testing | #1 |
| cdrscore | #1 |
| cancer patients cancer | #1 |
| edoxaban cancer patients | #1 |
| uedvt clinical | #1 |
| recurrent vte statin | #1 |
| early discharge strategies | #1 |
| models development studies | #1 |
| rhir lmwh | #1 |
| axa activity 5 | #1 |
| decisions duration | #1 |
| 36 papers | #1 |
| vivo coagulation factor | #1 |
| adjunct thrombolysis | #1 |
| elevated fviii age | #1 |
| crptest | #1 |
| intrinsic coagulation vivo | #1 |
| dvt impedance plethysmography | #1 |
| lowmolecularweight heparin category | #1 |
| diagnosis deepvein thrombosis | #1 |
| carriers thrombophilic defects | #1 |
| monoclonal antibodies apc | #1 |
| perfusion scan | #1 |
| reduceddose noacs | #1 |
| recurrent vte immobilization | #1 |
| idraparinux | #1 |
| rnapc2 united states | #1 |
| residual thrombotic mass | #1 |
| endotoxemia tests | #1 |
| tb402 enoxaparin | #1 |
| lmwh acute treatment | #1 |
| hyperhomocysteinemia relatives | #1 |
| initial heparin patients | #1 |
| absolute annual incidences | #1 |
| cdrscore combination | #1 |
| tb402 prevention | #1 |
| cancer edoxaban | #1 |
| elderly outpatients combination | #1 |
| heparins vitamin antagonists | #1 |
| pvo ctscan | #1 |
| cvc crt | #1 |
| women edoxaban | #1 |
| idraparinux versus | #1 |
| 69 conclusions | #1 |
| scores occult cancer | #1 |
| bmi fondaparinux | #1 |
| pyridines recurrence | #1 |
| low levels ft4 | #1 |
| doses 75 microg | #1 |
| pvoq | #1 |
| 6 months avidin | #1 |
| suspected cdr | #1 |
| feasibility venography | #1 |
| puerperium diagnostic suspicion | #1 |
| thromboembolism relatives | #1 |
| infections gentamicin | #1 |
| venography feasibility | #1 |
| limited screening 95 | #1 |
| plateletactivating antibodies risk | #1 |
| survival fondaparinux | #1 |
| symptomatic pts | #1 |
| practiceassistants | #1 |
| dalteparin 6 months | #1 |
| thrombophlebitis tomography | #1 |
| local radiologist | #1 |
| tomography angiography vte | #1 |
| edoxabantreated | #1 |
| carriers relative risks | #1 |
| botticelli dvt dose‐ranging | #1 |
| heparin vitamin antagonist | #1 |
| bleeding risk lmwh | #1 |
| guideline adherence justification | #1 |
| survival lmwh | #1 |
| 5‐snp scores | #1 |
| anticoagulant treatment patients | #1 |
| patients examiner | #1 |
| d‐dimer level | #1 |
| vitamin antagonist patients | #1 |
| efficacy vte | #1 |
| idraparinux patients | #1 |
| 15 lmwh | #1 |
| standalone ddimer testing | #1 |
| ultrasound compression ultrasound | #1 |
| enoxaparin vkas treatment | #1 |
| rfviia idraparinux | #1 |
| pulmonary embolism life | #1 |
| timeperiod | #1 |
| superficial thrombophlebitis incidence | #1 |
| obese controls difference | #1 |
| cancer clinical presentation | #1 |
| elevated ctni patients | #1 |
| probability lung scan | #1 |
| xageneration | #1 |
| 5mg apixaban | #1 |
| 50 rivaroxaban | #1 |
| pulmonary embolism role | #1 |
| topic thrombophlebitis | #1 |
| silent dvt | #1 |
| amplify trial | #1 |
| animal female heparin | #1 |
| doacs cirrhosis patients | #1 |
| individuals air travel | #1 |
| standardintensity vkas | #1 |
| normal lung scan | #1 |
| single‐detector row | #1 |
| study centre duration | #1 |
| patients tests prevalence | #1 |
| nadroparin aspirin | #1 |
| rule cdr | #1 |
| deepvein thrombosis incidence | #1 |
| ddimer test combination | #1 |
| uesvt uedvt | #1 |
| idraparinux 25 | #1 |
| women factor leiden | #1 |
| 378 patients edoxaban | #1 |
| reported incidence vte | #1 |
| nadroparin therapeutic dose | #1 |
| warfarin cstatistic | #1 |
| laalleles | #1 |
| antidote vitamin | #1 |
| analysis hokusai | #1 |
| pregnancyrelated complications relatives | #1 |
| study ecq | #1 |
| 547253 | #1 |
| quantitative ddimer tests | #1 |
| principal safety | #1 |
| venous thromboembolism idraparinux | #1 |
| 250 patients cancer | #1 |
| pulmonary embolism metaanalysis | #1 |
| idrabiotaparinux idraparinux | #1 |
| annual incidence patients | #1 |
| departments pharmacological prophylaxis | #1 |
| rnapc2 inhibition | #1 |
| wells simplified | #1 |
| mutation relatives | #1 |
| travel‐related venous thrombosis | #1 |
| vitamin anticoagulants | #1 |
| recurrent vte doacs | #1 |
| standard therapy months | #1 |
| withheld | #1 |
| presenting location women | #1 |
| elevated fviii | #1 |
| 95 elevated ctni | #1 |
| cdr ddimer test | #1 |
| sgs pretest probability | #1 |
| dimer clinical | #1 |
| matisse dvt | #1 |
| progression vte | #1 |
| vte fatal | #1 |
| anticoagulation period | #1 |
| combination nonhigh cdr | #1 |
| idraparinux vitamin antagonist | #1 |
| lmwh departments | #1 |
| patients antithrombotic prescriptions | #1 |
| major bleeding cancer | #1 |
| venous thrombosis pregnancy | #1 |
| apc resistance factor | #1 |
| predefined outcomes vte | #1 |
| specificity pulmonary embolism | #1 |
| realtime bmode ultrasonography | #1 |
| einsteinextension | #1 |
| symptomatic recurrent | #1 |
| uedvt recurrent vte | #1 |
| phase doacs | #1 |
| inherited thrombophilia patients | #1 |
| ivte clinical practice | #1 |
| uesvt median | #1 |
| fviii homocysteine | #1 |
| doacs anatomical extent | #1 |
| ifngamma pselectin | #1 |
| extensive screening cancer | #1 |
| crp test patients | #1 |
| normal ddimer result | #1 |
| protecht shr | #1 |
| cancer patients cdr | #1 |
| ventilation scan chest | #1 |
| failure rate efficiency | #1 |
| factor viii homocysteine | #1 |
| threemonth incidence | #1 |
| submassive incidence | #1 |
| early time recurrence | #1 |
| atherosclerosis hemophilia patients | #1 |
| dvt anticoagulants | #1 |
| 3 rfviia | #1 |
| heparin vitamin | #1 |
| clinically suspected uedvt | #1 |
| dvt 56 | #1 |
| rivaroxaban standard therapy | #1 |
| plasma concentration fviii | #1 |
| selective beta‐blocker treatment | #1 |
| cancer patients patients | #1 |
| intensity vkas doacs | #1 |
| reduceddose noacs warfarin | #1 |
| patients unexplained dvt | #1 |
| quantitative ddimer testing | #1 |
| category death | #1 |
| ventilation lung scanning | #1 |
| baseline characteristics duration | #1 |
| tb402 50 | #1 |
| vitamin antagonists time | #1 |
| wellscdr | #1 |
| thromboembolism 3 | #1 |
| cancer patients cvcs | #1 |
| pulmonary angiography ultrasonography | #1 |
| avidin vte | #1 |
| apixaban extended treatment | #1 |
| 12 kg1 enoxaparin | #1 |
| efficacy conventional treatment | #1 |
| patients tb402 | #1 |
| mutation arg506 | #1 |
| hemorrhage heparin | #1 |
| weight heparinoid | #1 |
| subsequent diagnosis malignancy | #1 |
| ultrasonography diagnostic | #1 |
| wells rule exclusion | #1 |
| members symptomatic carriers | #1 |
| svt lmwh | #1 |
| local radiologist experts | #1 |
| ccus 4 | #1 |
| anticoagulants chemotherapy | #1 |
| achieved inr patients | #1 |
| ipe expert radiologists | #1 |
| acenocoumarol initial treatment | #1 |
| quantitative ddimer test | #1 |
| aptt org 10172 | #1 |
| enoxaparin initial treatment | #1 |
| single dose tb402 | #1 |
| chromogenic endotoxin | #1 |
| current comprehensions | #1 |
| factor viii relatives | #1 |
| ultrasound strategies patients | #1 |
| simplified rule proportion | #1 |
| abnormal ipg | #1 |
| dose rnapc2 | #1 |
| time recombinant | #1 |
| patients mismatched scan | #1 |
| fondaparinux unfractionated | #1 |
| laalleles platelets | #1 |
| isolated deficiencies proteins | #1 |
| factual hemorrhage heparin | #1 |
| fetal loss miscarriage | #1 |
| clinical presentation category | #1 |
| equinox study | #1 |
| probability cdr | #1 |
| vte study | #1 |
| adjusted dose ufh | #1 |
| acute recurrent patients | #1 |
| fviii women | #1 |
| outcome recurrent | #1 |
| diagnostic management patients | #1 |
| vka netherlands | #1 |
| patients deep | #1 |
| strategies diagnostic management | #1 |
| lmwh replacement | #1 |
| types major bleeding | #1 |
| heparins cancer spread | #1 |
| thrombophilia patients doacs | #1 |
| tinaquant assay comparison | #1 |
| therapeutic doses lmwh | #1 |
| advanced malignancy | #1 |
| risk percentage points | #1 |
| vkas efficacy | #1 |
| idraparinux standard therapy | #1 |
| dimer result | #1 |
| venous thromboembolism episode | #1 |
| recurrent thrombosis pts | #1 |
| constans score | #1 |
| excluding pulmonary | #1 |
| efficacy outcome | #1 |
| women elevated levels | #1 |
| pulmonary embolism carriers | #1 |
| presenting location vte | #1 |
| vte occurred | #1 |
| outpatients symptomatic dvt | #1 |
| idraparinux recurrent thromboembolism | #1 |
| controlled trials thrombophilia | #1 |
| casedescription | #1 |
| respondents 60 | #1 |
| excluded pulmonary | #1 |
| category fxainhibitors | #1 |
| vte risk day | #1 |
| 750 μg l1 | #1 |
| vkas lmwh | #1 |
| malignancy achieved inr | #1 |
| wellscdrscore | #1 |
| fviii vte | #1 |
| relatives antithrombin | #1 |
| vka share | #1 |
| milliliter enoxaparin | #1 |
| replacement vka | #1 |
| nonhigh cdr | #1 |
| patients laalleles | #1 |
| acenocoumarol heparin | #1 |
| extra hospital visits | #1 |
| thrombophilia late loss | #1 |
| aged venous | #1 |
| compression ultrasonography presentation | #1 |
| successful attenuation | #1 |
| dvt costs | #1 |
| 97 compression ultrasonography | #1 |
| pioped study study | #1 |
| fviii concentration | #1 |
| intracranial clinical presentation | #1 |
| standard therapy rivaroxaban | #1 |
| influenza case patients | #1 |
| fviii venous thromboembolism | #1 |
| protein levels mortality | #1 |
| orthopedic thromboprophylaxis | #1 |
| perelated death classification | #1 |
| treated vka | #1 |
| patients normal tests | #1 |
| 95 intracranial | #1 |
| failure cip | #1 |
| inr studies | #1 |
| 2479 relatives | #1 |
| elderly patients dvt | #1 |
| avws prevalence | #1 |
| 208791 | #1 |
| einstein dvt patients | #1 |
| fetal loss carriers | #1 |
| tsh antitpo | #1 |
| placebo rnapc2 | #1 |
| controlledstudy | #1 |
| distal clots | #1 |
| ddimer test patients | #1 |
| riskstroponin | #1 |
| 95 3633 patients | #1 |
| patients inherited thrombophilia | #1 |
| prothrombin individuals | #1 |
| 393 patients warfarin | #1 |
| presenting vte location | #1 |
| 123362 | #1 |
| 0·620·74 | #1 |
| submassive elevated ctni | #1 |
| age∗10μg | #1 |
| postthrombotic symptoms patients | #1 |
| placebo 25mg apixaban | #1 |
| compression ultrasonography detection | #1 |
| impedance thrombophlebitis | #1 |
| undvt | #1 |
| administration lmwh | #1 |
| ctscanreading | #1 |
| gogh dvt trial | #1 |
| venous thrombosis recurrence | #1 |
| outcome clinically | #1 |
| iii plg | #1 |
| initial treatment patients | #1 |
| diagnostic strategies strategies | #1 |
| lmprovement | #1 |
| non‐invasive diagnostic work‐up | #1 |
| enoxaparin primary efficacy | #1 |
| warfarin cancer patients | #1 |
| fxiaso enoxaparin | #1 |
| cdr dimer | #1 |
| neoplasms heparin | #1 |
| vte location | #1 |
| rivaroxaban lmwh vka | #1 |
| lmwh plasma levels | #1 |
| orthopedic surgery netherlands | #1 |
| chest perfusion scintigraphy | #1 |
| rivaroxaban acute dvt | #1 |
| prospective management study | #1 |
| prevalence coagulation | #1 |
| normal venogram | #1 |
| longhaul flight | #1 |
| extended treatment edoxaban | #1 |
| netherlands 5 years | #1 |
| referral basis | #1 |
| patients compression ultrasonography | #1 |
| hokusai‐vte trial | #1 |
| incidental vte | #2 |
| performance constans rule | #2 |
| treated edoxaban | #2 |
| thromboinflammation cardiovascular disease | #2 |
| patients oral factor | #2 |
| dimer thresholds | #2 |
| mild risk factor | #2 |
| coumarin sensitivity | #2 |
| raskob | #2 |
| heparin treatment influenza | #2 |
| administration rviia | #2 |
| beta‐receptor blockade | #2 |
| endotoxininduced activation coagulation | #2 |
| decision rule | #2 |
| apixaban lmwh vka | #2 |
| clinical probability estimate | #2 |
| sr34006 | #2 |
| plasmin activity inhibition | #2 |
| extended constans score | #2 |
| heparin compounds | #2 |
| duration anticoagulant | #2 |
| fibrinolysis pentoxifylline | #2 |
| travel venous | #2 |
| quality warfarin treatment | #2 |
| brain metastases doacs | #2 |
| influenza prothrombotic state | #2 |
| gauge plethysmography | #2 |
| 8292 patients | #2 |
| cha2ds2vasc nri | #2 |
| treatment ttr | #2 |
| pregnancy venous thrombosis | #2 |
| heparin administered | #2 |
| risk anticoagulation therapy | #2 |
| hmb primary outcome | #2 |
| embolism safely | #2 |
| hemorr2hages atria scores | #2 |
| low‐molecular‐weight heparin | #2 |
| gcpg | #2 |
| pulmonary embolism asthma | #2 |
| simplified wells | #2 |
| n1423 | #2 |
| death vte | #2 |
| patients prior vte | #2 |
| intrinsic cascade | #2 |
| mutations cleavage sites | #2 |
| vitamin antagonist rivaroxaban | #2 |
| negative ageadjusted ddimer | #2 |
| employees longhaul flight | #2 |
| thrombosis normal | #2 |
| fibrinolytic proteins | #2 |
| coagulation fibrinolytic | #2 |
| pravastatin therapy children | #2 |
| intermediate phenotype vte | #2 |
| ageadjusted ddimer testing | #2 |
| hokusai vtecancer study | #2 |
| crnm bleeds | #2 |
| uedvt performance | #2 |
| nematode anticoagulant | #2 |
| bleeding complications treatment | #2 |
| efficiency diagnostic strategies | #2 |
| pulmonary embolism purpose | #2 |
| absolute incidence | #2 |
| clinical pretest probability | #2 |
| endogenous activated protein | #2 |
| thromboembolism thrombophilia | #2 |
| levels coagulation factors | #2 |
| impedance plethysmography patients | #2 |
| vein compressibility | #2 |
| blood coagulation inhibition | #2 |
| recurrent deep | #2 |
| pentasaccharide fondaparinux | #2 |
| symptomatic outpatients | #2 |
| thyroid hormone coagulation | #2 |
| apixaban enoxaparin warfarin | #2 |
| risk khorana | #2 |
| lowmolecularweight heparin women | #2 |
| pharmacological strategies | #2 |
| major bleeding edoxaban | #2 |
| patients khorana score | #2 |
| hyperglycemia diagnosis | #2 |
| subsegmental emboli | #2 |
| treatment deep | #2 |
| resource utilisation treatment | #2 |
| annual incidences | #2 |
| hokusai vte | #2 |
| cancer addition | #2 |
| vte svt | #2 |
| oral direct inhibitors | #2 |
| venographically | #2 |
| relation coagulation factors | #2 |
| deficiencies proteins | #2 |
| recurrence thromboembolism | #2 |
| suspected upper | #2 |
| months 25 | #2 |
| levothyroxine exposure | #2 |
| analysis venous | #2 |
| coagulation factors prolactin | #2 |
| life treatment duration | #2 |
| 95 0·2 | #2 |
| bleeding occurred | #2 |
| computed venous | #2 |
| rfviia injection rfviia | #2 |
| prothrombin pulmonary embolism | #2 |
| prolactin relation | #2 |
| arterial thrombotic disease | #2 |
| exclude pulmonary | #2 |
| central localization | #2 |
| patients hemorr2hages | #2 |
| bleeding rate patients | #2 |
| uedvt efficiency | #2 |
| euro138 | #2 |
| serum tnf activity | #2 |
| 95 cancer patients | #2 |
| uedvt cancer patients | #2 |
| primary healthcare secondary | #2 |
| factor iia | #2 |
| received edoxaban | #2 |
| regression pravastatin | #2 |
| influenza coagulation | #2 |
| ultrasonography patients | #2 |
| major clinically | #2 |
| plasma d‐dimer concentration | #2 |
| efficiency strategy | #2 |
| vidas assay | #2 |
| compression doppler | #2 |
| ventilation scanning | #2 |
| years 36 | #2 |
| mdct reference standard | #2 |
| plasma concentrations endotoxin | #2 |
| measurement ankle brachial | #2 |
| scan normal | #2 |
| hospitalbased strategies | #2 |
| thrombophilic defects risk | #2 |
| test cancer | #2 |
| acquired antithrombin | #2 |
| failure rate strategy | #2 |
| 3306 patients | #2 |
| 95 comparator individuals | #2 |
| incidental venous | #2 |
| subcutaneous length | #2 |
| medscape | #2 |
| safety pravastatin therapy | #2 |
| major bleeding recurrent | #2 |
| normal ddimer test | #2 |
| principal safety outcome | #2 |
| fvl carriers carriers | #2 |
| recombinant hirudin cgp | #2 |
| n832 | #2 |
| concomitant thrombophilic | #2 |
| enoxaparin difference | #2 |
| clinical prediction model | #2 |
| referred patients secondary | #2 |
| efficiency original score | #2 |
| amuse strategy | #2 |
| interleukin‐10 response | #2 |
| treated anticoagulants | #2 |
| major bleeding intermediate | #2 |
| lmwh efficacy | #2 |
| vitamin antagonists quality | #2 |
| lower clinical utility | #2 |
| uptake noacs | #2 |
| 17 apixaban | #2 |
| pulmonary embolism efficacy | #2 |
| cancer recurrent vte | #2 |
| secondary efficiency | #2 |
| rnapc2 | #2 |
| surgical casts | #2 |
| mutation 35 | #2 |
| presentation dvt | #2 |
| venous thrombophlebitis | #2 |
| venous | #2 |
| 6 months scores | #2 |
| warfarintreated | #2 |
| simplired test | #2 |
| vte elevated fviii | #2 |
| mutations propeptide | #2 |
| vte orthopedic surgery | #2 |
| angioplasty clopidogrel | #2 |
| 20210a mutations | #2 |
| nonpermanent heart failure | #2 |
| recurrent vte risk | #2 |
| tinaquant vidas | #2 |
| antagonists vka | #2 |
| recombinant nematode | #2 |
| ate cancer patients | #2 |
| incidence recurrent | #2 |
| venous thromboembolism enoxaparin | #2 |
| hellp syndrome prevalence | #2 |
| blood coagulation rnapc2 | #2 |
| c1173t dimorphism | #2 |
| rivaroxaban 30 bid | #2 |
| comparator individuals 95 | #2 |
| nct00633893 | #2 |
| vte 1000 personyears | #2 |
| fviii increased risk | #2 |
| screening fvl | #2 |
| patients low probability | #2 |
| rule combined | #2 |
| composite scores area | #2 |
| pregnancy coc | #2 |
| secondary strategies | #2 |
| sspe patients patients | #2 |
| current clinical challenges | #2 |
| ddimer assay | #2 |
| vte 12 | #2 |
| global public awareness | #2 |
| outcome symptomatic | #2 |
| cdr wells cdr | #2 |
| common alternative diagnoses | #2 |
| inflammation neutrophils thrombosis | #2 |
| alife study | #2 |
| hasbled score hemorr2hages | #2 |
| age‐adjusted d‐dimer testing | #2 |
| rivaroxaban thiazoles | #2 |
| single administration tb402 | #2 |
| undiagnosed malignancy | #2 |
| wells cdr patients | #2 |
| risk deep | #2 |
| heparin nadroparin | #2 |
| bleeding edoxaban | #2 |
| diagnostic lung | #2 |
| normohomocysteinemic relatives | #2 |
| anticoagulated patients permanent | #2 |
| idraparinux vitamin | #2 |
| suspected pulmonary embolism | #2 |
| duration anticoagulant treatment | #2 |
| embolism primary | #2 |
| ddimer determination | #2 |
| ufh survival | #2 |
| computerized impedance | #2 |
| clinically suspected | #2 |
| healthcare settings findings | #2 |
| cdr variables cdr | #2 |
| rule proportion | #2 |
| patients peripheral graft | #2 |
| patients abi measurement | #2 |
| 8 wk risk | #2 |
| standardised time intervals | #2 |
| exclusion pulmonary embolism | #2 |
| enoxaparin warfarin | #2 |
| relevant patient subgroups | #2 |
| amadeus study | #2 |
| impedance plethysmography diagnosis | #2 |
| biomarkers casecontrol studies | #2 |
| wells cdr cdr | #2 |
| events severe | #2 |
| primary efficacy outcome | #2 |
| suspected pulmonary | #2 |
| heparin effective | #2 |
| adapted ddimer thresholds | #2 |
| women therapeutic doses | #2 |
| rnapc2 doses | #2 |
| 95 dvt | #2 |
| thrombophilic disorders | #2 |
| limits cancer | #2 |
| statins recurrent vte | #2 |
| f5 r506q | #2 |
| primary hospitalbased strategies | #2 |
| lmwh users | #2 |
| embolism deep | #2 |
| protein rnapc2 | #2 |
| model cancer patients | #2 |
| graft occlusion patients | #2 |
| exposure flights | #2 |
| major bleeding cindexes | #2 |
| fibrinolysis influenza | #2 |
| score dimer | #2 |
| khorana protecht | #2 |
| crd42017056309 | #2 |
| ufh 6 months | #2 |
| sustained antithrombotic | #2 |
| coagulation influence | #3 |
| cancer randomised trials | #3 |
| compensated dic | #3 |
| antithrombin iii concentrate | #3 |
| patients gastrointestinal cancer | #3 |
| incidence enoxaparin | #3 |
| older children vte | #3 |
| safely exclude | #3 |
| introduction mdct | #3 |
| dimer blood | #3 |
| incidence total vte | #3 |
| platelet agents | #3 |
| endogenous apc | #3 |
| patients venography | #3 |
| crt cancer patients | #3 |
| probability dimer | #3 |
| ddimer threshold | #3 |
| primary wells rule | #3 |
| discontinuation ufh | #3 |
| influence heparins | #3 |
| dvt systematic differences | #3 |
| proximalvein thrombosis | #3 |
| lmwh pph | #3 |
| cancer patients ate | #3 |
| safely excluded | #3 |
| single diagnostic | #3 |
| capillary blood sample | #3 |
| favour lmwh | #3 |
| healthy donor fmt | #3 |
| thrombophlebitis treatment | #3 |
| nadroparin placebo | #3 |
| recurrence thrombophlebitis | #3 |
| protein thrombophilia | #3 |
| bleeding 3 | #3 |
| patients 6 months | #3 |
| safely | #3 |
| ultrasonography strategies | #3 |
| vte major burden | #3 |
| 12month study period | #3 |
| recombinant hirudin rhir | #3 |
| vte performance | #3 |
| vte 3 | #3 |
| heparin heparin | #3 |
| treatment vitamin antagonists | #3 |
| wells rule gestalt | #3 |
| clinical models patients | #3 |
| venous arterial | #3 |
| mechanisms heparin | #3 |
| 6575 years | #3 |
| svt vte | #3 |
| treatment low | #3 |
| ctnt risk stratification | #3 |
| approaches primary | #3 |
| patients venous | #3 |
| knee factor | #3 |
| cardiac troponine | #3 |
| venous thromboembolism | #3 |
| heparins cancer | #3 |
| factor viiic | #3 |
| subcutaneous lmwh | #3 |
| thromboembolism background | #3 |
| enoxaparin follow | #3 |
| failurerate | #3 |
| subcutaneous fondaparinux | #3 |
| stable acute | #3 |
| time venous thrombosis | #3 |
| venous thrombosis cancer | #3 |
| deep vein | #3 |
| pulmonary embolism gestalt | #3 |
| dvt einstein | #3 |
| prolactin controls | #3 |
| therapy venous | #3 |
| hasbled | #3 |
| apc protective | #3 |
| ft4 risk | #3 |
| baseline values placebo | #3 |
| mutation venous | #3 |
| normal result | #3 |
| factors prothrombin | #3 |
| tfindependent | #3 |
| thombosis | #3 |
| intravenous loading dose | #3 |
| diagnosis pulmonary embolism | #3 |
| venous thrombosis travel | #3 |
| bleeding major | #3 |
| users incidence | #3 |
| adult patients vte | #3 |
| treatment vte recurrence | #3 |
| impedance predictive | #3 |
| diagnosis pulmonary | #3 |
| chemotherapy prophylaxis | #3 |
| inhibition blood coagulation | #3 |
| embolism‐related | #3 |
| oral hormonal cross | #3 |
| thiophenes venous | #3 |
| outcome venous | #3 |
| venous thrombosis positive | #3 |
| normal ctnt presentation | #3 |
| patients 6575 years | #3 |
| idrabiotaparinux | #3 |
| incidental pulmonary embolism | #3 |
| einstein dvt | #3 |
| dvt major | #3 |
| hokusai‐vte | #3 |
| female hemorrhage humans | #3 |
| fxiaso | #3 |
| dose reduction edoxaban | #3 |
| cancer active cancer | #3 |
| rnapc2 fviia | #3 |
| gestalt probability | #3 |
| wells rule dvt | #3 |
| outpatients dvt | #3 |
| pad smokers | #3 |
| dvt primary | #3 |
| vte low | #3 |
| placebo n4 | #3 |
| prevalence avws | #3 |
| axa activity | #3 |
| simplified wells specificity | #3 |
| pulmonary embolism models | #3 |
| recurrent thromboembolic | #3 |
| patients proximalvein thrombosis | #3 |
| thromboembolism low | #3 |
| gestalt 95 | #3 |
| activecontrol | #3 |
| einstein studies | #3 |
| idrabiotaparinux warfarin | #3 |
| ipe cancer patients | #3 |
| venous thromboembolism thrombophilia | #3 |
| pulmonary embolism‐related death | #3 |
| studies hemorrhage | #3 |
| alternative diagnoses | #3 |
| female humans inhibitors | #3 |
| pph lmwh | #3 |
| coagulation air travel | #3 |
| 100 years year | #3 |
| venous thromboembolism apixaban | #3 |
| definition perelated death | #3 |
| strategies efficiency | #3 |
| composite stroke | #3 |
| patients ultrasonography | #3 |
| administration rnapc2 | #3 |
| predictable pharmacokinetics | #3 |
| prevalence hemostatic abnormalities | #3 |
| products follow | #3 |
| sensitivity compression | #3 |
| lmwh | #3 |
| travel venous thrombosis | #3 |
| outpatient treatment dvt | #3 |
| patients wells | #3 |
| idiopathic venous | #3 |
| 02011 | #3 |
| 3633 patients | #3 |
| lowmolecularweight heparin placebo | #3 |
| revised geneva efficiency | #3 |
| “gestalt | #3 |
| dip placebo | #3 |
| cohort study employees | #3 |
| atria hemorr2hages | #3 |
| 95 wells rule | #3 |
| nct00643201 | #3 |
| negative predictive proportion | #3 |
| dalteparin difference | #3 |
| tinaquant assay | #3 |
| age annual incidence | #3 |
| studies cus strategies | #3 |
| cancer patients ipe | #3 |
| hf severity risk | #3 |
| vein thrombosis | #3 |
| desogestrelcontaining | #3 |
| tb‐402 | #3 |
| einstein patients | #3 |
| thrombophilic defect | #3 |
| patients incidental vte | #3 |
| safety acenocoumarol | #3 |
| death clinical studies | #3 |
| diagnosis deep | #3 |
| heparin edoxaban | #3 |
| plethysmography impedance | #3 |
| dvt hip | #3 |
| 3month vte incidence | #3 |
| treatment lowmolecularweight heparin | #3 |
| primary rule | #3 |
| ddimer assays | #3 |
| ventilation scan | #3 |
| multiple comorbidities polypharmacy | #3 |
| cdr combination | #3 |
| selectine | #3 |
| iii deficiency | #3 |
| lowmolecularweight humans length | #3 |
| combination wells score | #3 |
| warfarin subgroup | #3 |
| monoclonal replacement | #3 |
| presenting location | #3 |
| efficacy heparin | #3 |
| vte denmark | #3 |
| extensive screening | #3 |
| detection dvt | #3 |
| standard therapy treatment | #3 |
| pulmonary embolism primary | #3 |
| low probability models | #3 |
| patients ft4 level | #3 |
| treatment vka | #3 |
| topic heparin heparin | #3 |
| 3month incidence | #3 |
| vte venous thrombosis | #3 |
| 20210ga | #3 |
| risk occult cancer | #4 |
| negative point | #4 |
| vte highincome countries | #4 |
| 6 months prophylaxis | #4 |
| venography patients | #4 |
| coagulation endotoxin | #4 |
| pregnancies carriers | #4 |
| advanced cancer 95 | #4 |
| sankyo | #4 |
| extended treatment | #4 |
| patients clinically | #4 |
| embolism background | #4 |
| embolism dimer | #4 |
| lmwh female heparin | #4 |
| travel thrombosis | #4 |
| vitamin antagonists patients | #4 |
| vte global | #4 |
| thrombophilia 95 | #4 |
| postthrombotic symptoms | #4 |
| life duration | #4 |
| venous thromboembolism patients | #4 |
| clinically relevant bleeding | #4 |
| received warfarin | #4 |
| recurrent vte months | #4 |
| chemotherapy shr | #4 |
| patients nonpermanent | #4 |
| clot resolution | #4 |
| symptomatic deep | #4 |
| contraindications treatment | #4 |
| probability prospective | #4 |
| global disease burden | #4 |
| thrombosis symptomatic | #4 |
| impedance plethysmography | #4 |
| activation fibrinolytic | #4 |
| abdomen relationship | #4 |
| preexisting heparin | #4 |
| hemorr2hages | #4 |
| noacs cancer patients | #4 |
| embolism tomography | #4 |
| thromboembolism occurred | #4 |
| 335 patients | #4 |
| patients venous thromboembolism | #4 |
| dutch orthopedic | #4 |
| chemotherapy vte prophylaxis | #4 |
| ddimer assay patients | #4 |
| patients dimer | #4 |
| protecht | #4 |
| fibrin generation test | #4 |
| edoxaban patients | #4 |
| disease burden vte | #4 |
| predilution postdilution | #4 |
| “reversal | #4 |
| amadeus trial | #4 |
| procoagulant factors | #4 |
| tinaquant | #4 |
| serial impedance plethysmography | #4 |
| diagnostic prediction models | #4 |
| thrombosis ischemic stroke | #4 |
| patients edoxaban | #4 |
| prophylaxis lmwh | #4 |
| 35±4 | #4 |
| vitamin antagonists | #4 |
| vka treatment | #4 |
| vte treatment patients | #4 |
| noacs netherlands | #4 |
| embolism roc | #4 |
| idiopathic venous thrombosis | #4 |
| thromboembolism vitamin | #4 |
| vte global burden | #4 |
| thrombosis deep | #4 |
| diagnosis uedvt | #4 |
| disease vte | #4 |
| serial impedance | #4 |
| 150 microg levonorgestrel | #4 |
| arterial thrombotic | #4 |
| enoxaparin female humans | #4 |
| death survey | #4 |
| patients alternative diagnosis | #4 |
| levels ft4 | #4 |
| chromogenic compounds | #4 |
| daily netilmicin | #4 |
| leiden carriers | #4 |
| patients fondaparinux | #4 |
| thromboembolism systematic | #4 |
| 3587 | #4 |
| estrogen therapy patients | #4 |
| primary failure rate | #4 |
| 150 microg desogestrel | #4 |
| vte netherlands | #4 |
| ageadjusted cutoff patients | #4 |
| thromboembolism study | #4 |
| oral rivaroxaban | #4 |
| thrombophilic families | #4 |
| proximal patients | #4 |
| cancer vwf | #4 |
| patients primary healthcare | #4 |
| risk vkas | #4 |
| bleeding anticoagulants | #4 |
| women apc resistance | #4 |
| diagnostic management strategies | #4 |
| lowmolecularweight heparin | #4 |
| 0651 | #4 |
| population rivaroxaban | #4 |
| chads2 p0001 | #4 |
| warfarin 3 months | #4 |
| venous thrombosis levels | #4 |
| treatment unfractionated heparin | #4 |
| mbe patients | #4 |
| cleavage sites apc | #4 |
| netherlands pulmonary | #4 |
| patients submassive | #4 |
| 10172 | #4 |
| thromboembolism factor | #4 |
| episode venous | #4 |
| criteria dose reduction | #4 |
| control anticoagulation | #4 |
| rfviia injection | #4 |
| coagulation factors risk | #4 |
| lmwhs standard heparin | #4 |
| patients crcl 60 | #4 |
| measurement abi | #4 |
| dose noacs | #4 |
| gramnegative bacteria humans | #4 |
| dimer assays | #4 |
| vitamin antagonist treatment | #4 |
| refuted | #4 |
| total vte | #4 |
| thrombosis air | #4 |
| thromboembolism arterial | #4 |
| questionnaires venous | #4 |
| nct00571649 | #4 |
| hemostatic profile | #4 |
| patient education treatment | #4 |
| thrombosis uedvt | #4 |
| rivaroxaban 20 | #4 |
| clot lysis patients | #4 |
| safety pravastatin | #4 |
| point dimer | #4 |
| diagnostic management | #4 |
| primary pulmonary embolism | #4 |
| thromboembolism treatment | #4 |
| enoxaparin day | #4 |
| patient category | #4 |
| rviia thrombin generation | #4 |
| hyperhomocysteinemic relatives | #4 |
| series venograms | #4 |
| rule pulmonary | #4 |
| vte total | #4 |
| apixaban efficacy | #4 |
| doac studies | #4 |
| women normal levels | #4 |
| lmwh cancer patients | #4 |
| chinese korean ethnicity | #4 |
| lowmolecular weight heparins | #4 |
| ultrasonography venous | #4 |
| global burden vte | #4 |
| adjusted dimer | #5 |
| endotoxin testing | #5 |
| deepvein thrombosis | #5 |
| upper extremity thrombosis | #5 |
| embolism reproducibility | #5 |
| pregnancy pph | #5 |
| coronary angioplasty angioplasty | #5 |
| vte 6 | #5 |
| inhibition plasminogen activation | #5 |
| burden vte | #5 |
| 8491 | #5 |
| specificity thrombophlebitis | #5 |
| efficiency patients | #5 |
| phlebography plethysmography | #5 |
| fviia rnapc2 | #5 |
| outpatients hospital | #5 |
| asymptomatic carriers mutation | #5 |
| ventricular dysfunction echocardiography | #5 |
| cgp 39393 | #5 |
| sensitivity negative predictive | #5 |
| diagnosis questionnaire | #5 |
| antithrombotic drug treatment | #5 |
| heparin compared | #5 |
| recurrent dvt patients | #5 |
| vte factor | #5 |
| normal ctpa | #5 |
| pad smoking | #5 |
| iii plasminogen | #5 |
| predilution | #5 |
| bleeding cancer | #5 |
| venous thromboembolism studies | #5 |
| repeated ultrasonography | #5 |
| isolated calfvein thrombosis | #5 |
| consensus strategy | #5 |
| patients wells score | #5 |
| clinical presentation clinical | #5 |
| molecularweight heparin | #5 |
| patients pulmonary embolism | #5 |
| risk prediction scores | #5 |
| 8292 | #5 |
| dvt prevalence | #5 |
| lmwh recommended | #5 |
| treatment acute dvt | #5 |
| thromboembolism thrombosis | #5 |
| fh patients cvd | #5 |
| rivaroxaban enoxaparin vka | #5 |
| day rivaroxaban | #5 |
| incidence prognostic significance | #5 |
| factor leiden 95 | #5 |
| patients subtherapeutic | #5 |
| coc pregnancy | #5 |
| fviii families | #5 |
| patients recurrent dvt | #5 |
| vte patients cancer | #5 |
| low molecularweight humans | #5 |
| gestalt | #5 |
| patients superficial thrombophlebitis | #5 |
| suspected uedvt | #5 |
| thromboembolism | #5 |
| transfusion blood loss | #5 |
| treatment fondaparinux | #5 |
| thrombosis primary | #5 |
| hirudin treatment | #5 |
| outcome major | #5 |
| cdr patients | #5 |
| secondary dvt | #5 |
| exclusion venous thromboembolism | #5 |
| secondary venous thrombosis | #5 |
| pulmonary embolism patients | #5 |
| panwards | #5 |
| endotoxin chimpanzees | #5 |
| ft4 level | #5 |
| cancer strategy | #5 |
| clinical probability | #5 |
| thrombophlebitis ultrasonography | #5 |
| vka patients | #5 |
| compression ultrasound | #5 |
| thromboembolism idraparinux | #5 |
| dimer combination | #5 |
| thrombosis upper | #5 |
| 2 rules | #5 |
| endogenous activated | #5 |
| thrombosis leg | #5 |
| clinical probability assessment | #5 |
| patients parenteral anticoagulants | #5 |
| netilmicin patients | #5 |
| medea study | #5 |
| thromboembolism studies | #5 |
| elevated plasma level | #5 |
| southern latin america | #5 |
| women warfarin | #5 |
| hokusai | #5 |
| severe pph women | #5 |
| lmwh incidence | #5 |
| low‐molecular‐weight | #5 |
| diagnostic strategies | #5 |
| daiichi sankyo | #5 |
| previous venous thromboembolism | #5 |
| preschool contraceptives | #5 |
| patients proximal | #6 |
| daily gentamicin | #6 |
| antagonists treatment | #6 |
| treatment ufh | #6 |
| anticoagulants hemorrhage | #6 |
| myocardial infarction ctni | #6 |
| efficiency proportion | #6 |
| rate major bleeding | #6 |
| conventional therapy treatment | #6 |
| cancer primary patients | #6 |
| 12month cumulative incidence | #6 |
| vte controls | #6 |
| severe dic | #6 |
| selective beta | #6 |
| duration rivaroxaban | #6 |
| neoplasms pulmonary embolism | #6 |
| svt extension | #6 |
| c1173 | #6 |
| treatment intermittent claudication | #6 |
| low absolute risk | #6 |
| women hyperhomocysteinemia | #6 |
| synthetic pentasaccharides | #6 |
| oral anticoagulants dabigatran | #6 |
| fviia inhibition | #6 |
| isolated deficiencies | #6 |
| subcutaneous nadroparin | #6 |
| thromboembolism bleeding | #6 |
| stressinduced hyperglycaemia | #6 |
| lmwh users users | #6 |
| repeatedly normal | #6 |
| patients factor mutation | #6 |
| patients pulmonary angiography | #6 |
| combined utility | #6 |
| perioperative blood loss | #6 |
| levonorgestrel desogestrel | #6 |
| subcutaneous low | #6 |
| 10±4 | #6 |
| embolism pulmonary | #6 |
| dvt trial | #6 |
| thrombophilic defects | #6 |
| compression stockings patients | #6 |
| funding bayer | #6 |
| vte anticoagulant treatment | #6 |
| patients suspected | #6 |
| anticoagulants female | #6 |
| endotoxin assays | #6 |
| clinically relevant subgroups | #6 |
| grade 1a ufh | #6 |
| 39393 | #6 |
| severe antithrombin | #6 |
| subjects vte | #6 |
| patients anticoagulation clinic | #6 |
| diagnostic workup | #6 |
| patients uedvt | #6 |
| ultrasonography normal | #6 |
| amplify | #6 |
| recurrent pulmonary | #6 |
| effects levonorgestrel | #6 |
| outcome occurred | #6 |
| patients iohexol | #6 |
| anticoagulant treatment | #6 |
| fixeddose regimen | #6 |
| wells rule | #6 |
| patients tests | #6 |
| assay fibrin | #6 |
| vte cancer | #6 |
| leiden | #6 |
| pulmonary embolism presence | #6 |
| pembqol questionnaire | #6 |
| 393 patients | #6 |
| endotoxininduced activation | #6 |
| oral edoxaban | #6 |
| warfarin venous thromboembolism | #6 |
| elisapositive | #6 |
| dabigatran etexilate dabigatran | #6 |
| treatment svt | #6 |
| standardized morbidity ratio | #6 |
| risk increasing levels | #6 |
| effects ufh | #6 |
| patients diagnostic | #6 |
| probability pulmonary | #6 |
| symptomatic legs | #6 |
| arterial cardiovascular | #6 |
| simplired dimer | #6 |
| embolism ventricular | #6 |
| thrombosis guidelines | #6 |
| factor leiden carriers | #6 |
| 049 95 | #6 |
| blood coagulation mechanism | #6 |
| apixaban treatment dose | #6 |
| dalteparin dose | #6 |
| prevalence vte | #6 |
| treatment pulmonary embolism | #6 |
| d‐dimer testing | #6 |
| patients lowmolecularweight heparin | #6 |
| edoxaban efficacy | #6 |
| dimer cut | #6 |
| lmwh cancer | #6 |
| risk khorana score | #6 |
| initial heparin treatment | #6 |
| incidence recurrence | #6 |
| enoxaparin incidence | #6 |
| venograms | #6 |
| ft4 patients | #6 |
| proportion cancer patients | #6 |
| symptoms intermittent claudication | #6 |
| vka | #6 |
| diagnostic suspicion | #7 |
| placebo rivaroxaban | #7 |
| doppler skin | #7 |
| primary efficacy | #7 |
| pulmonary embolism sensitivity | #7 |
| carriers defects | #7 |
| treatment doac | #7 |
| nondiagnostic lung scans | #7 |
| major bleeding rate | #7 |
| mutations factor viii | #7 |
| venous thrombosis treatment | #7 |
| statin treatment risk | #7 |
| vitamin antagonists vka | #7 |
| incidence recurrent vte | #7 |
| general practitioners guideline | #7 |
| relation prolactin levels | #7 |
| diagnosis venous thrombosis | #7 |
| negative predictive npv | #7 |
| heparin org | #7 |
| vte cancer diagnosis | #7 |
| administration bsf | #7 |
| major bleeding | #7 |
| coagulation humans | #7 |
| rivaroxaban 10 | #7 |
| arterial cardiovascular disease | #7 |
| factor female humans | #7 |
| silent pulmonary embolism | #7 |
| recurrent dvt | #7 |
| plasma levels ifngamma | #7 |
| negative ddimer test | #7 |
| 597939 | #7 |
| etexilate oral | #7 |
| tnf injection | #7 |
| embolism prospective | #7 |
| thrombophlebitis adolescent | #7 |
| patients standard heparin | #7 |
| phenprocoumon polymorphism | #7 |
| inhibitor apixaban | #7 |
| dvt ipg | #7 |
| tb402 | #7 |
| leg ultrasonography | #7 |
| thrombophilia pregnancy loss | #7 |
| rates edoxaban | #7 |
| relation levels | #7 |
| day initial treatment | #7 |
| proportion older patients | #7 |
| anticoagulant parameters | #7 |
| presence cteph | #7 |
| antithrombin protein | #7 |
| noncompressibility | #7 |
| aspirin combined | #7 |
| lung scan | #7 |
| thromboembolism total | #7 |
| vka therapy | #7 |
| primary dvt | #7 |
| unselected women | #7 |
| 680 | #7 |
| major bleeding vkas | #7 |
| mpc1609 | #7 |
| thromboembolism vte | #7 |
| levels factor viii | #7 |
| protein protein deficiencies | #7 |
| blood coagulation humans | #7 |
| specific antidotes | #7 |
| spiral sensitivity | #7 |
| prothrombin risk | #7 |
| ufh treatment | #7 |
| combination ipg | #7 |
| carriers venous thromboembolism | #7 |
| ottawa score | #7 |
| deepvein thrombosis patients | #7 |
| thromboembolism adult | #7 |
| 220 dabigatran | #7 |
| stockings control | #7 |
| perelated death | #7 |
| neoplasms pulmonary | #7 |
| severe preeclampsia patients | #8 |
| agnelli | #8 |
| overt cancer | #8 |
| objectively confirmed | #8 |
| apixaban enoxaparin | #8 |
| 1599 patients | #8 |
| vascular endothelial barrier | #8 |
| probability lung | #8 |
| patients excluded | #8 |
| aged phlebography | #8 |
| xii deficient | #8 |
| cancer pulmonary embolism | #8 |
| recurrent vte mb | #8 |
| levonorgestrelcontaining | #8 |
| thrombosis adolescent | #8 |
| inherited thrombophilic | #8 |
| chemotherapy low risk | #8 |
| thrombosis prophylaxis | #8 |
| symptomatic deepvein thrombosis | #8 |
| normal computed | #8 |
| low clinical probability | #8 |
| enoxaparin vka | #8 |
| point ultrasonography | #8 |
| prospective management | #8 |
| inr determination | #8 |
| inr values patients | #8 |
| nafronyl | #8 |
| leiden prothrombin | #8 |
| international organisations | #8 |
| vitamin antagonists vkas | #8 |
| tests pulmonary | #8 |
| patients symptomatic vte | #8 |
| bnp ctnt | #8 |
| duration treatment | #8 |
| fxi aso | #8 |
| anticoagulants antineoplastic | #8 |
| 0·2 | #8 |
| 150 enoxaparin | #8 |
| comorbidity polypharmacy | #8 |
| carriers fvl | #8 |
| lmwh grade 1a | #8 |
| warfarin hazard ratio | #8 |
| discontinuation anticoagulant treatment | #8 |
| euro55 | #8 |
| physicians stockings | #8 |
| p0001 hasbled score | #8 |
| oral apixaban | #8 |
| risks dvt | #8 |
| arg506 factor | #8 |
| dimer tests | #8 |
| ageadjusted ddimer cutoff | #8 |
| proximal deepvein thrombosis | #8 |
| occult cancer patients | #8 |
| heparin vitamin antagonists | #8 |
| oac adherence | #8 |
| compression surveys | #8 |
| nondiagnostic scan | #8 |
| persistent risk factors | #8 |
| patients extended anticoagulation | #8 |
| increased fibrinolytic | #8 |
| wells scores | #8 |
| deficiency antithrombin | #8 |
| initial heparin | #8 |
| anticoagulation unprovoked vte | #8 |
| treatment venous thrombosis | #8 |
| risk employees | #8 |
| products humans | #8 |
| venous thrombosis hyperhomocysteinaemia | #8 |
| contrast venography | #8 |
| oral glucocorticoids risk | #8 |
| unprovoked vte patients | #8 |
| recurrent vte bleeding | #8 |
| structured algorithm | #8 |
| dimer concentration | #8 |
| prevention vte | #8 |
| administration low | #8 |
| funding daiichi | #8 |
| consecutive outpatients | #8 |
| acute symptomatic vte | #8 |
| 97 95 | #8 |
| current approach | #8 |
| v617f jak2 | #8 |
| vte score | #8 |
| homocysteine markers | #8 |
| pvoct | #8 |
| optimal intensity | #8 |
| proximal deep | #8 |
| vka lmwh | #8 |
| testing rule | #8 |
| years cumulative incidence | #8 |
| analysis apixaban | #8 |
| ufh initial treatment | #8 |
| patients fxa inhibitors | #9 |
| cancer cell extravasation | #9 |
| cancer episode | #9 |
| therapeutic dose patients | #9 |
| oral antithrombins | #9 |
| anticoagulant pathways | #9 |
| ultrasonogram | #9 |
| abnormal vaginal | #9 |
| compression stockings prevention | #9 |
| lmwh mortality | #9 |
| longterm treatment vte | #9 |
| strategies dimer | #9 |
| diagnosis mdct | #9 |
| method enoxaparin | #9 |
| weight heparin | #9 |
| acute medical illnesses | #9 |
| combination stroke | #9 |
| daiichisankyo | #9 |
| nonpermanent | #9 |
| serotonin platelet | #9 |
| thrombosis thromboinflammation | #9 |
| thromboembolism cancer | #9 |
| independent committee | #9 |
| treatment prophylaxis | #9 |
| prothrombin 20210a | #9 |
| carriers factor leiden | #9 |
| incidental pulmonary | #9 |
| fondaparinux cancer patients | #9 |
| atiii concentrates | #9 |
| vte relatives | #9 |
| characteristics severity | #9 |
| edoxaban major bleeding | #9 |
| diagnostic prediction model | #9 |
| vte rcts | #9 |
| factors thrombophlebitis | #9 |
| apixaban oral factor | #9 |
| fxa inhibitor | #9 |
| embolism venous | #9 |
| treatment edoxaban | #9 |
| male oligosaccharides | #9 |
| tafi levels | #9 |
| comorbidities polypharmacy | #9 |
| cancer factor | #9 |
| discontinuing anticoagulation | #9 |
| oral contraceptive pregnancy | #9 |
| cofact | #9 |
| bled bleeding | #9 |
| concomitant cancer | #9 |
| büller | #9 |
| placebo plasma levels | #9 |
| postdilution | #9 |
| incidence postthrombotic syndrome | #9 |
| thrombosis compared | #9 |
| months efficacy | #9 |
| crcl 60 | #9 |
| lipoproteina women | #9 |
| normal ddimer | #9 |
| thrombosis venous thromboembolism | #9 |
| generation pill | #9 |
| iii concentrate | #9 |
| heparin therapy patients | #9 |
| hemorr2hages atria | #9 |
| patients active cancer | #9 |
| enoxaparin factor | #9 |
| homocysteine women | #9 |
| major bleeding treatment | #9 |
| dvt lower extremity | #10 |
| pregnancy carriers | #10 |
| thr incidence | #10 |
| anticoagulants | #10 |
| bled scores | #10 |
| 4470 | #10 |
| embolism clinical | #10 |
| heparin nomogram | #10 |
| simplified geneva | #10 |
| incidence major bleeding | #10 |
| inr cases | #10 |
| thrombosis background | #10 |
| subcutaneous metaanalysis | #10 |
| cancer patients lmwh | #10 |
| thrombophlebitis adult | #10 |
| probability pulmonary embolism | #10 |
| cus diagnosis | #10 |
| 100 years discontinuation | #10 |
| schedule heparin | #10 |
| aged antithrombin | #10 |
| rates recurrent vte | #10 |
| injection avidin | #10 |
| intimamedia thickness imt | #10 |
| nadroparine | #10 |
| embolism patients | #10 |
| venous thromboembolic event | #10 |
| induced coagulation | #10 |
| extremity deep | #10 |
| rabbits administration | #10 |
| leg veins | #10 |
| snp scores | #10 |
| severity clinical | #10 |
| lmwh studies | #10 |
| magellan study | #10 |
| retrospective study efficacy | #10 |
| asymptomatic pulmonary embolism | #10 |
| fii mutation | #10 |
| single loss | #10 |
| patients endotoxemia | #10 |
| cvd fh patients | #10 |
| oral thrombin inhibitor | #10 |
| deficiencies antithrombin | #10 |
| incidence 1000 personyears | #10 |
| treatment uedvt | #10 |
| wells | #10 |
| year years | #10 |
| hypocoagulable state | #10 |
| normohomocysteinemic | #10 |
| inherited thrombophilic factors | #10 |
| major bleeding crnmb | #10 |
| vte efficacy | #10 |
| patients venous thrombosis | #10 |
| magellan trial | #10 |
| rfviia blood loss | #10 |
| factor levels patients | #10 |
| gramnegative septicemia | #10 |
| animal heparin | #10 |
| venous thrombosis | #10 |
| oral administration dabigatran | #10 |
| ageadjusted cutoff | #10 |
| fondaparinux risk | #10 |
| treatment vitamin | #10 |
| vnv | #10 |
| cancer patients vte | #10 |
| 1215 patients | #10 |
| ddimer concentration | #10 |
| 598 patients | #10 |
| protein dic | #10 |
| factor prevention | #10 |
| treatment aprotinin | #10 |
| crp test | #10 |
| screening cancer | #11 |
| org 10172 | #11 |
| fondaparinux hemorrhage | #11 |
| sulfates dermatan | #11 |
| weight humans | #11 |
| recombinant human tnf | #11 |
| combination dimer | #11 |
| lmwh pregnancy | #11 |
| hospital lmwh | #11 |
| embolism recurrence | #11 |
| endotoxin assay | #11 |
| intensity anticoagulation | #11 |
| 30 microg ethinylestradiol | #11 |
| d‐dimer levels | #11 |
| pyridines thiazoles | #11 |
| thromboembolism major | #11 |
| 880 patients | #11 |
| factor venous | #11 |
| cancer patients dvt | #11 |
| embolism prevalence | #11 |
| carriers factor | #11 |
| pregnancyrelated complications | #11 |
| oral dabigatran | #11 |
| adult anticoagulants | #11 |
| previous venous | #11 |
| patients cancer vte | #11 |
| mutations prevalence | #11 |
| heparinoid org | #11 |
| incidence major | #11 |
| clinical pretest | #11 |
| endotoxin pentoxifylline | #11 |
| dabigatran enoxaparin | #11 |
| gps training | #11 |
| patients anticoagulant treatment | #11 |
| reference testing | #11 |
| haemophilia vwd | #11 |
| air travel | #11 |
| pulmonary embolism incidence | #11 |
| variation inr | #11 |
| lmwh pregnancies | #11 |
| 750 μg | #11 |
| knee clinical trials | #11 |
| inhibitors hemorrhage | #11 |
| dvt | #11 |
| medical conferences | #11 |
| gentamicin treatment patients | #11 |
| edoxaban | #11 |
| pcc dabigatran | #11 |
| ldfr | #11 |
| cancer patients evidence | #11 |
| pulmonary angiography venography | #11 |
| vte vwf | #11 |
| crnmb 95 | #11 |
| patients cvcs | #11 |
| levels prolactin | #11 |
| patients probability | #11 |
| ufh studies | #11 |
| warfarin recurrent vte | #12 |
| 9295 | #12 |
| perelated | #12 |
| pioped study | #12 |
| prevention venous thrombosis | #12 |
| nephro | #12 |
| factor leiden prothrombin | #12 |
| proximal vein | #12 |
| thrombin generation fibrinolysis | #12 |
| vte recurrence risk | #12 |
| deficient women | #12 |
| 72 children | #12 |
| doseadjustment | #12 |
| paulin | #12 |
| recurrent vte anticoagulation | #12 |
| patients incidental | #12 |
| topic venous | #12 |
| concomitant disorders | #12 |
| venous thromboembolism incidence | #12 |
| hirulog1 | #12 |
| outcomes venous thromboembolism | #12 |
| subsegmental pulmonary emboli | #12 |
| anticoagulation unprovoked | #12 |
| 9702 | #12 |
| noacs vka | #12 |
| ageadjusted ddimer | #12 |
| risk venous | #12 |
| thrombosis dvt | #12 |
| geneva score | #12 |
| livebirth rate | #12 |
| female heparin humans | #12 |
| months primary | #12 |
| bnp cardiac troponin | #12 |
| stopping anticoagulation | #12 |
| safety efficiency | #12 |
| dvt treatment | #12 |
| anticoagulant factor | #12 |
| vka noacs | #12 |
| proximal veins | #12 |
| patients lupus anticoagulant | #12 |
| outpatient management patients | #12 |
| patients lmwhs | #12 |
| humanized arthroplasty | #12 |
| bayer schering pharma | #12 |
| warfarin treated | #12 |
| fondaparinux unfractionated heparin | #12 |
| warfarin therapy inr | #12 |
| crd42013003526 | #12 |
| control metaanalysis | #12 |
| peghirudin | #12 |
| event recurrence | #12 |
| recurrent vte | #12 |
| annual incidence vte | #12 |
| women factor | #12 |
| hemodynamically stable | #12 |
| thrombophilic | #12 |
| treatment crt | #12 |
| observation risk | #12 |
| vte major | #13 |
| concomitant antiplatelet therapy | #13 |
| 86 percent | #13 |
| dabigatran vte | #13 |
| pselectin patients | #13 |
| randomized cross | #13 |
| antithrombin iii activity | #13 |
| spiral computed tomography | #13 |
| major hip | #13 |
| thrombosis young | #13 |
| marder score | #13 |
| dabigatran 220 | #13 |
| recombinant hirudin rhirudin | #13 |
| plethysmography | #13 |
| obesity haemophilia patients | #13 |
| vte | #13 |
| thrombosis acute | #13 |
| factor leiden mutation | #13 |
| dimer testing | #13 |
| clinical decision rules | #13 |
| continuous intravenous heparin | #13 |
| dimer threshold | #13 |
| 95 carriers | #13 |
| patients anticoagulant | #13 |
| patients thrombophilia | #13 |
| groups inr | #13 |
| arterial thromboembolism ate | #13 |
| association venous thrombosis | #13 |
| heparin low | #13 |
| strain gauge plethysmography | #13 |
| deepvein thrombosis dvt | #13 |
| dvt lower | #13 |
| selective testing | #13 |
| inhibition tnf | #13 |
| indication anticoagulation | #13 |
| superficial thrombophlebitis | #13 |
| arixtra | #13 |
| vte groups | #13 |
| time prothrombin | #13 |
| daily subcutaneous | #13 |
| safety doacs | #13 |
| conventional anticoagulants | #13 |
| ufh dalteparin | #13 |
| nct00986154 | #13 |
| vte female humans | #13 |
| vte recurrence 95 | #13 |
| prevention venous thromboembolism | #13 |
| plethysmograms | #13 |
| bleeding events edoxaban | #13 |
| inferiority efficacy | #13 |
| category studies | #13 |
| rivaroxaban thiophenes | #13 |
| uedvt | #13 |
| bayer healthcare | #13 |
| factor viii apc | #13 |
| occult cancer | #13 |
| safety oral | #13 |
| hematologic pregnancy trimester | #13 |
| treatment venous thromboembolism | #13 |
| levels factor | #13 |
| vte 64 | #13 |
| symptomatic pulmonary | #14 |
| plasminogen apoa | #14 |
| cadherins endothelium | #14 |
| low molecular | #14 |
| thrombosis | #14 |
| crnm | #14 |
| gastrointestinal bleeding patients | #14 |
| edoxaban oral factor | #14 |
| effects hyperthyroidism | #14 |
| costs dvt | #14 |
| patients dvt | #14 |
| edoxaban warfarin | #14 |
| pregnancy venous | #14 |
| dvt lower extremities | #14 |
| atiii deficiency | #14 |
| 12 kg1 | #14 |
| factor viii levels | #14 |
| treated lmwh | #14 |
| revised geneva | #14 |
| fvl carriers | #14 |
| thrombophilia patients | #14 |
| cancer patients anticoagulation | #14 |
| riete score | #14 |
| vte statin | #14 |
| thromboembolism age | #14 |
| anticoagulant rivaroxaban | #14 |
| unprovoked vte vte | #14 |
| female fibrin | #14 |
| limited screening | #14 |
| treatment duration patients | #14 |
| conventionaltherapy | #14 |
| awareness pad | #14 |
| aged anticoagulants | #14 |
| acute deep | #14 |
| lmwh vka | #14 |
| patients outpatients | #14 |
| loss women | #14 |
| experimental endotoxaemia | #14 |
| patients acute vte | #14 |
| patients vka therapy | #14 |
| placebo rfviia | #14 |
| doseranging study | #14 |
| safety edoxaban | #14 |
| recurrent venous thromboembolism | #14 |
| standard heparin | #14 |
| recurrent venous | #14 |
| ultrasound strategies | #14 |
| bolus intravenous injection | #14 |
| higher ddimer levels | #14 |
| obstetric complications women | #14 |
| 17 placebo | #14 |
| aged plethysmography | #14 |
| aspirin women | #14 |
| vte months | #14 |
| incidence severe pph | #14 |
| vitaminkantagonists | #15 |
| studies pulmonary | #15 |
| inr patient | #15 |
| thyroid hormone excess | #15 |
| thrombinography | #15 |
| prophylaxis venous thromboembolism | #15 |
| clinically relevant endpoints | #15 |
| 500 pg | #15 |
| patients ctpa | #15 |
| anticoagulants patients | #15 |
| antagonist vka | #15 |
| lomoparan | #15 |
| cardiovascular diseases thrombosis | #15 |
| patients vitamin antagonists | #15 |
| pregnancy outcome pregnancy | #15 |
| hyperthyroidism atrial fibrillation | #15 |
| cteph incidence | #15 |
| experimental thrombosis | #15 |
| edoxaban treatment | #15 |
| symptomatic events | #15 |
| oral direct factor | #15 |
| abdominal pelvic | #15 |
| subcutaneous regimen | #15 |
| inr range | #15 |
| probability assessment | #15 |
| thrombus growth | #15 |
| doacs aspirin | #15 |
| fondaparinux efficacy | #15 |
| treatment 12 months | #15 |
| prior venous thromboembolism | #15 |
| coagulation | #15 |
| coc vte | #15 |
| enoxaparin vte | #15 |
| activation contact | #15 |
| factor leiden | #15 |
| thrombosis diagnosis | #15 |
| established vte | #15 |
| khorana score | #15 |
| lmwh ufh | #15 |
| generation oral | #15 |
| primary safety outcome | #15 |
| arg562 | #15 |
| control subjects prevalence | #15 |
| subcutaneous enoxaparin | #15 |
| recombinant factor viia | #15 |
| arg506 | #15 |
| diagnosis venous | #15 |
| venous thrombosis warfarin | #16 |
| major bleeding anticoagulation | #16 |
| factors major | #16 |
| subsequent pregnancy loss | #16 |
| 6 months placebo | #16 |
| vte khorana score | #16 |
| thrombosis low | #16 |
| positivity threshold | #16 |
| factor inhibitor | #16 |
| major bleeding events | #16 |
| patients acenocoumarol | #16 |
| arterial vascular events | #16 |
| test clinical | #16 |
| vterelated death | #16 |
| occult cancer detection | #16 |
| netilmicin gentamicin | #16 |
| women unexplained | #16 |
| cancer screening patients | #16 |
| thrombosis association | #16 |
| thrombosis haemostasis | #16 |
| impaired fibrinolysis | #16 |
| thromboembolism time | #16 |
| bleeding aged | #16 |
| dvt lmwh | #16 |
| warfarin acenocoumarol | #16 |
| abdomino | #16 |
| 100 95 | #16 |
| combination clinical | #16 |
| analysis rivaroxaban | #16 |
| cancer cancer patients | #16 |
| risk clinically | #16 |
| viia activity | #16 |
| deep venous thrombosis | #16 |
| recurrent symptomatic | #16 |
| avws patients | #16 |
| ddimer levels patients | #16 |
| postthrombotic syndrome children | #16 |
| thrombosis adult | #16 |
| rivaroxaban oral factor | #17 |
| diagnosis svt | #17 |
| thrombosis clinical | #17 |
| lmwhs patients | #17 |
| vkorc1 gene | #17 |
| female humans vte | #17 |
| endotoxemia bacteremia | #17 |
| women mutation | #17 |
| factor monoclonal | #17 |
| dvt prevention | #17 |
| 12 months patients | #17 |
| vte edoxaban | #17 |
| fragment f1 | #17 |
| patients impedance | #17 |
| recurrent vte events | #17 |
| 2688 | #17 |
| topic hemorrhage humans | #17 |
| anticoagulant therapy patients | #17 |
| fibrinolysis treatment | #17 |
| pharmo record linkage | #17 |
| incidence pts | #17 |
| patients overt hypothyroidism | #17 |
| excessive blood loss | #17 |
| gentamicin netilmicin | #17 |
| permanent patients | #17 |
| management crt | #17 |
| anticoagulants clinical | #17 |
| prohemostatic | #17 |
| ctscans | #17 |
| anticoagulants drug | #17 |
| compared enoxaparin | #17 |
| thromboembolism patients | #17 |
| dimer assay | #17 |
| lower specificity | #17 |
| hematoma heparin | #17 |
| scan classification | #17 |
| factors venous | #17 |
| 516 patients | #17 |
| mutation women | #17 |
| hivinfected patients cart | #18 |
| poc test | #18 |
| apc thrombin generation | #18 |
| antithrombotic treatment patients | #18 |
| patients strategy | #18 |
| warfarin hazard | #18 |
| vka edoxaban | #18 |
| outcome events | #18 |
| weight adjusted | #18 |
| proximal vein thrombosis | #18 |
| relevant nonmajor | #18 |
| 4 clinical | #18 |
| intravenous heparin therapy | #18 |
| treatment vkas | #18 |
| 023 | #18 |
| lmwh doacs | #18 |
| diagnostic strategy | #18 |
| edoxaban vte | #18 |
| aptt heparin | #18 |
| cancer vte | #18 |
| annual incidence | #18 |
| prothrombin g20210a | #18 |
| thrombosis pulmonary | #18 |
| sanofi aventis | #18 |
| combined form | #18 |
| favor lmwh | #18 |
| venous thromboembolism rivaroxaban | #18 |
| stable anticoagulation | #18 |
| simplired | #18 |
| flight hours | #18 |
| thromboembolism venous | #18 |
| thrombosis total | #18 |
| women pregnancy loss | #18 |
| commercial airline pilots | #18 |
| vka vte | #18 |
| dvt rivaroxaban | #19 |
| symptomatic dvt | #19 |
| adjusted dose | #19 |
| systemic activation coagulation | #19 |
| oral dabigatran enoxaparin | #19 |
| prognostic echocardiography | #19 |
| vitamin antagonist | #19 |
| lmwh patients | #19 |
| objective testing | #19 |
| doubleblinding | #19 |
| ufh lmwh | #19 |
| acute recurrent | #19 |
| 56 95 | #19 |
| 35 women | #19 |
| treatment heparin | #19 |
| patients major bleeding | #19 |
| patients prevalence | #19 |
| studies factor | #19 |
| active search | #19 |
| abnormal ultrasound | #19 |
| fibrinolytic response | #19 |
| low platelets | #19 |
| recurrence vte | #19 |
| subcutaneous dalteparin | #19 |
| thromboembolism administration | #19 |
| ddimer tests | #19 |
| increased fibrinolytic activity | #19 |
| coagulation studies | #19 |
| local angiogenesis | #19 |
| fondaparinux enoxaparin | #19 |
| venography sensitivity | #19 |
| venous thromboembolism relatives | #19 |
| recurrent venous thrombosis | #19 |
| increased risk relatives | #19 |
| retropubic prostatectomy | #19 |
| vwf vte | #19 |
| extended oral | #19 |
| edoxaban dose | #19 |
| patients derivation | #19 |
| antibodynegative | #19 |
| ipdma | #19 |
| patients sspe | #19 |
| versions version | #19 |
| endogenous fibrinolysis | #19 |
| patients elevated biomarkers | #19 |
| malignancy time | #20 |
| thrombophilia vte | #20 |
| antagonists vkas | #20 |
| excluded patients | #20 |
| abi measurement | #20 |
| warfarin edoxaban | #20 |
| nadroparin | #20 |
| established atherosclerosis | #20 |
| antitpo | #20 |
| proteins thrombin | #20 |
| prothrombin mutation | #20 |
| shr 95 | #20 |
| risk thrombophilia | #20 |
| absolute risk | #20 |
| impedance plethysmography ipg | #20 |
| new agent | #20 |
| diagnostic workup patients | #20 |
| versions questionnaire | #20 |
| thrombosis ultrasonography | #20 |
| therapy rivaroxaban | #20 |
| subsegmental | #20 |
| abi risk factors | #20 |
| calf veins | #20 |
| statin vte | #20 |
| residual venous | #20 |
| life venous thrombosis | #20 |
| standardtherapy hazard ratio | #20 |
| control situation | #20 |
| synthetic cross | #20 |
| cancer severity | #20 |
| injections subcutaneous | #20 |
| single criterion | #20 |
| pregnancyrelated vte | #20 |
| intravenous injections | #20 |
| compared ufh | #20 |
| treatment vte | #20 |
| portola | #20 |
| anticoagulation clinic | #20 |
| dabigatran 150 | #20 |
| guidance ssc | #20 |
| symptomatic venous thrombosis | #20 |
| blindly | #20 |
| carriers prothrombin | #20 |
| patients ddimer testing | #20 |
| distance treatment | #20 |
| recurrence bleeding | #20 |
| ctnt bnp | #20 |
| incidences death | #20 |
| thrombosis anticoagulants | #21 |
| prothrombin 20210 | #21 |
| d‐dimer | #21 |
| treatment acenocoumarol | #21 |
| carriers noncarriers | #21 |
| hemodynamically stable patients | #21 |
| outcome incidence | #21 |
| discriminatory performance | #21 |
| disease ischemic | #21 |
| thromb | #21 |
| distance quality | #21 |
| internists cardiologists | #21 |
| current standard treatment | #21 |
| treatment apixaban | #21 |
| hemostatic abnormalities | #21 |
| fibrinolysis inflammation | #21 |
| doacs lmwhs | #21 |
| deep venous | #21 |
| patients 3 months | #21 |
| concomitant anti | #21 |
| risk cohort study | #21 |
| ddimer concentrations | #21 |
| venogram | #21 |
| occult malignancy | #21 |
| major bleeding patients | #21 |
| vte patients | #21 |
| host defense response | #22 |
| patients severe hf | #22 |
| thrombophilia screening | #22 |
| dose subcutaneous | #22 |
| cttr | #22 |
| dichotomously | #22 |
| bleeding treatment | #22 |
| anticoagulants heparin | #22 |
| anticoagulants humans | #22 |
| doppler venous thrombosis | #22 |
| acute vte | #22 |
| hormonal cross | #22 |
| cmax ctrough | #22 |
| treatment dvt | #22 |
| dimer age | #22 |
| public awareness | #22 |
| patients immobilization | #22 |
| patientyears | #22 |
| recurrent thromboembolism | #22 |
| venous thromboembolic | #22 |
| time inr | #22 |
| patients recurrent symptoms | #22 |
| riskbenefit ratio | #22 |
| daily enoxaparin | #22 |
| lpa plasminogen | #22 |
| vascular endotoxins | #22 |
| alternative anticoagulation | #22 |
| safety treatment | #22 |
| ttr inr | #22 |
| 2 investigators | #23 |
| n1157 | #23 |
| enoxaparin 40 | #23 |
| 5392 | #23 |
| patients coagulation disorders | #23 |
| fondaparinux | #23 |
| ambulatory cancer patients | #23 |
| 011 | #23 |
| gentamicin patients | #23 |
| cancer patients risk | #23 |
| odis | #23 |
| kakkar | #23 |
| clotbound thrombin | #23 |
| percentage increase | #23 |
| elevated ctni | #23 |
| development dic | #23 |
| normal angiogram | #23 |
| thromboembolism anticoagulants | #23 |
| lower extremity amputation | #23 |
| direct factor inhibitors | #23 |
| prevalence venous thromboembolism | #23 |
| hasbled score | #23 |
| vte studies | #23 |
| bidirectional relation | #23 |
| venous arterial thrombosis | #23 |
| recurrence venous | #23 |
| life pulmonary embolism | #23 |
| standardduration | #23 |
| time platelet | #23 |
| rivaroxaban dosing | #23 |
| fondaparinux placebo | #24 |
| overt hyperthyroidism | #24 |
| recurrent pulmonary embolism | #24 |
| prevalence deficiencies | #24 |
| thrombosis carriers | #24 |
| ddimer testing | #24 |
| recurrent thromboembolism patients | #24 |
| levels fviii | #24 |
| presence dvt | #24 |
| predefined criteria | #24 |
| food drugs | #24 |
| independent external validation | #24 |
| patients acute treatment | #24 |
| bleeding complication | #24 |
| a21gly | #24 |
| years episode | #24 |
| desogestrel levonorgestrel | #24 |
| specific antidote | #24 |
| subtherapeutic | #24 |
| safety fondaparinux | #24 |
| patients severe bleeding | #24 |
| month incidence | #24 |
| patients abnormal perfusion | #24 |
| 049 | #24 |
| viiic | #24 |
| ufh patients | #24 |
| parameters fibrinolysis | #24 |
| rates venous thromboembolism | #24 |
| followup incidence | #24 |
| therapy heparin | #24 |
| lowmolecularweight humans | #24 |
| cha2ds2vasc chads2 | #25 |
| middeldorp | #25 |
| suggestions improvement | #25 |
| fatima | #25 |
| specificity efficiency | #25 |
| willebrand factor adamts13 | #25 |
| patients gastrointestinal bleeding | #25 |
| anatomical extent | #25 |
| vte clinical | #25 |
| sepsis intravascular coagulation | #25 |
| amadeus | #25 |
| lmwh treatment | #25 |
| thromboembolism acute | #25 |
| expert radiologists | #25 |
| f1 2 levels | #25 |
| fibrinogen degradation | #25 |
| perfusion lung scan | #25 |
| studies lmwh | #25 |
| influence smoking | #25 |
| xii activity | #25 |
| treatment symptomatic | #25 |
| factors anticoagulants | #25 |
| dalteparin ufh | #26 |
| specificity negative predictive | #26 |
| unprovoked vte | #26 |
| major bleeding bleeding | #26 |
| asymptomatic carriers | #26 |
| thromboprophylaxis hospitalized patients | #26 |
| parameters risk | #26 |
| ecq | #26 |
| failure rate | #26 |
| miscarriage stillbirth | #26 |
| hormonal manipulation | #26 |
| patients cdr | #26 |
| doacs vitamin antagonists | #26 |
| 9715 | #26 |
| edoxaban versus | #26 |
| events year | #26 |
| viia complex | #26 |
| venous thromboemboli | #26 |
| edoxaban vka | #26 |
| rethoracotomy | #26 |
| homozygous carriers | #26 |
| patients essential thrombocythaemia | #26 |
| treatment lmwh | #26 |
| patients symptomatic dvt | #26 |
| rate recurrent vte | #26 |
| training gps | #27 |
| lmwh prophylaxis | #27 |
| airline pilots | #27 |
| anticoagulants factor | #27 |
| months studies | #27 |
| npv patients | #27 |
| treating physician | #27 |
| patients elevated levels | #27 |
| perfusion lung | #27 |
| female heterozygote | #27 |
| 0·63 | #27 |
| low molecularweight heparin | #27 |
| enoxaparin female | #27 |
| lowmolecularweight heparin patients | #27 |
| patients major hemorrhage | #27 |
| unprovoked venous | #27 |
| thrombocytopenia antibodies | #27 |
| thrombosis venous | #27 |
| thrombophlebitis | #27 |
| vte doacs | #27 |
| cancer spread | #27 |
| patients 50 | #27 |
| nonmajor | #27 |
| day 35 | #27 |
| extremity venous | #27 |
| venous thromboembolism carriers | #27 |
| anticoagulants blood | #27 |
| combined training | #27 |
| current guidance | #27 |
| vte thr | #27 |
| noncarriers 95 | #27 |
| objective tests | #28 |
| pembqol | #28 |
| cancer venous thromboembolism | #28 |
| rfviia placebo | #28 |
| factors recurrent | #28 |
| anticoagulation women | #28 |
| pph severe pph | #28 |
| embolism retrospective | #28 |
| vte 6 months | #28 |
| specific reversal agent | #28 |
| presentation followup | #28 |
| receiving rivaroxaban | #28 |
| hirudin therapy | #28 |
| anticoagulants compared | #28 |
| acutely medical patients | #28 |
| 2½ | #28 |
| patients unprovoked | #28 |
| coagulation tissue factor | #28 |
| apc plasma | #28 |
| monitoring therapy | #28 |
| unexplained | #28 |
| vitamin aged | #28 |
| tests diagnostic | #28 |
| therapeutic doses | #28 |
| 4650 | #28 |
| blind trials | #29 |
| acenocoumarol patients | #29 |
| g20210a mutation | #29 |
| major bleeding rivaroxaban | #29 |
| pulmonary embolism death | #29 |
| heparin versus | #29 |
| spread cancer | #29 |
| years year | #29 |
| direct oral anticoagulants | #29 |
| dabigatran pcc | #29 |
| pulmonary angiography | #29 |
| pulmonary embolism recurrence | #29 |
| aspirin placebo | #29 |
| dutch famine | #29 |
| dvt pulmonary embolism | #29 |
| diagnosis dvt | #29 |
| 1000 individuals | #29 |
| plateletactivating antibodies | #29 |
| patients avws | #29 |
| patients standard therapy | #29 |
| authors incidence | #29 |
| current management strategies | #29 |
| pbac score | #29 |
| bleeding increased | #29 |
| thrombo | #29 |
| septicemia | #29 |
| oral glucocorticoids | #29 |
| resistance activated protein | #29 |
| aged morpholines | #29 |
| thrombosis treatment | #29 |
| 8240 | #29 |
| aminoglycoside therapy | #29 |
| cindexes | #29 |
| sex‐specific differences | #29 |
| thrombosis 95 | #29 |
| prediction scores | #29 |
| recurrence svt | #29 |
| 95 risk | #30 |
| administration pentoxifylline | #30 |
| ufh vte | #30 |
| thromboembolism warfarin | #30 |
| xii factor | #30 |
| prevention venous | #30 |
| doac vka | #30 |
| rule patients | #30 |
| f1 2 | #30 |
| costs diagnosis | #30 |
| 1000 personyears incidence | #30 |
| embolism risk | #30 |
| vte coc | #30 |
| markers coagulation activation | #30 |
| new anticoagulants | #30 |
| support techniques | #30 |
| residual thrombosis | #30 |
| cancer venous | #30 |
| direct oral factor | #30 |
| subcutaneous heparin | #30 |
| patients vte | #30 |
| imaging sensitivity specificity | #31 |
| experimental endotoxemia | #31 |
| thromboprophylaxis risk | #31 |
| recurrent episode | #31 |
| pharmacological prophylaxis | #31 |
| ventilation scintigraphy | #31 |
| activation blood coagulation | #31 |
| dimer cutoff | #31 |
| incidence pph | #31 |
| iii activity | #31 |
| antithrombotic therapies | #31 |
| bled | #31 |
| rhir | #31 |
| 0206 | #31 |
| recurrent patients | #31 |
| vte ufh | #31 |
| ufh fondaparinux | #31 |
| inhibitor edoxaban | #31 |
| analysis reviewers | #31 |
| recurrent vte patients | #31 |
| dvt pulmonary | #31 |
| prevalence probability | #31 |
| 2 antiplasmin | #31 |
| incidence cteph | #31 |
| placebo observation | #31 |
| women recurrent miscarriage | #31 |
| term risk | #31 |
| patients deepvein thrombosis | #31 |
| 8755 | #31 |
| events 95 | #31 |
| apixaban placebo | #31 |
| thromboembolism adolescent | #31 |
| extended prophylaxis | #31 |
| standardtherapy | #31 |
| rfviia novoseven | #31 |
| negative septicemia | #32 |
| age adjusted | #32 |
| resistance activated | #32 |
| year 95 | #32 |
| treatment anticoagulants | #32 |
| suspected patients | #32 |
| factors thrombolytic | #32 |
| low clinical | #32 |
| netherlands predictive | #32 |
| international society thrombosis | #32 |
| normal genotype | #32 |
| ufh | #32 |
| warfarin vte | #32 |
| varicosis | #32 |
| factor female | #32 |
| khorana score patients | #32 |
| leiden mutation | #32 |
| generation patients | #32 |
| parenteral anticoagulation | #32 |
| parenteral anticoagulants | #32 |
| negative dimer | #32 |
| mega study | #33 |
| pulmonary angiogram | #33 |
| active implementation | #33 |
| cancer patients diagnosis | #33 |
| rhirudin | #33 |
| data meta | #33 |
| activation factors | #33 |
| unitage | #33 |
| low probability | #33 |
| subcutaneous male | #33 |
| apixaban treatment | #33 |
| warfarin risks | #33 |
| factor viii patients | #33 |
| heparin lmwh | #33 |
| nephrotoxicity gentamicin | #33 |
| prophylaxis vte | #33 |
| chapter patients | #33 |
| thromboembolism young | #33 |
| anticoagulant protein | #33 |
| additional tests | #33 |
| subsegmental pulmonary embolism | #34 |
| compare efficacy | #34 |
| anticoagulant | #34 |
| 590 | #34 |
| 3 months treatment | #34 |
| 9241 | #34 |
| bilateral venography | #34 |
| phytonadione | #34 |
| pregnancy loss women | #34 |
| 10 95 | #34 |
| warfarin adult | #34 |
| plasmin alpha | #34 |
| hemorrhage heparin humans | #34 |
| reocclusion patients | #34 |
| grade 1a | #34 |
| deficiency protein | #34 |
| thrombosis lower | #34 |
| lmwh unfractionated heparin | #34 |
| apcsr | #34 |
| vte compared | #34 |
| control trials | #34 |
| vte thrombophilia | #34 |
| radiologists diagnosis | #35 |
| enoxaparin prevention | #35 |
| weekly subcutaneous | #35 |
| activation coagulation | #35 |
| patients efficiency | #35 |
| risk members | #35 |
| lung scanning | #35 |
| prevention model | #35 |
| pph blood loss | #35 |
| rviia | #35 |
| neoplasms venous | #35 |
| surgery hip | #35 |
| embolism | #35 |
| anticoagulants benzimidazoles | #35 |
| 36 95 | #35 |
| statin association | #35 |
| factors travel | #36 |
| levels coagulation | #36 |
| viii levels | #36 |
| venous thromboembolism dabigatran | #36 |
| fibrinolytic activation | #36 |
| 287 patients | #36 |
| acute symptomatic | #36 |
| iii antithrombin | #36 |
| treatment acute vte | #36 |
| dose reduction patients | #36 |
| novoseven | #36 |
| fibrinogen depletion | #36 |
| 1698 | #36 |
| peripheral endovascular | #36 |
| studies echocardiography | #36 |
| catheterrelated infection | #36 |
| thrombophilia venous | #36 |
| hellp patients | #36 |
| inherited risk factors | #36 |
| regular monitoring | #36 |
| venous thromboembolic disease | #36 |
| 4139 | #36 |
| riskbenefit | #36 |
| bagsvaerd | #37 |
| cumulative incidence vte | #37 |
| thrombosis humans | #37 |
| factors thrombophilia | #37 |
| venography | #37 |
| ctpa patients | #37 |
| suspected venous | #37 |
| pad studies | #37 |
| risk venous thrombosis | #37 |
| tat complexes | #37 |
| recombinant hirudin | #37 |
| genotype 95 | #37 |
| rivaroxaban thromboprophylaxis | #37 |
| outcome composite | #37 |
| lwmh | #37 |
| vte increased | #37 |
| risk factors pts | #37 |
| excluding | #37 |
| ototoxicity nephrotoxicity | #37 |
| magellan | #37 |
| anticoagulant action | #37 |
| prophylactic heparin | #37 |
| warfarin 95 | #37 |
| perelated mortality | #37 |
| anticoagulants prevention | #37 |
| screening occult | #37 |
| restenosis reocclusion | #38 |
| coagulation protein | #38 |
| fetal loss women | #38 |
| age recurrence | #38 |
| doac lmwh | #38 |
| sensitivity biomarkers | #38 |
| vte bleeding | #38 |
| submassive pulmonary | #38 |
| 3306 | #38 |
| catheterrelated thrombosis | #38 |
| anticoagulants female humans | #38 |
| patients ddimer levels | #38 |
| 10 total | #38 |
| vte cancer patients | #38 |
| recurrence day | #38 |
| nonmajor bleeding | #38 |
| rivaroxaban placebo | #38 |
| 2835 | #38 |
| congenital deficiencies | #38 |
| specificity patients | #39 |
| superficial vein thrombosis | #39 |
| heparins lmwhs | #39 |
| low molecular weight | #39 |
| systemic inflammatory responses | #39 |
| 277 patients | #39 |
| doacs | #39 |
| incidence cancer | #39 |
| diagnostic prediction | #39 |
| incidence patients | #39 |
| time compression | #39 |
| enoxaparin placebo | #39 |
| septic syndrome | #39 |
| continued treatment | #39 |
| children familial hypercholesterolemia | #39 |
| embolus | #39 |
| submassive | #39 |
| subcutaneous intention | #39 |
| fibrin fibrinogen | #39 |
| compression stocking | #39 |
| tfmp | #40 |
| pemb | #40 |
| clotting activation | #40 |
| dalteparin treatment | #40 |
| anticoagulation therapy patients | #40 |
| standardized definition | #40 |
| day 6 months | #40 |
| anticoagulant therapy | #40 |
| grade 1a patients | #40 |
| episode venous thromboembolism | #40 |
| fviiic | #40 |
| activatable fibrinolysis | #40 |
| common femoral vein | #40 |
| patients normal | #40 |
| endotoxininduced | #40 |
| therapeutic dosages | #40 |
| ambulatory cancer | #40 |
| international clinical | #40 |
| arterial vascular | #40 |
| thrombinantithrombin complexes | #40 |
| bleeding | #40 |
| endotoxin induced | #41 |
| 7268 | #41 |
| anticoagulated patients | #41 |
| lowmolecularweight heparins | #41 |
| placebo 6 months | #41 |
| cancer lmwh | #41 |
| heparin therapy | #41 |
| calf vein thrombosis | #41 |
| risk recurrent vte | #41 |
| lung scintigraphy | #41 |
| triage tests | #41 |
| 95 genotype | #41 |
| pentasaccharides | #41 |
| dabigatran etexilate | #41 |
| submassive pulmonary embolism | #41 |
| stroke thrombosis | #42 |
| anticoagulation risk | #42 |
| patients prospective | #42 |
| 8101 | #42 |
| major contributor | #42 |
| patients silent | #42 |
| patients vasopressors | #42 |
| type graft | #42 |
| prophylaxis venous | #42 |
| netilmicin | #42 |
| thrombosis administration | #42 |
| neoplasms thrombosis | #42 |
| cell extravasation | #42 |
| standardization committee | #42 |
| warfarin anticoagulants | #43 |
| venous thromboembolism vte | #43 |
| initial treatment | #43 |
| venous thrombosis thrombophilia | #43 |
| ischemic events | #43 |
| rtap | #43 |
| fetal loss | #43 |
| post‐thrombotic syndrome | #43 |
| patients vte risk | #43 |
| heparin risk | #43 |
| cancer adjusted | #43 |
| 543 patients | #43 |
| draft document | #43 |
| probability patients | #43 |
| vkas patients | #43 |
| monthly incidence | #43 |
| experimental venous thrombosis | #44 |
| enoxaparin risk | #44 |
| 20 30 | #44 |
| restoration euthyroidism | #44 |
| nonvka oral anticoagulants | #44 |
| expert physicians | #44 |
| indications patients | #44 |
| protein sepsis | #44 |
| patients tinzaparin | #44 |
| 95 pulmonary embolism | #44 |
| factors thromboembolism | #44 |
| recurrent vte 95 | #44 |
| mild hyperhomocysteinaemia | #44 |
| role coagulation | #44 |
| 10–14 | #44 |
| edoxaban therapy | #44 |
| rate venous | #44 |
| efficiency models | #44 |
| uedvt patients | #44 |
| dvt patients | #45 |
| 95 warfarin | #45 |
| revascularisation procedures | #45 |
| coagulation activation | #45 |
| oral direct | #45 |
| venous thrombotic | #45 |
| treated warfarin | #45 |
| coumarin therapy | #45 |
| years algorithm | #45 |
| fondaparinux patients | #45 |
| wells score | #45 |
| dose lmwh | #45 |
| patients bnp | #45 |
| dose adjusted | #45 |
| patients unprovoked vte | #46 |
| daily rivaroxaban | #46 |
| bleeding rivaroxaban | #46 |
| day levels | #46 |
| management venous | #46 |
| pioped | #46 |
| percent confidence | #46 |
| abtpo | #46 |
| ssc isth | #46 |
| major bleeding placebo | #46 |
| hospital outpatients | #46 |
| stroke risk assessment | #46 |
| healthcare settings | #46 |
| ruling | #46 |
| extended duration | #46 |
| standard therapy | #46 |
| prothrombin fragment f1 | #46 |
| treatment model | #46 |
| bristol myers squibb | #47 |
| boehringer ingelheim | #47 |
| central venous lines | #47 |
| ambulatory anticoagulants | #47 |
| mechanical prophylaxis | #47 |
| iiia receptors | #47 |
| plasma ddimer levels | #47 |
| new oral anticoagulant | #47 |
| male methimazole | #47 |
| episode vte | #47 |
| mutation pregnancy | #47 |
| roccurve | #47 |
| outcome vitamin | #47 |
| intermediate risk risk | #48 |
| risk recurrent | #48 |
| thrombotic burden | #48 |
| elevated plasma levels | #48 |
| patients acute dvt | #48 |
| thromboprophylactic | #48 |
| patients pulmonary | #48 |
| subcommittee | #48 |
| recurrence venous thromboembolism | #48 |
| factors rivaroxaban | #48 |
| fondaparinux heparin | #48 |
| diagnosis physicians | #48 |
| rivaroxaban compared | #48 |
| travel risk | #48 |
| daiichi | #48 |
| small studies | #48 |
| enoxaparin | #49 |
| lowmolecularweight heparin lmwh | #49 |
| levels protein | #49 |
| vte diagnosis | #49 |
| factor viii deficiency | #49 |
| rivaroxaban prevention | #49 |
| women aspirin | #49 |
| calf vein | #49 |
| vitamink antagonists | #50 |
| thromboembolism aged | #50 |
| acute respiratory insufficiency | #50 |
| treatment threshold | #50 |
| etexilate | #50 |
| buller | #50 |
| incidence venous thromboembolism | #50 |
| cardiac surgery mortality | #50 |
| atria patients | #50 |
| outpatient therapy | #50 |
| dvt diagnosis | #50 |
| intensity treatment | #50 |
| prospective diagnostic | #50 |
| nonselective betablockers | #50 |
| transient risk factor | #50 |
| normal perfusion | #51 |
| acenocoumarol | #51 |
| discrimination model | #51 |
| effects coagulation | #51 |
| global disease | #51 |
| tomography pulmonary | #51 |
| patients 11 | #51 |
| previous survey | #51 |
| protein deficiencies | #51 |
| factor vte | #51 |
| 95 apixaban | #51 |
| strategies treatment | #51 |
| risk venous thromboembolism | #52 |
| patients comorbid conditions | #52 |
| free thyroxine ft4 | #52 |
| inhibitors heparin | #52 |
| hematologic malignancies patients | #52 |
| pdvt | #52 |
| doacs vka | #52 |
| 1·12 | #52 |
| vte major bleeding | #52 |
| lung scans | #52 |
| 3 month | #52 |
| svt patients | #52 |
| unnecessarily | #52 |
| apixaban vte | #52 |
| lmwh fondaparinux | #52 |
| warfarintreated patients | #53 |
| absolute risks | #53 |
| patients initially | #53 |
| hemostatic balance | #53 |
| 1522 | #53 |
| reported incidence | #53 |
| thrombophilic factors | #53 |
| 40 daily | #53 |
| thromboembolism prevention | #53 |
| preference patients | #53 |
| postthrombotic syndrome | #53 |
| suspected venous thromboembolism | #53 |
| cross study | #53 |
| versus enoxaparin | #53 |
| 479 patients | #53 |
| bled score | #54 |
| 2537 | #54 |
| antithrombotic drug | #54 |
| 034 | #54 |
| acquired risk factors | #54 |
| patients incidence | #54 |
| familial thrombophilia | #54 |
| endocrine disorders | #54 |
| pai1 levels patients | #54 |
| chads2 cha2ds2vasc | #54 |
| male pulmonary embolism | #54 |
| thromboembolism death | #54 |
| prethrombotic | #54 |
| vte mortality | #54 |
| 378 patients | #54 |
| patients obese | #54 |
| major bleeds | #54 |
| methods randomized | #55 |
| treatment thresholds | #55 |
| dosereduction | #55 |
| long term risk | #55 |
| proximal extent | #55 |
| nondeficient | #55 |
| unfractionated heparin | #55 |
| insurances | #55 |
| anticoagulants arthroplasty replacement | #55 |
| biological pan | #55 |
| rivaroxaban | #55 |
| compared lmwh | #55 |
| unfractionated heparin ufh | #55 |
| legs patients | #55 |
| reduced capacity | #56 |
| inr values | #56 |
| physicians guidelines | #56 |
| vasopressors | #56 |
| preeclampsia hellp syndrome | #56 |
| weight heparins | #56 |
| 20210a | #56 |
| level mortality | #56 |
| time event | #56 |
| enoxaparin rivaroxaban | #56 |
| major bleeding apixaban | #56 |
| seventh accp conference | #56 |
| vte death | #56 |
| risk major bleeding | #56 |
| enoxaparin patients | #56 |
| tromboembólica | #56 |
| vitamin warfarin | #56 |
| venous outflow obstruction | #56 |
| deficiency prevalence | #56 |
| antithrombin iii heparin | #57 |
| calf dvt | #57 |
| levels survival | #57 |
| clinical models | #57 |
| subsegmental pulmonary | #57 |
| inhibitors female humans | #57 |
| ctscan | #57 |
| risk factors vte | #57 |
| doacs patients | #58 |
| spiral computed | #58 |
| malignancy mortality | #58 |
| pharmo | #58 |
| unfractionated heparin patients | #58 |
| inhibitors female | #58 |
| thrombin activatable | #58 |
| fibrinolysis humans | #58 |
| lowmolecular weight heparin | #58 |
| ruled | #58 |
| incidence symptomatic | #59 |
| aventis | #59 |
| bias trial | #59 |
| direct oral | #59 |
| clot lysis time | #59 |
| factor generation | #59 |
| mutation prothrombin | #59 |
| risk factors sensitivity | #59 |
| safety warfarin | #59 |
| warfarin treatment | #59 |
| acute venous thromboembolism | #59 |
| heterozygous factor | #59 |
| risk periods | #59 |
| risk vte | #59 |
| thrombosis aged | #59 |
| awareness risk factors | #60 |
| pulmonary embolism 95 | #60 |
| anticoagulants treatment | #60 |
| acute pulmonary embolism | #60 |
| 079 95 | #60 |
| atrial fibrillation metaanalysis | #60 |
| target inr | #60 |
| fixeddose | #60 |
| prevalence pulmonary | #60 |
| constans | #60 |
| pediatric venous thromboembolism | #60 |
| hemorrhage humans | #60 |
| women difference | #60 |
| cdr score | #61 |
| dvt 95 | #61 |
| benzimidazoles dabigatran | #61 |
| amuse | #61 |
| long‐term treatment | #61 |
| hypocoagulable | #61 |
| free thyroxine | #61 |
| month surgery | #61 |
| perfusion ventilation | #61 |
| tests prevalence | #61 |
| association protein | #61 |
| 3633 | #61 |
| rosendaal | #61 |
| protein fibrinogen | #62 |
| 250 patients | #62 |
| general practitioners patients | #62 |
| 273 patients | #62 |
| combined contraceptives oral | #62 |
| patients administration | #62 |
| human endotoxemia | #62 |
| procoagulant state | #62 |
| informatizado | #62 |
| post thrombotic | #62 |
| ttr patients | #62 |
| activated partial | #62 |
| revised geneva score | #63 |
| quantitative test | #63 |
| management anticoagulation | #63 |
| cvrs | #63 |
| 33 women | #63 |
| women mutations | #63 |
| factor leiden risk | #63 |
| rivaroxaban lmwh | #63 |
| treatment network | #63 |
| common odds ratio | #63 |
| physicians predictive | #63 |
| injection endotoxin | #63 |
| symptoms dvt | #63 |
| venous thromboembolisms | #63 |
| smoking smoking cessation | #63 |
| vte thromboprophylaxis | #63 |
| superficial vein | #64 |
| acute pulmonary | #64 |
| prior vte | #64 |
| blinded trial | #64 |
| cancer noncancer patients | #64 |
| bleeding events patients | #64 |
| vkas treatment | #64 |
| thrombophilic risk | #64 |
| dvts | #64 |
| decision rules | #64 |
| postthrombotic | #64 |
| factor inhibitors | #64 |
| oral thrombin | #64 |
| heparin fondaparinux | #64 |
| selfadjustment | #64 |
| patients aortic valve | #64 |
| stroke thromboembolism | #65 |
| prevalence abnormalities | #65 |
| prothrombin g20210a mutation | #65 |
| ultrasonograms | #65 |
| fvl vte | #65 |
| accuracy diagnostic tests | #65 |
| treatment pad | #65 |
| death classification | #66 |
| statin therapy risk | #66 |
| axa | #66 |
| newer anticoagulants | #66 |
| risk factor thrombosis | #66 |
| female heparin | #66 |
| elfa | #66 |
| dvt sensitivity | #66 |
| 95 bleeding | #66 |
| rapid triage | #66 |
| 0 points | #66 |
| atrial fibrillation stroke | #67 |
| 1127 | #67 |
| apixaban | #67 |
| patients factor | #67 |
| rate major | #67 |
| patients tertiles | #67 |
| standard therapy patients | #67 |
| patients bnp levels | #68 |
| academic medical centre | #68 |
| 3594 | #68 |
| 05 95 | #68 |
| ranging study | #68 |
| fibrinolytic | #68 |
| 20210g | #68 |
| patients benefits | #68 |
| perioperative blood | #68 |
| 1894 | #68 |
| coagulation fibrinolysis | #68 |
| heparin ufh | #69 |
| justify | #69 |
| recurrent thrombosis patients | #69 |
| postphlebitic | #69 |
| ionis | #69 |
| suspected | #69 |
| plasma interleukin | #69 |
| thrombosis blood | #69 |
| certoparin | #69 |
| enfermedad tromboembólica | #69 |
| vwfrco | #70 |
| cutoff levels | #70 |
| mantelhaenszel | #70 |
| major bleeding complications | #70 |
| ischemic events patients | #70 |
| withhold | #70 |
| 8190 | #70 |
| gramnegative sepsis | #70 |
| patients protein | #70 |
| thrombosis recurrence | #70 |
| test patients | #70 |
| α2ap | #70 |
| fixed dose | #70 |
| elevated cardiac | #70 |
| aged predictive | #70 |
| rivaroxaban treatment | #70 |
| asymptomatic atherosclerosis | #71 |
| clopidogrel placebo | #71 |
| diagnostic sensitivity specificity | #71 |
| levels vwf | #71 |
| unfractionated | #71 |
| topic costs | #71 |
| vte vka | #71 |
| thromboprophylaxis | #71 |
| plasminogen plg | #71 |
| tests prospective | #71 |
| elevated factor | #72 |
| overt hypothyroidism | #72 |
| viia factor | #72 |
| pooled rate | #72 |
| trifurcation | #72 |
| complications hematologic | #72 |
| activation prothrombin | #72 |
| new anticoagulant | #72 |
| patients lmwh | #72 |
| hf studies | #72 |
| antithrombin iii iii | #72 |
| versus vitamin | #72 |
| ddimer values | #72 |
| ddimer measurement | #73 |
| analysis diagnostic | #73 |
| ingelheim | #73 |
| tomography spiral | #73 |
| soluble fibrin | #73 |
| noacs | #73 |
| reversal agent | #73 |
| 12 months 95 | #73 |
| prolongations | #73 |
| proteins patients | #74 |
| 5395 | #74 |
| study selection | #74 |
| suspected dvt | #74 |
| 1732 | #74 |
| 2124 | #74 |
| longterm risk | #74 |
| female hemorrhage | #74 |
| 2550 | #74 |
| soluble thrombomodulin | #74 |
| experimental metastasis | #74 |
| dvt study | #74 |
| prethrombotic state | #74 |
| carriers | #74 |
| incidence bleeding events | #75 |
| retrospective follow | #75 |
| 8492 | #75 |
| carotid femoral arteries | #75 |
| selective factor | #75 |
| 1334 | #75 |
| 2904 | #75 |
| postoperative dvt | #75 |
| thrombolytic therapy patients | #75 |
| tests primary | #76 |
| factor xii deficiency | #76 |
| angiography ctpa | #76 |
| early time | #76 |
| oral combined contraceptives | #76 |
| risk thrombosis | #76 |
| extended anticoagulation | #76 |
| duration thromboprophylaxis | #76 |
| combined contraceptives | #76 |
| social aspects | #77 |
| boehringer | #77 |
| p023 | #77 |
| individual patient | #77 |
| thrombosis pregnancy | #77 |
| patients secondary | #77 |
| ipg | #78 |
| women thrombophilia | #78 |
| unprovoked | #78 |
| arterial thromboembolism | #78 |
| 20 daily | #78 |
| elevated dimer | #78 |
| arterial wall thickness | #78 |
| female fibrinolysis | #78 |
| factor adult | #79 |
| vkas | #79 |
| humans pulmonary | #79 |
| vte fvl | #79 |
| time therapeutic | #79 |
| suspected acute | #79 |
| efficacy agents | #79 |
| limulus test | #79 |
| 2486 | #79 |
| topic heparin | #79 |
| daily bid | #80 |
| alife | #80 |
| validation models | #80 |
| vte rate | #80 |
| patient data | #80 |
| subhazard ratio | #80 |
| thromboembolism incidence | #80 |
| heterozygous deficiency | #80 |
| suspected cancer | #80 |
| bleeding mortality | #80 |
| 95 05 | #80 |
| sspe patients | #80 |
| weitz | #81 |
| topic risk | #81 |
| walking distance | #81 |
| vascular events | #81 |
| test evaluation | #81 |
| knee arthroplasty patients | #81 |
| lmwh vte | #81 |
| outpatient basis | #81 |
| prothrombin complex concentrate | #81 |
| systemic inflammatory | #81 |
| prospective validation | #82 |
| symptomatic carriers | #82 |
| 50 micrograms | #82 |
| crnmb | #82 |
| placebo women | #82 |
| thrombosis thrombophilia | #82 |
| posthoc analysis | #82 |
| thrombolytic drugs | #82 |
| thrombosis incidence | #82 |
| heparin prevention | #82 |
| common practice | #82 |
| clinical sign | #82 |
| timeperiods | #82 |
| 3month followup | #82 |
| mammography patients | #82 |
| bistro | #83 |
| dimer patients | #83 |
| bleeding women | #83 |
| inhibitor dabigatran | #83 |
| patients thrombi | #83 |
| 2213 | #83 |
| 287 | #83 |
| elective coronary | #83 |
| normotensive patients | #84 |
| heparin treatment | #84 |
| screening humans | #84 |
| inhibitor rivaroxaban | #84 |
| healthcare setting | #84 |
| inherited thrombophilia | #84 |
| diagnostic outcome | #84 |
| duration therapy | #84 |
| prophylactic dose | #84 |
| peripheral vascular diseases | #85 |
| anticoagulants antiphospholipid | #85 |
| asymptomatic dvt | #85 |
| thrombosis svt | #85 |
| endotoxins | #85 |
| venous thrombosis patients | #85 |
| normal levels | #85 |
| antithrombin iii protein | #85 |
| 75 microg | #86 |
| elevated ddimer levels | #86 |
| dabigatran vka | #86 |
| 10⁶ | #86 |
| 4576 | #86 |
| major bleeding warfarin | #86 |
| venovenous hemofiltration | #86 |
| rhapc | #86 |
| 95 100 | #87 |
| obstetric patients | #87 |
| avws | #87 |
| contact activation | #87 |
| clinical impact | #87 |
| post‐hoc analysis | #87 |
| vidas | #87 |
| ≤50 | #87 |
| acute venous | #87 |
| patients 28 | #87 |
| venographic | #88 |
| activation factor | #88 |
| 4 points | #88 |
| treatment incidence | #88 |
| aged multicenter | #88 |
| internist | #88 |
| treatment statins | #88 |
| lmwhs | #88 |
| 3319 | #88 |
| washout period | #88 |
| cdr | #88 |
| adequate treatment | #89 |
| matisse | #89 |
| unexplained recurrent | #89 |
| reversal strategies | #89 |
| safety noacs | #89 |
| stroke bleeding | #89 |
| ventilation lung | #89 |
| anticoagulants dabigatran | #89 |
| costs patient | #89 |
| beta blockers | #89 |
| severe hf | #89 |
| smoking incidence | #89 |
| cytokine release | #89 |
| tests test | #89 |
| ddimer | #89 |
| rates major bleeding | #89 |
| vte venous thromboembolism | #89 |
| popliteal vein | #90 |
| vka dabigatran | #90 |
| venous thrombosis risk | #90 |
| 2293 | #90 |
| new patients | #90 |
| pediatric venous | #90 |
| outweighs | #90 |
| fibrinolytic factors | #90 |
| thrombophilic risk factors | #90 |
| primary thromboprophylaxis | #90 |
| thromboembolism pregnancy | #91 |
| perfusion ratio | #91 |
| inconvenience | #91 |
| pyridines pyridones | #91 |
| 60 95 | #91 |
| agents hemorrhage | #91 |
| 20210 | #91 |
| thrombosis women | #91 |
| cdrs | #91 |
| anticoagulants doacs | #91 |
| prophylaxis incidence | #92 |
| combined clinical | #92 |
| thrombotic disease | #92 |
| single intravenous | #92 |
| scenario analyses | #93 |
| incidence knee | #93 |
| rivaroxaban edoxaban | #93 |
| direct thrombin inhibitors | #93 |
| 95 years | #93 |
| anticoagulation reversal | #93 |
| compression patients | #93 |
| patients symptomatic | #94 |
| vte surgery | #94 |
| heparins | #94 |
| atherogenic lipid | #94 |
| hf severity | #94 |
| 1027 | #94 |
| children vte | #94 |
| test result | #94 |
| 125 patients | #94 |
| viia rfviia | #95 |
| 2 levels | #95 |
| european consensus statement | #95 |
| direct oral anticoagulant | #95 |
| xii deficiency | #96 |
| randomised crossover study | #96 |
| risk symptomatic | #96 |
| symptomatic vte | #96 |
| ddimer level | #96 |
| efficacy rivaroxaban | #96 |
| 6 12 months | #96 |
| fondaparinux treatment | #96 |
| fibrin generation | #97 |
| abnormal perfusion | #97 |
| doacs risk | #97 |
| symptomatic pulmonary embolism | #97 |
| tpa release | #97 |
| difference rates | #97 |
| studies evaluated | #97 |
| pyrazoles pyridones | #97 |
| haemophilia patients | #97 |
| invasive testing | #97 |
| 2875 | #98 |
| major bleed | #98 |
| activated protein apc | #98 |
| simplify | #98 |
| 16slice | #98 |
| hypercoagulable | #98 |
| essential thrombocythaemia | #98 |
| pregnancy postpartum period | #98 |
| supervised exercise therapy | #98 |
| probast | #99 |
| 2·0 | #99 |
| risk arterial | #99 |
| perfusion scintigraphy | #99 |
| hirudin | #99 |
| acute dvt | #99 |
| unselected | #99 |
| lmwh warfarin | #99 |
| increasing levels | #100 |
| gbd 2010 | #100 |
| previews | #100 |
| prevention recurrent | #100 |
| fatty foods | #100 |
| doubleblind trial | #100 |
| patient groups | #100 |
| 1116 | #100 |
| warfarin patients | #100 |
| 3 trials | #100 |
| aptts | #101 |
| factor viia | #101 |
| morpholines | #101 |
| factor vii factor | #101 |
| low pretest probability | #102 |
| 265 patients | #102 |
| pts patients | #102 |
| 40 microg | #102 |
| alternative diagnosis | #102 |
| enoxaparin fondaparinux | #102 |
| venous thromboembolism women | #102 |
| endogenous thrombin | #103 |
| 338 | #103 |
| adjudicated | #103 |
| pregnancy puerperium | #103 |
| cteph patients | #103 |
| therapeutic consequences | #103 |
| arthroscopic anterior | #103 |
| doppler method | #103 |
| absolute increase | #104 |
| oral factor | #104 |
| recurrence women | #104 |
| separate analyses | #104 |
| term treatment | #104 |
| antithrombin iii | #104 |
| diagnostic imaging humans | #104 |
| assay variation | #104 |
| apparent increase | #104 |
| heparin pregnancy | #104 |
| partial restoration | #104 |
| fibrin degradation products | #104 |
| conventional therapy patients | #105 |
| embryo loss | #105 |
| 7 children | #105 |
| 1089 | #105 |
| essentials | #106 |
| thrombophilia | #106 |
| 314 | #106 |
| chest ray | #106 |
| study total | #106 |
| fibrinolytic systems | #106 |
| thromboprophylaxis patients | #106 |
| thrombosis age | #106 |
| elevated levels | #106 |
| hospitalized patients hf | #106 |
| blind double | #106 |
| 2479 | #106 |
| topic recurrence | #107 |
| thromboembolic | #107 |
| survival cancer patients | #107 |
| vte risk | #107 |
| simplified version | #107 |
| definition classification | #107 |
| ddimer levels | #107 |
| specific subgroups | #108 |
| human volunteers | #108 |
| grade 1c | #108 |
| cardiovascular death stroke | #108 |
| post thrombotic syndrome | #108 |
| noncancer patients | #108 |
| patients cancer | #108 |
| 1235 | #109 |
| embolism treatment | #109 |
| 500μg | #109 |
| factor mutation | #109 |
| synthetic pentasaccharide | #109 |
| evaluation studies | #109 |
| thrombin antithrombin | #109 |
| 039 | #109 |
| anticoagulants cohort | #109 |
| viia | #109 |
| routine coagulation | #109 |
| antiplasmin | #110 |
| embolism quality | #110 |
| thrombosis treated | #110 |
| cancer activity | #110 |
| subsequent pregnancy | #110 |
| vka doac | #110 |
| inferiority trial | #110 |
| primary safety | #110 |
| negative predictive 100 | #111 |
| humans intermittent | #111 |
| anticoagulants biomarkers | #111 |
| treatment risk factors | #111 |
| predefined | #111 |
| siset | #111 |
| obstetric complications | #111 |
| comparison control | #111 |
| emergency situations | #112 |
| publication anticoagulants | #112 |
| topic guidelines | #112 |
| thromboembolic diseases | #112 |
| patients ventricular dysfunction | #112 |
| rivaroxaban enoxaparin | #112 |
| patients 70 | #112 |
| chromogenic | #112 |
| recurrence treatment | #112 |
| epidemiology risk factors | #112 |
| efficacy prevention | #112 |
| risk rivaroxaban | #112 |
| metabolic response | #113 |
| nonionic contrast | #113 |
| heterozygous carriers | #113 |
| lmwh risk | #113 |
| inappropriate treatment | #113 |
| patients nephrotoxicity | #113 |
| 0·0 | #114 |
| patients intermediate | #114 |
| total knee replacement | #114 |
| dialysers | #114 |
| cancerassociated vte | #114 |
| study centre | #114 |
| postphlebitic syndrome | #114 |
| fibrinogen vwf | #115 |
| patients recurrent | #115 |
| 393 | #115 |
| hyperhomocysteinaemia | #115 |
| positive predictive values | #115 |
| global public | #115 |
| reference standard | #116 |
| anticoagulants arthroplasty | #116 |
| topic dabigatran | #116 |
| women severe preeclampsia | #116 |
| heparin warfarin | #116 |
| vte data | #116 |
| agents heparin | #116 |
| effects tnf | #116 |
| life treatment | #116 |
| major bleeding 95 | #116 |
| computed tomography patients | #116 |
| vte complications | #117 |
| vte children | #117 |
| fibrinolytic parameters | #117 |
| protein inhibitor pci | #117 |
| arthroscopies | #117 |
| protein resistance | #117 |
| 2460 | #117 |
| women caesarean | #117 |
| proximal dvt | #118 |
| arterial thrombosis patients | #118 |
| 4118 | #118 |
| 2744 | #118 |
| patients extensive | #118 |
| autopsyconfirmed | #118 |
| incidence pulmonary embolism | #119 |
| compared warfarin | #119 |
| patients doac | #119 |
| compression stockings | #119 |
| humans leg | #119 |
| lactoferrin leukocyte | #120 |
| previous vte | #120 |
| acquired deficiency | #120 |
| rivaroxaban patients | #120 |
| mortality diseases | #120 |
| risk thromboembolism | #120 |
| dabigatran factor | #120 |
| thrombosis study | #120 |
| months follow | #120 |
| healthy humans | #120 |
| patients prostatic cancer | #121 |
| thrombocytopenia thrombosis | #121 |
| anti factor | #122 |
| fatal pulmonary embolism | #122 |
| studies venous | #122 |
| oral hormonal | #122 |
| patients 6 | #122 |
| placebo standard | #123 |
| early dynamics | #123 |
| factor xia | #123 |
| venous thromboembolism pregnancy | #123 |
| heparin hirudin | #123 |
| 100 patients | #123 |
| acute infection | #123 |
| heparin | #123 |
| minor bleeding | #123 |
| ft4 levels | #124 |
| treatment data | #124 |
| statin risk | #124 |
| thrombophilia pregnancy | #124 |
| atherogenic lipid profile | #124 |
| vte lmwh | #124 |
| association level | #124 |
| bayer | #125 |
| fibrinolysis inhibitor | #125 |
| peripheral arterial disease | #125 |
| thromboembolism recurrence | #125 |
| incidence thrombosis | #125 |
| puerperal disorders | #125 |
| nonsignificantly | #125 |
| intravenous heparin | #125 |
| elevated liver enzymes | #125 |
| treatment indication | #125 |
| diseases mortality | #125 |
| skin perfusion | #125 |
| distal dvt | #126 |
| upper extremity | #126 |
| doacs treatment | #126 |
| patients ventilation | #127 |
| patients permanent | #127 |
| thromboprophylaxis lmwh | #127 |
| marder | #127 |
| occurrence vte | #127 |
| performance scores | #127 |
| unacceptably | #127 |
| 50 age | #128 |
| prevention | #128 |
| development vte | #128 |
| treatment months | #128 |
| resistance apc | #128 |
| patients conventional therapy | #128 |
| direct factor | #128 |
| venous thromboembolism risk | #128 |
| elevated biomarkers | #129 |
| 060 | #129 |
| mortality cancer patients | #129 |
| ctrough | #129 |
| riete registry | #129 |
| 1041 | #129 |
| patients episode | #130 |
| day 10 | #130 |
| 220 | #130 |
| hospital discharge records | #130 |
| anticoagulants antithrombins | #130 |
| 194 patients | #130 |
| plaster cast | #130 |
| internists | #130 |
| pooled incidence | #131 |
| linear interpolation | #131 |
| 05 patients | #131 |
| long‐term clinical outcomes | #131 |
| tests specificity | #131 |
| obviating | #131 |
| hoc analysis | #132 |
| postpartum period women | #132 |
| hypocoagulability | #132 |
| rivaroxaban versus | #132 |
| direct inhibitors | #133 |
| 80 anticoagulants | #133 |
| started | #133 |
| enoxaparin treatment | #133 |
| cha2ds2vasc | #133 |
| fxa inhibitors | #133 |
| avidin | #133 |
| instituted | #134 |
| rco vwf | #134 |
| embolism acute | #134 |
| selectin levels | #134 |
| risk pad | #134 |
| pulmonary angiography patients | #134 |
| activator plasminogen | #135 |
| prevalence dvt | #135 |
| anticoagulant prophylaxis | #135 |
| bnp concentration | #135 |
| clinical prediction | #136 |
| east asian patients | #136 |
| 0056 | #136 |
| thrombotic syndrome | #136 |
| months anticoagulation | #136 |
| severe pph | #136 |
| apixaban edoxaban | #136 |
| followup patients | #136 |
| 2283 | #137 |
| phase 3 trials | #137 |
| 99 patients | #137 |
| point‐of‐care | #137 |
| sequential application | #137 |
| diagnostic work | #137 |
| factor prothrombin | #137 |
| acquired thrombophilia | #137 |
| studies mortality | #138 |
| enhanced factor | #138 |
| bleeding warfarin | #138 |
| national guidelines | #138 |
| antidote | #138 |
| intravascular coagulation dic | #138 |
| complete inhibition | #138 |
| 95 major bleeding | #139 |
| risk fatal | #139 |
| oral anticoagulant treatment | #139 |
| factor viii factor | #139 |
| reproducibility risk | #139 |
| 2465 | #139 |
| direct inhibitor | #139 |
| 3 weeks | #139 |
| patients comparison | #139 |
| 0114 | #140 |
| 80 cohort | #140 |
| human activated | #140 |
| 20 iu | #140 |
| ottawa | #140 |
| distal deep | #140 |
| dvt incidence | #140 |
| 12 95 | #140 |
| vwf rco | #140 |
| thromboembolic disorders | #141 |
| pharmacy records | #141 |
| antidotes | #141 |
| thrombin potential | #142 |
| carriership | #142 |
| ischaemic events | #143 |
| points 95 | #143 |
| jugular veins | #143 |
| active malignancy | #143 |
| escherichia humans | #143 |
| warfarin administration | #143 |
| treatment pulmonary | #143 |
| geneva | #143 |
| doac treatment | #144 |
| pregnancy female humans | #144 |
| fatal pulmonary | #144 |
| compared treatment | #144 |
| postoperative venous | #144 |
| topic practice patterns | #144 |
| management vte | #144 |
| dose rivaroxaban | #145 |
| referred patients | #145 |
| filters venous | #145 |
| patient populations | #145 |
| serial testing | #145 |
| thrombosis model | #145 |
| hyperthyroxinemia | #145 |
| months treatment | #146 |
| protein factor | #146 |
| death cancer patients | #146 |
| derived microvesicles | #146 |
| personal fees | #147 |
| tissue factor pathway | #147 |
| acute medical illness | #148 |
| intention treat | #148 |
| rebuttal | #148 |
| embolism diagnosis | #148 |
| long‐acting | #148 |
| antithrombotic drugs | #148 |
| 2076 | #148 |
| partial thromboplastin | #148 |
| 10 years patients | #148 |
| individual patient data | #149 |
| vte hospitalization | #149 |
| procoagulant | #149 |
| relevant publications | #149 |
| thrombocyte | #149 |
| risk subgroups | #149 |
| diagnostic score | #149 |
| 0·45 | #149 |
| dimer level | #150 |
| humans injections | #151 |
| enoxaparin unfractionated heparin | #151 |
| coagulation dic | #151 |
| additional imaging | #151 |
| longterm treatment | #152 |
| bleeding patients | #152 |
| patient eligibility | #152 |
| continuous venovenous | #152 |
| patients primary outcome | #152 |
| hypercoagulable state | #153 |
| extracorporeal circuit | #153 |
| point systems | #153 |
| thrombosis prevention | #153 |
| cardiopulmonary bypass surgery | #153 |
| direct thrombin | #154 |
| angioplasty patients | #154 |
| thrombosis factor | #154 |
| bleeding scores | #154 |
| active cancer | #154 |
| activity mortality | #154 |
| dimer levels | #154 |
| warfarin apixaban | #155 |
| tomography patients | #155 |
| thromboembolic event | #155 |
| drug factor | #155 |
| fiia | #155 |
| states venous | #155 |
| curve sensitivity | #155 |
| daily oral | #156 |
| enoxaparin dose | #156 |
| patients gastrointestinal | #156 |
| fvl | #156 |
| stockings | #156 |
| coagulant activity | #156 |
| 09 | #156 |
| vte treatment | #156 |
| recurrent symptoms | #156 |
| prophylaxis patients | #157 |
| hemodynamically | #157 |
| cross‐sectional survey | #157 |
| increased thrombin | #157 |
| 97 | #158 |
| months chemotherapy | #158 |
| dfl | #158 |
| duration anticoagulation | #158 |
| underlying malignancy | #158 |
| 2126 | #158 |
| increased risk thrombosis | #159 |
| adjusted relative risk | #159 |
| plasma dimer | #160 |
| antithrombotic efficacy | #160 |
| 120 minutes | #160 |
| schering | #160 |
| 145 patients | #160 |
| thrombotic disorders | #160 |
| guidelines prevention | #160 |
| children fh | #160 |
| prophylactics | #161 |
| pvo | #161 |
| antagonists patients | #161 |
| incidence vte | #162 |
| lysine analogues | #162 |
| patients imaging | #162 |
| women time | #162 |
| 2206 | #162 |
| 198 patients | #163 |
| imaging test | #163 |
| rates vte | #163 |
| coagulation blood | #163 |
| lmwh therapy | #163 |
| venous thrombus | #163 |
| increased plasma levels | #163 |
| strain gauge | #163 |
| factors bleeding | #163 |
| inborn humans | #164 |
| age comorbidity | #164 |
| observer variability | #164 |
| 028 | #164 |
| justified | #164 |
| relatives patients | #165 |
| patients enoxaparin | #165 |
| mutation factor | #165 |
| subhazard | #165 |
| viii factor | #166 |
| strategies patients | #166 |
| pravastatin therapy | #166 |
| management venous thromboembolism | #166 |
| stockings compression | #166 |
| phlebography | #166 |
| microvascular thrombosis | #166 |
| recurrent thrombosis | #167 |
| thrombin venous | #167 |
| ankle brachial abi | #167 |
| 3658 | #167 |
| treatment 3 months | #168 |
| current clinical practice | #168 |
| syndrome pts | #168 |
| recurrent acute | #168 |
| double heterozygosity | #168 |
| warfarin | #168 |
| cstatistics | #168 |
| cvcs | #168 |
| postthrombotic syndrome pts | #169 |
| risk profile | #169 |
| therapeutic range | #169 |
| 3 12 | #169 |
| fold increased | #169 |
| patients infections | #169 |
| preexistent | #169 |
| interobserver agreement | #170 |
| postoperative blood loss | #170 |
| thrombosis cancer | #170 |
| heavy menstrual bleeding | #170 |
| cart patients | #170 |
| aged algorithms | #171 |
| 57 years | #171 |
| adamts‐13 | #171 |
| venous thrombotic events | #171 |
| recombinant factor | #171 |
| clinical trials patients | #172 |
| antifibrinolytic | #172 |
| vaginal bleeding | #172 |
| lmw heparin | #172 |
| risk factors patients | #172 |
| pulmonology | #172 |
| patients blood transfusion | #172 |
| hospitalized medical patients | #173 |
| pulmonary | #173 |
| bleeds | #173 |
| inr | #173 |
| clinically bleeding | #174 |
| laboratory monitoring | #174 |
| bleeding tendency | #174 |
| patients initial | #174 |
| arterial occlusions | #174 |
| vte common | #175 |
| data control | #175 |
| reocclusion | #175 |
| arterial venous | #175 |
| fragment 1 | #175 |
| mitsubishi | #177 |
| picotamide | #177 |
| prothrombin | #177 |
| aspirin ticlopidine | #178 |
| short‐ | #178 |
| intention analysis | #178 |
| hyperthyroidism hypothyroidism | #178 |
| 122 | #178 |
| vte event | #179 |
| baseline day | #179 |
| noninferior | #179 |
| oral female humans | #179 |
| concomitance | #179 |
| patients deficiency | #180 |
| referral bias | #180 |
| thromboplastin time | #180 |
| ventilation perfusion | #180 |
| isth | #180 |
| additional risk factors | #180 |
| aged partial | #181 |
| antithrombin | #182 |
| painkillers | #182 |
| testing patients | #182 |
| acute episode | #182 |
| patients major | #183 |
| biological variation | #183 |
| 2–4 | #183 |
| hyperhomocysteinemic | #183 |
| prognosis pulmonary | #184 |
| thromboinflammation | #184 |
| subsequent diagnosis | #184 |
| pregnancy vte | #184 |
| 4150 | #184 |
| n110 | #184 |
| incidental | #184 |
| coagulation factors | #184 |
| antithrombin iii atiii | #184 |
| risk bleeding | #184 |
| treat analysis | #184 |
| vte age | #185 |
| deficient patients | #185 |
| live birth rate | #186 |
| hemostatic effects | #186 |
| symptomatic | #186 |
| anticoagulated | #186 |
| patients thromboprophylaxis | #186 |
| brain natriuretic | #186 |
| patients intensive units | #186 |
| studies heparin | #186 |
| safety apixaban | #187 |
| patients haemophilia | #187 |
| antifibrinolytic agents | #187 |
| cutoff level | #187 |
| risk composite | #187 |
| absolute rate | #188 |
| ratio inr | #188 |
| 926 | #188 |
| prevalence cancer | #188 |
| humans international | #188 |
| spontaneous rupture | #188 |
| doacs vkas | #188 |
| willebrand factor antigen | #189 |
| patients netherlands | #189 |
| blood loss patients | #189 |
| viia female | #189 |
| fibrinolysis | #189 |
| clinical validity | #189 |
| riete | #189 |
| heparin administration | #189 |
| 64slice | #189 |
| current views | #190 |
| ischemic event | #190 |
| ccus | #190 |
| anticoagulant drugs | #190 |
| thrombosis patients | #190 |
| attending physicians | #191 |
| venous outflow | #191 |
| score patients | #191 |
| acute thrombosis | #191 |
| gogh | #191 |
| 07 | #191 |
| stroke systemic | #192 |
| 058 | #192 |
| 1495 | #192 |
| coagulation assays | #193 |
| endothelial cell activation | #193 |
| 070 | #194 |
| anticoagulation | #194 |
| prothrombin activation | #194 |
| heparin patients | #194 |
| blood coagulation | #194 |
| 65 months | #195 |
| risk major | #195 |
| target range | #195 |
| antixa levels | #195 |
| antagonist treatment | #195 |
| recurrent ischemic events | #195 |
| abnormal test | #196 |
| coagulation status | #196 |
| 29 95 | #196 |
| complications cardiovascular | #196 |
| sew2871 | #198 |
| ate | #198 |
| vwf adamts13 | #198 |
| difference treatment | #198 |
| treatment groups patients | #198 |
| vii rfviia | #198 |
| coagulation monitoring | #199 |
| patient diagnosis | #199 |
| cachectin | #199 |
| incidence cardiovascular events | #200 |
| screening patients | #200 |
| patients 12 months | #200 |
| obese controls | #200 |
| patients abnormal | #201 |
| vte incidence | #201 |
| validation sets | #201 |
| thromboembolic disease | #201 |
| thrombin factor | #201 |
| peritoneovenous | #202 |
| arterial thrombosis | #202 |
| 17 95 | #202 |
| johnson | #202 |
| worldwide survey | #203 |
| induced activation | #203 |
| heparin dose | #203 |
| invitees | #203 |
| symptomatic pad | #203 |
| levonorgestrel | #204 |
| antithrombotic agents | #204 |
| extended thromboprophylaxis | #205 |
| period time | #205 |
| low incidence | #205 |
| 0 95 | #205 |
| stroke systemic embolism | #205 |
| thrombophilia risk | #205 |
| fgt | #206 |
| varese | #206 |
| venous ultrasonography | #206 |
| data synthesis | #206 |
| patients anticoagulant therapy | #206 |
| objectively | #207 |
| platelet activation patients | #207 |
| systematic review studies | #207 |
| death female humans | #207 |
| algorithms anticoagulants | #207 |
| 06 | #207 |
| desogestrel | #207 |
| fviii | #207 |
| cardiologist | #207 |
| methods consecutive | #207 |
| imt patients | #207 |
| bleeding compared | #208 |
| patients hypothyroidism | #208 |
| thrombocythaemia | #208 |
| deficiency risk | #209 |
| free protein | #209 |
| hirudins | #210 |
| women frequency | #210 |
| antixa activity | #210 |
| tgt | #210 |
| toxaemia | #211 |
| systemic embolism patients | #211 |
| stocking | #211 |
| ioxaglate | #211 |
| atrial fibrillation study | #212 |
| anticoagulation management | #212 |
| plasminogen activator activity | #213 |
| heparitin sulfate | #213 |
| correct interpretation | #214 |
| dabigatran dose | #214 |
| topic practice | #214 |
| standard duration | #215 |
| studies rivaroxaban | #215 |
| thrombin inhibition | #215 |
| current developments | #215 |
| factors vte | #215 |
| deamino | #216 |
| betatg | #216 |
| warfarin stroke | #216 |
| community hospital | #216 |
| duplex venous | #216 |
| obviates | #217 |
| studies difference | #217 |
| mildest | #217 |
| diagnostic algorithm | #217 |
| undergoing total | #217 |
| conclusive evidence | #218 |
| plasminogen activator inhibitor | #218 |
| npv 100 | #218 |
| cstatistic | #218 |
| g20210a | #218 |
| cancer | #219 |
| deamino arginine | #219 |
| 077 95 | #219 |
| patients cart | #219 |
| data extraction | #220 |
| hip replacement surgery | #220 |
| viii female | #220 |
| techniques female | #220 |
| vii factor | #220 |
| heparin humans | #221 |
| postoperative vte | #221 |
| healthy human subjects | #221 |
| preventive measures | #221 |
| hmvec | #221 |
| apc resistance | #222 |
| proximally | #222 |
| vte events | #222 |
| 1541 | #223 |
| 1 january | #223 |
| pulmonologists | #223 |
| substantial proportion | #223 |
| engl | #223 |
| topic factor | #224 |
| protein pathway | #224 |
| subsequent cancer | #224 |
| thromboendarterectomy | #224 |
| thrombosis warfarin | #225 |
| neoplasms prospective | #225 |
| balloon coronary anticoagulants | #225 |
| kruskalwallis | #225 |
| org | #225 |
| inr monitoring | #226 |
| vascular events patients | #226 |
| 0·67 | #226 |
| extremity amputation | #226 |
| 16 95 | #226 |
| tests diagnosis | #227 |
| acute medical | #227 |
| 35 ± | #227 |
| haemostasis | #227 |
| mild hyperhomocysteinemia | #228 |
| ipe | #228 |
| residual thrombus | #229 |
| cgp | #229 |
| dalteparin | #229 |
| scant | #229 |
| 037 | #230 |
| advocated | #230 |
| thiazoles | #231 |
| major orthopaedic surgery | #231 |
| urosepsis | #231 |
| ft4 | #231 |
| habitual abortion | #231 |
| resource utilisation | #231 |
| equinox | #231 |
| 6 studies | #231 |
| patients discontinuation | #231 |
| severe preeclampsia | #231 |
| aspirin dipyridamole | #232 |
| patients warfarin | #232 |
| humans netherlands | #233 |
| cancer prevalence | #233 |
| anticoagulant effects | #233 |
| endogenous thrombin potential | #233 |
| dimer | #233 |
| recurrence risk factors | #233 |
| surgical embolectomy | #233 |
| effective alternative | #234 |
| prothrombotic state | #235 |
| graduated compression | #235 |
| doac | #235 |
| humans meta | #236 |
| venous thromboembolic events | #236 |
| brain natriuretic peptide | #236 |
| oral anticoagulants | #237 |
| treatment continuation | #237 |
| myocardial infarction 95 | #237 |
| patients vkas | #238 |
| 009 | #238 |
| 6500 | #238 |
| predictive tests | #238 |
| crossover study | #239 |
| factor tnf | #239 |
| rational approach | #239 |
| anticoagulants aspirin | #239 |
| factor viii fviii | #239 |
| arterial venous thrombosis | #240 |
| patients initial treatment | #240 |
| aspirin heparin | #241 |
| 045 | #241 |
| hip knee arthroplasty | #241 |
| time therapeutic range | #242 |
| bleeding incidence | #242 |
| prothrombin fragment | #243 |
| patients intermittent claudication | #243 |
| pivotal trials | #243 |
| iohexol | #244 |
| n89 | #245 |
| vte risk factors | #245 |
| casecontrol | #246 |
| children neonates | #246 |
| thrombogenesis | #246 |
| vte cases | #246 |
| lipoproteina levels | #247 |
| 23 95 | #247 |
| antithrombotic | #247 |
| warfarin aged | #247 |
| treatment compared | #248 |
| committees | #248 |
| patients solid tumours | #248 |
| coronary anticoagulants | #248 |
| anti activity | #248 |
| multiple comorbidities | #249 |
| diagnostic models | #249 |
| bleeding rates | #249 |
| score risk | #249 |
| fv leiden | #250 |
| protein risk | #250 |
| ischemic strokes | #250 |
| ioxaglic | #250 |
| finalized | #251 |
| patients contraindications | #251 |
| microthrombosis | #251 |
| 8595 | #251 |
| simplification | #252 |
| vkas doacs | #252 |
| somit | #252 |
| thrombin thrombosis | #253 |
| incidence | #253 |
| treatment duration | #254 |
| agents anticoagulants | #254 |
| fibrinolytic activity | #255 |
| palga | #255 |
| activation humans | #256 |
| haul | #256 |
| medea | #256 |
| activity assay | #257 |
| clinical utility | #257 |
| q24h | #257 |
| bleeding risk | #257 |
| cost‐effectiveness | #257 |
| continuous intravenous | #257 |
| fibrin degradation | #258 |
| patient subgroups | #258 |
| ctpa | #258 |
| unpublished data | #259 |
| 30 50 | #259 |
| sspe | #260 |
| dvt risk | #260 |
| heparin dosing | #261 |
| toxicosis | #261 |
| noncarriers | #261 |
| thrombus size | #261 |
| patients hospitalization | #262 |
| optimal duration | #263 |
| risk pulmonary | #263 |
| blind study | #264 |
| graft type | #265 |
| 400 patients | #266 |
| pbac | #267 |
| einstein | #267 |
| endotoxaemia | #268 |
| statins risk | #268 |
| versus aspirin | #269 |
| lysis time | #269 |
| randomised cross | #269 |
| relation time | #269 |
| malignancy patients | #269 |
| propeptide | #269 |
| protein patients | #270 |
| exclusion | #270 |
| single test | #270 |
| discontinuing | #270 |
| hormonal replacement therapy | #271 |
| protein apc | #271 |
| platelet serotonin | #271 |
| thrombosis inflammation | #271 |
| 3·0 | #271 |
| orthopaedic patients | #271 |
| bleeding patient | #272 |
| vte recurrence | #272 |
| clopidogrel ticlopidine | #272 |
| groups levels | #272 |
| patients combination | #272 |
| efficacy analysis | #273 |
| ankle brachial | #273 |
| risk levels | #274 |
| prevalence pad | #274 |
| cleavage sites | #274 |
| months 12 | #274 |
| performance score | #275 |
| international normalized | #275 |
| parenteral nutrition patients | #275 |
| fourth quartile | #276 |
| antithrombotic agent | #276 |
| smoking hypertension | #277 |
| time aptt | #277 |
| imaging sensitivity | #278 |
| normalized ratio | #278 |
| dose reduction | #278 |
| rco | #279 |
| blood test | #279 |
| aptt | #279 |
| intracranial hemorrhage patients | #280 |
| hospitalized medical | #280 |
| propositi | #280 |
| obviate | #280 |
| exclusion criteria | #280 |
| partial thromboplastin time | #280 |
| patients presence | #281 |
| thromboplastin | #282 |
| diagnostic test | #282 |
| thyroid diseases | #283 |
| diagnostic sensitivity | #283 |
| neutrophil degranulation | #283 |
| puerperal | #283 |
| presentation patients | #283 |
| favor | #284 |
| departments | #284 |
| animals anticoagulants | #284 |
| test characteristics | #284 |
| outpatient treatment | #284 |
| noninferiority margin | #284 |
| major orthopaedic | #285 |
| gentamicin treatment | #286 |
| plasma bnp | #286 |
| patients apixaban | #286 |
| 2630 | #286 |
| clinically | #287 |
| subdistribution | #287 |
| patients pancreatic cancer | #287 |
| disseminated intravascular | #287 |
| levels measured | #287 |
| premature atherosclerosis | #288 |
| oral combined | #288 |
| md patients | #288 |
| 227 | #288 |
| clot lysis | #289 |
| vte women | #289 |
| vte rates | #289 |
| cvt patients | #289 |
| substantiation | #289 |
| n59 | #290 |
| thrombin time | #290 |
| 0·50 | #290 |
| 016 | #291 |
| carriers mutation | #291 |
| extracted data | #291 |
| oral contraceptives | #291 |
| current clinical | #291 |
| 2 studies | #292 |
| willebrand disease vwd | #292 |
| 1603 | #292 |
| activator inhibitor | #292 |
| 1000 personyears | #293 |
| plasmin activity | #293 |
| patients dabigatran | #293 |
| adverse outcome patients | #293 |
| pentasaccharide | #293 |
| cardiac troponin ctnt | #294 |
| patients rivaroxaban | #294 |
| lower extremities | #294 |
| tissuetype plasminogen activator | #294 |
| scenario analysis | #295 |
| extremity dvt | #295 |
| 1025 | #295 |
| peripheral vascular | #296 |
| coagulation factor viii | #296 |
| classified | #296 |
| observer agreement | #297 |
| routine monitoring | #297 |
| recurrent miscarriage | #298 |
| specificity npv | #298 |
| episode patients | #298 |
| thrombocytes | #298 |
| patients inr | #299 |
| inferiority | #300 |
| heparitin | #301 |
| 041 | #301 |
| thromboglobulin | #302 |
| subclinical thyroid dysfunction | #302 |
| aged neoplasms | #302 |
| 155 patients | #302 |
| toxemia | #302 |
| 1214 | #304 |
| absolute difference | #304 |
| rivaroxaban dabigatran | #305 |
| prophylactic administration | #306 |
| medline embase | #306 |
| chimpanzees | #307 |
| noninvasive testing | #308 |
| complex concentrate | #309 |
| thrombotic | #310 |
| surgery day | #310 |
| vte pregnancy | #310 |
| hematologic pregnancy | #310 |
| 105 patients | #311 |
| percentage points | #311 |
| patients 100 | #311 |
| clinical presentation | #311 |
| antithrombins blood | #311 |
| leg male | #312 |
| 598 | #312 |
| obesity risk factor | #313 |
| hereditary thrombophilia | #313 |
| negative reactions | #313 |
| vte 95 | #313 |
| diagnosis | #314 |
| cardiologists | #315 |
| puerperium | #315 |
| postpartum haemorrhage | #315 |
| heparin aspirin | #315 |
| funding | #315 |
| therapeutic dose | #316 |
| apixaban versus | #316 |
| patients followup | #317 |
| adjudicators | #317 |
| deciding | #318 |
| 0·92 | #318 |
| failure rates | #319 |
| decision model | #319 |
| safety outcomes | #319 |
| influenza infections | #320 |
| patients pregnancy | #320 |
| catheter thrombosis | #320 |
| combined administration | #320 |
| 1731 | #320 |
| bnp levels | #320 |
| ventricular dysfunction patients | #321 |
| additional data | #322 |
| patients noacs | #322 |
| intermediate phenotype | #322 |
| difference risk | #322 |
| peripheral arterial | #324 |
| glaxosmithkline | #324 |
| inrs | #324 |
| convincing evidence | #325 |
| mortality odds ratio | #325 |
| blood coagulation factor | #326 |
| 122 patients | #326 |
| mechanical heart valves | #326 |
| pulmonary embolus | #326 |
| surgery trauma | #327 |
| clinical | #327 |
| association vte | #329 |
| vitamin administration | #331 |
| pregnancy outcome women | #331 |
| thrombotic event | #331 |
| incidence bleeding | #331 |
| new oral | #332 |
| analysis trials | #333 |
| embase databases | #333 |
| 95 percent | #333 |
| n69 | #333 |
| 95 confidence limits | #334 |
| incidences | #334 |
| minor effects | #334 |
| complicate | #334 |
| rationale design | #335 |
| fibrillation benzimidazoles | #335 |
| patients healthy volunteers | #335 |
| pulmonary perfusion | #336 |
| central venous catheter | #336 |
| septicaemia | #336 |
| plethysmographic | #337 |
| 2 points | #337 |
| recurrent | #337 |
| total hip replacement | #337 |
| 035 | #337 |
| 065 | #337 |
| aged netherlands | #338 |
| coagulation abnormalities | #338 |
| outpatient management | #338 |
| fatal bleeding | #338 |
| prospective clinical study | #339 |
| noacs warfarin | #339 |
| placebo trials | #339 |
| antithrombotic effects | #340 |
| patients 12 | #340 |
| 024 | #340 |
| activatable | #341 |
| coagulation markers | #341 |
| 217 | #341 |
| noac patients | #342 |
| knee arthroscopy | #342 |
| patients covid19 infection | #344 |
| pretest | #344 |
| vte prevention | #345 |
| rfviia | #345 |
| splanchnic vein thrombosis | #345 |
| antithrombotic strategies | #345 |
| diagnosis vte | #346 |
| embolisms | #346 |
| 073 | #347 |
| patients thrombosis | #347 |
| activated protein resistance | #347 |
| 044 | #348 |
| cochrane central | #348 |
| 2575 | #349 |
| bsf | #349 |
| chads2 | #349 |
| randomized studies | #350 |
| tafia | #350 |
| brain predictive | #350 |
| trousseau | #350 |
| 013 | #351 |
| versus warfarin | #351 |
| factor viii | #351 |
| selection bias | #352 |
| dermatan sulphate | #352 |
| factor activation | #352 |
| anticoagulants noacs | #352 |
| relative efficacy | #353 |
| oral anticoagulant therapy | #353 |
| vein | #353 |
| 1590 | #353 |
| 5075 | #353 |
| aged pulmonary | #354 |
| international normalized ratio | #354 |
| patients gp | #355 |
| studies diagnostic accuracy | #355 |
| protein deficiency | #356 |
| tests prospective studies | #357 |
| intestinal microbiome | #357 |
| categorised | #357 |
| post hoc | #357 |
| 127 patients | #358 |
| pilots | #360 |
| sucra | #360 |
| intermittent claudication | #361 |
| treatment risk | #362 |
| consensus agreement | #362 |
| anticoagulation patients | #364 |
| humans risk | #365 |
| conventional therapy | #365 |
| topic female | #366 |
| bleeding rate | #366 |
| prediction models | #367 |
| time recurrence | #368 |
| infrainguinal | #368 |
| patients 3 | #368 |
| thrombin inhibitor | #369 |
| 6week | #370 |
| patients acl reconstruction | #370 |
| influenza infection | #370 |
| venous stasis | #371 |
| endotoxin infusion | #371 |
| 055 | #372 |
| 803 | #372 |
| knee surgery | #373 |
| aprotinin blood | #373 |
| clinical suspicion | #373 |
| recombinant activated | #373 |
| patients svt | #373 |
| patients scores | #374 |
| human cytomegalovirus infection | #374 |
| helical computed tomography | #374 |
| subcutaneous | #375 |
| hmb | #375 |
| lyg | #377 |
| subclinical hyperthyroidism | #378 |
| contraceptives oral | #380 |
| stroke venous | #380 |
| tafi | #381 |
| ethinyloestradiol | #381 |
| antitnf | #382 |
| prefilter | #383 |
| thromboembolic complications | #384 |
| reassessed | #384 |
| standardized questionnaire | #384 |
| 0·8 | #384 |
| multivariate regression analysis | #384 |
| systemic activation | #385 |
| alpha2m | #385 |
| surrogate outcome | #386 |
| bleeding events | #386 |
| conference proceedings | #386 |
| cumulative incidences | #387 |
| antithrombins | #387 |
| sensitivity npv | #387 |
| major orthopedic | #388 |
| delegates | #388 |
| referred | #389 |
| safety rivaroxaban | #389 |
| 880 | #389 |
| systemic embolism | #389 |
| apixaban warfarin | #390 |
| vitt | #390 |
| tinzaparin | #390 |
| increased bleeding | #391 |
| comparison patients | #391 |
| biosis | #391 |
| abi | #391 |
| drug prescription | #391 |
| postop | #391 |
| time presentation | #392 |
| patients chest | #392 |
| topic female humans | #392 |
| factors thrombosis | #393 |
| kappa values | #393 |
| injections intravenous | #394 |
| clinical score | #394 |
| background patients | #394 |
| pulmonary emboli | #394 |
| 007 | #395 |
| popliteal | #396 |
| bleeding event | #396 |
| 95 12 | #396 |
| factors factor | #397 |
| 665 | #397 |
| embolic events | #397 |
| hirudins humans | #397 |
| replacement surgery | #397 |
| risk score patients | #399 |
| risk factors asthma | #400 |
| heparin induced | #400 |
| echography | #400 |
| patients risk | #400 |
| hemostatic parameters | #401 |
| fibrinolytic agents | #402 |
| dabigatran | #403 |
| controversy | #403 |
| increased risk vte | #403 |
| massive pulmonary embolism | #405 |
| treatment patient | #406 |
| 075 | #406 |
| 2215 | #406 |
| thrombolytic agents | #406 |
| oral anticoagulant | #408 |
| factor levels | #408 |
| biologic effects | #410 |
| fviii levels | #411 |
| patients assigned | #411 |
| noacs patients | #411 |
| safety combination | #411 |
| transfusion patients | #412 |
| major risk factor | #412 |
| 20 microg | #412 |
| maastricht | #414 |
| euthyroidism | #414 |
| coagulation patients | #414 |
| aged odds | #415 |
| hypocortisolism | #415 |
| xii | #415 |
| intravascular coagulation | #416 |
| dose heparin | #416 |
| pai1 levels | #416 |
| deserve | #416 |
| 95 10 | #417 |
| comparable | #417 |
| data risk | #417 |
| pretest probability | #418 |
| 95 | #418 |
| carotid femoral | #418 |
| 269 | #419 |
| risk factors thrombosis | #419 |
| dermatan | #419 |
| xia | #420 |
| ototoxicity | #420 |
| fibrillation risk | #421 |
| 2850 | #422 |
| fibrillation clinical | #422 |
| 1989 | #422 |
| tests radiography | #422 |
| fibrinolysin | #423 |
| fviia | #424 |
| subanalysis | #424 |
| prevalence patients | #425 |
| adjunct | #426 |
| cancer cohort | #426 |
| randomised double | #426 |
| fii | #426 |
| consecutive | #427 |
| activated factor | #427 |
| plg | #428 |
| daily practice | #428 |
| excessive bleeding | #428 |
| conferences | #428 |
| daily clinical practice | #429 |
| undergoing elective | #429 |
| patients testing | #429 |
| prolactin levels | #429 |
| idiopathic myelofibrosis | #429 |
| 1904 | #430 |
| bleeding complications | #431 |
| heparinoids | #431 |
| rule | #431 |
| 04 | #432 |
| outpatients | #433 |
| incidence length | #433 |
| patients systematic review | #434 |
| ncb | #434 |
| blood cultures | #436 |
| firstdegree relatives patients | #436 |
| 059 | #437 |
| bolus injection | #437 |
| proven | #439 |
| composite point | #439 |
| prostatic cancer | #439 |
| dose adjustment | #439 |
| women compared | #439 |
| concomitant medications | #441 |
| highrisk populations | #441 |
| rate vte | #442 |
| 074 | #442 |
| –control study | #444 |
| standard therapies | #444 |
| prespecified | #445 |
| patients atrial fibrillation | #446 |
| febrile patients | #446 |
| female fibrinolytic | #447 |
| patients parenteral nutrition | #449 |
| 58 | #449 |
| hellp | #449 |
| utrecht | #449 |
| 3 12 months | #450 |
| prevalence distribution | #450 |
| category | #451 |
| stigmatisation | #451 |
| pipecolic | #452 |
| aspirin risk | #453 |
| fatal disease | #453 |
| thrombin generation | #453 |
| noninvasive tests | #453 |
| portal blood | #454 |
| factor xii | #454 |
| 30 40 | #454 |
| placebo day | #454 |
| 12week | #455 |
| 026 | #455 |
| microthrombi | #455 |
| fviii vwf | #456 |
| dichotomized | #456 |
| onwards | #457 |
| squibb | #457 |
| dicumarol | #457 |
| hazard ratio 95 | #458 |
| anti levels | #458 |
| iii complexes | #458 |
| svt | #460 |
| plasma lipoprotein | #460 |
| recommend | #460 |
| gastrointestinal cancer | #461 |
| factor fxa | #461 |
| hip arthroplasty replacement | #462 |
| expert consensus document | #462 |
| curve biomarkers | #462 |
| guidelines patients | #463 |
| haemolysis | #463 |
| patients values | #464 |
| studies ultrasonography | #464 |
| gp iib | #464 |
| month follow | #465 |
| diabetes stroke | #466 |
| cancerassociated thrombosis | #466 |
| accuracy detection | #467 |
| thrombin formation | #467 |
| prophylaxis | #468 |
| patients nsaids | #468 |
| intimamedia thickness | #468 |
| teaching hospitals | #469 |
| eligible studies | #469 |
| bmi≥30 | #469 |
| 077 | #470 |
| test probability | #470 |
| hemihepatectomy | #470 |
| roc analysis | #470 |
| inr patients | #470 |
| placebo recipients | #471 |
| hypercoagulability | #472 |
| case control study | #472 |
| prophylactic anticoagulation | #472 |
| cardiovascular risk assessment | #473 |
| thrombophilia testing | #474 |
| patients heparin | #475 |
| plethysmograph | #475 |
| heterozygote humans | #475 |
| endotoxemia | #475 |
| intermittent pneumatic | #475 |
| 15 95 | #475 |
| atria | #477 |
| patients score | #479 |
| 08 | #479 |
| haemophiliacs | #479 |
| versus standard | #480 |
| acutely | #481 |
| thrombosis cvt | #481 |
| hit patients | #481 |
| transportability | #482 |
| advisory | #482 |
| 1162 | #482 |
| postoperative blood | #482 |
| thrombin inhibitors | #483 |
| events mortality | #484 |
| diagnostic efficacy | #485 |
| patients hematologic malignancies | #485 |
| awaited | #486 |
| composite scores | #487 |
| secondary prophylaxis | #487 |
| silent | #488 |
| travel | #488 |
| activity patients | #489 |
| 98 | #490 |
| blinded | #491 |
| treatment period | #493 |
| p00007 | #493 |
| hemophilic | #493 |
| residual risk | #493 |
| pan troglodytes | #493 |
| new therapy | #493 |
| vcf | #494 |
| activated protein | #495 |
| dose oral | #496 |
| heterozygote | #496 |
| favour | #496 |
| replacement hip arthroplasty | #496 |
| 271 | #497 |
| topic risk factors | #497 |
| blockages | #498 |
| risk factors stroke | #498 |
| discriminative ability | #498 |
| willebrand disease | #498 |
| hip knee | #501 |
| nri | #502 |
| ptp | #502 |
| deficiencies | #503 |
| ft4 tsh | #503 |
| subcategories | #503 |
| rapid decrease | #504 |
| patients referred | #505 |
| complications pulmonary | #505 |
| nondiagnostic | #505 |
| 1107 | #505 |
| net clinical | #506 |
| 310 | #506 |
| nonionic | #507 |
| oftentimes | #507 |
| day surgery | #507 |
| inhibitors rivaroxaban | #508 |
| coagulation tests | #509 |
| contraceptives | #509 |
| aminocaproates | #509 |
| 13 95 | #509 |
| guidelines diagnosis | #509 |
| thrombosis animals | #510 |
| degradation products | #510 |
| new oral anticoagulants | #510 |
| angiography patients | #510 |
| viii fviii | #511 |
| 019 | #512 |
| epiphenomenon | #512 |
| serial | #513 |
| 056 | #514 |
| interim analysis | #514 |
| highintensity | #514 |
| daycare | #515 |
| safety | #516 |
| crcl | #517 |
| thrombotic diseases | #518 |
| protein antithrombin | #518 |
| bleeding outcomes | #518 |
| thrombophilia thrombosis | #518 |
| sensitivity diagnosis | #518 |
| treatment cancer patients | #519 |
| groups treatment | #519 |
| study sensitivity | #520 |
| 8090 | #521 |
| 1599 | #521 |
| duration intensity | #521 |
| warfarin therapy | #524 |
| fixed doses | #525 |
| general practitioner | #525 |
| 062 | #527 |
| cancer age | #528 |
| cindices | #528 |
| convincing | #529 |
| 051 | #529 |
| 378 | #529 |
| 923 | #529 |
| health female | #530 |
| fatal | #530 |
| medically patients | #531 |
| humans postoperative | #531 |
| thrombosis hemostasis | #531 |
| betaalanine | #531 |
| intensive units icu | #532 |
| 068 | #532 |
| thrombosis risk | #532 |
| ≥50 years | #532 |
| factor thrombin | #534 |
| therapy cancer | #534 |
| 730 | #536 |
| factor pathway | #537 |
| 449 | #538 |
| patients idiopathic | #538 |
| humans neoplasms | #538 |
| ddavp | #539 |
| cbo | #539 |
| comprehensive search | #539 |
| concise | #539 |
| clinical review | #540 |
| diagnostic accuracy studies | #540 |
| diagnosis acute | #540 |
| conventional treatment | #543 |
| vascular obstruction | #543 |
| thrombotic risk | #543 |
| 234 | #543 |
| patients eligible | #543 |
| bleeding episodes | #543 |
| coagulative | #544 |
| jak2 mutation | #544 |
| 00 | #544 |
| pad abi | #544 |
| v617f | #545 |
| prospective cohort study | #545 |
| hellp syndrome | #545 |
| perc | #545 |
| association statin | #546 |
| screening strategies | #546 |
| bureau | #547 |
| prothrombin complex | #547 |
| primary | #548 |
| adequate | #549 |
| overt | #549 |
| 95 difference | #549 |
| platelet inhibitors | #550 |
| percent patients | #550 |
| conduction anesthesia | #550 |
| cancer type | #550 |
| 1103 | #550 |
| reviewers | #550 |
| management bleeding | #552 |
| amsterdam | #552 |
| careful | #552 |
| 500 patients | #552 |
| day patients | #552 |
| studies sensitivity | #552 |
| femoral arteries | #553 |
| general population patients | #554 |
| ttr | #556 |
| humans infusions | #557 |
| vivo treatment | #558 |
| factor vii | #558 |
| 66 patients | #558 |
| orthopedic surgery | #559 |
| bleeding time | #559 |
| limulus | #561 |
| board directors | #563 |
| female humans tests | #563 |
| patients transfusion | #563 |
| risk development | #563 |
| appears | #564 |
| hip replacement | #564 |
| anamnesis | #564 |
| hyperfibrinolysis | #565 |
| increasing risk | #565 |
| solid tumours | #566 |
| withholding | #566 |
| cardiac troponins | #566 |
| n46 | #568 |
| roc curves | #568 |
| patients 2 years | #568 |
| levothyroxine | #571 |
| alpha1antitrypsin | #571 |
| aggravation | #572 |
| ctnt | #573 |
| revascularization procedures | #574 |
| cutoff point | #574 |
| menstrual bleeding | #574 |
| subcutaneously | #575 |
| major bleedings | #575 |
| women proportion | #575 |
| progression cancer | #577 |
| patients vka | #578 |
| endothelial barrier | #578 |
| thiophenes | #579 |
| endotoxin | #579 |
| pharma | #579 |
| 99 | #580 |
| diagnostic tools | #580 |
| notice | #580 |
| cancer thrombosis | #581 |
| subgroups patients | #583 |
| dummy | #584 |
| unselected patients | #584 |
| coagulation disorders | #585 |
| 094 | #585 |
| chondroitin sulfates | #586 |
| major orthopedic surgery | #588 |
| feasibility safety | #588 |
| helminth proteins | #589 |
| beta alanine | #590 |
| malignancy | #590 |
| healthy human | #590 |
| thrombophilias | #590 |
| reversal agents | #590 |
| massive pulmonary | #592 |
| conventional management | #592 |
| doppler ultrasound | #592 |
| bmi30 | #594 |
| factor fv | #595 |
| replacement knee | #597 |
| patency rates | #597 |
| severe bleeding | #597 |
| major hemorrhage | #597 |
| ldf | #597 |
| infusions intravenous | #598 |
| analysis topic | #599 |
| loss surgical | #600 |
| tests sensitivity | #600 |
| 046 | #601 |
| association patients | #602 |
| vwd | #603 |
| comorbid conditions | #604 |
| events occurred | #604 |
| clinical characteristics patients | #604 |
| diagnostic studies | #606 |
| patients antibodies | #607 |
| activated coagulation | #607 |
| 0·3 | #607 |
| initial increase | #607 |
| treatment acute | #608 |
| tissue factor | #609 |
| arbitrage | #609 |
| pfizer | #609 |
| airline | #610 |
| benefit risk | #610 |
| 100 years | #610 |
| patients death | #610 |
| clinical evaluation | #611 |
| ultrasonography | #613 |
| coagulation inflammation | #614 |
| leg | #615 |
| patients bariatric surgery | #615 |
| reluctant | #615 |
| complications risk | #616 |
| treatment rivaroxaban | #617 |
| arterial disease | #617 |
| 467 | #618 |
| stroke atrial fibrillation | #618 |
| occurred | #618 |
| fh patients | #620 |
| compared placebo | #620 |
| advisory committees | #621 |
| patients elevated | #621 |
| 1002 | #622 |
| thyrotoxic | #623 |
| sgs | #623 |
| thrombocytopenia hit | #623 |
| cochrane central register | #625 |
| peptide bnp | #625 |
| topic practice guidelines | #626 |
| stopped | #626 |
| stroke warfarin | #627 |
| 5000 | #628 |
| warfarin risk | #628 |
| 66 | #628 |
| women risk factors | #628 |
| diagnostic algorithms | #629 |
| referral patients | #629 |
| human subjects | #629 |
| physical training | #629 |
| absolute | #630 |
| sanofi | #630 |
| atiii | #632 |
| risk treatment | #633 |
| screening strategy | #634 |
| uneventful | #635 |
| outweigh | #635 |
| pentoxifylline | #637 |
| travelling | #638 |
| 14 95 | #640 |
| 95 allcause mortality | #640 |
| study quality | #641 |
| proceedings | #641 |
| 3050 | #642 |
| predictive performance | #642 |
| neutrophilia | #643 |
| threatening bleeding | #643 |
| association mortality | #647 |
| primary outcome measure | #647 |
| necessitating | #648 |
| studies efficacy | #648 |
| statin treatment | #648 |
| thrombolysis patients | #651 |
| 036 | #651 |
| fixed | #651 |
| organisations | #652 |
| troglodytes | #652 |
| fxa | #653 |
| hemorrhagic stroke | #653 |
| 127 | #655 |
| patients review | #657 |
| bleeding death | #659 |
| coronary stent implantation | #659 |
| 69 | #659 |
| haematoma | #660 |
| physical examination | #661 |
| tertiles | #661 |
| coagulation proteins | #661 |
| clinical presentations | #662 |
| haemophilia | #662 |
| 1028 | #663 |
| 95 studies | #663 |
| long term treatment | #664 |
| provoked | #664 |
| sepsis shock | #665 |
| deep | #666 |
| phase iii studies | #666 |
| onethird | #667 |
| patients completed | #667 |
| presence patients | #667 |
| guideline adherence | #667 |
| male medical | #668 |
| 8 wk | #669 |
| 1110 | #671 |
| phenprocoumon | #672 |
| patients cteph | #673 |
| elevated plasma | #673 |
| managing | #674 |
| hospitalization hf | #674 |
| il6 levels | #675 |
| inhibitor 1 | #675 |
| clotting factors | #675 |
| highincome countries | #676 |
| prothrombotic | #676 |
| asymptomatic subjects | #677 |
| favourably | #678 |
| jugular | #679 |
| medicine humans | #681 |
| pulmonary endarterectomy | #681 |
| suspicion | #682 |
| conclude | #687 |
| apolipoproteina | #688 |
| efficacy safety | #690 |
| patients bleeding | #692 |
| ambulatory patients | #692 |
| graduated | #693 |
| myocardial infarctions | #693 |
| activator pa | #693 |
| administer | #694 |
| composite outcome | #694 |
| precise mechanisms | #694 |
| intracranial bleeding | #694 |
| 1718 | #695 |
| combined oral contraceptives | #696 |
| moyamoya | #696 |
| stroke prevention patients | #696 |
| difference 95 | #698 |
| participant data | #698 |
| ratio male | #698 |
| compression devices | #700 |
| episode | #700 |
| prothrombin gene | #702 |
| diagnostic errors | #702 |
| therapeutic management | #702 |
| patients confirmed | #703 |
| veins venous | #703 |
| surgery risk | #703 |
| willebrand | #704 |
| data incidence | #706 |
| subclinical hypothyroidism | #708 |
| clinical expression | #709 |
| directors | #709 |
| starters | #711 |
| 048 | #712 |
| gastrointestinal bleeding | #712 |
| medical patients | #712 |
| gynaecology | #712 |
| radionuclide imaging | #713 |
| neurosurgical patients | #714 |
| rate death | #714 |
| 1098 | #714 |
| intravenous bolus | #715 |
| menstrual period | #716 |
| rivaroxaban stroke | #716 |
| cancer groups | #717 |
| adequately | #717 |
| solid cancer | #718 |
| falsely | #718 |
| 10 30 | #718 |
| reagent kits | #719 |
| plasminogen | #719 |
| pulmonary medicine | #720 |
| nordisk | #721 |
| pyrazoles pyridines | #721 |
| clinical judgment | #721 |
| accp | #721 |
| s1p1 | #722 |
| 95 hazard ratio | #724 |
| follow period | #726 |
| abnormal | #726 |
| gentamicins | #727 |
| 59 patients | #727 |
| diagnostic therapeutic | #728 |
| orthopaedic surgery | #728 |
| diagnostic tests | #730 |
| gentamicin | #732 |
| leeches | #732 |
| oral contraception | #733 |
| tumor necrosis factor | #733 |
| relative risk 95 | #734 |
| hull | #735 |
| patients levels | #735 |
| disease pad | #735 |
| tests retrospective studies | #736 |
| clinical prediction rule | #736 |
| atrial fibrillation risk | #736 |
| post hoc analysis | #739 |
| 6 12 | #739 |
| anti tnf | #740 |
| evaluable patients | #741 |
| unclear | #742 |
| early pregnancy loss | #742 |
| 040 | #742 |
| topic predictive | #743 |
| illness time factors | #744 |
| molecular weight | #744 |
| betathromboglobulin | #744 |
| 285 | #746 |
| antithrombin activity | #746 |
| etp | #746 |
| patients 50 years | #746 |
| leukocyte activation | #748 |
| thrombolytic therapy | #749 |
| hospitalization heart failure | #750 |
| indication | #752 |
| advisable | #754 |
| fibrin formation | #754 |
| primary patients | #755 |
| 95 combination | #756 |
| 95 risk factors | #756 |
| answer | #756 |
| hf risk | #756 |
| pneumatic compression | #756 |
| venovenous | #757 |
| 1·7 | #758 |
| 85 | #759 |
| loe | #759 |
| inflammation coagulation | #760 |
| patients peripheral | #761 |
| proportion women | #763 |
| 435 | #763 |
| start treatment | #764 |
| cprs | #764 |
| hip surgery | #765 |
| 689 | #767 |
| risk pregnancy | #767 |
| aspirin clopidogrel | #767 |
| 732 | #768 |
| method drug | #769 |
| groups patients | #770 |
| relevant | #770 |
| 566 | #770 |
| graft patency | #772 |
| baseline values | #772 |
| patients criteria | #773 |
| bmi patients | #774 |
| subcutaneous injections | #774 |
| 1·5 | #776 |
| 992 | #777 |
| study groups | #778 |
| dose intravenous | #778 |
| patients 65 years | #778 |
| dose warfarin | #778 |
| miscarriage | #779 |
| patients hyperthyroidism | #780 |
| 066 | #780 |
| thromboembolism prophylaxis | #780 |
| plasmin generation | #780 |
| age ≥ | #782 |
| onefifth | #785 |
| factor ixa | #785 |
| abnormalities patients | #786 |
| 100 personyears | #787 |
| polypharmacy | #787 |
| topic disease models | #787 |
| cteph | #787 |
| general practitioners | #787 |
| preferable | #788 |
| secondary outcome | #791 |
| mechanical heart | #793 |
| recombinant tissue | #793 |
| risk factors risk | #795 |
| 047 | #795 |
| inactivators | #795 |
| patency | #796 |
| patient years | #796 |
| netherlands | #797 |
| studies prevalence | #797 |
| eligible | #797 |
| lupus anticoagulant | #798 |
| femoropopliteal | #798 |
| patients lower | #799 |
| theme | #799 |
| estrogen therapy | #799 |
| hemophilia patients | #800 |
| willebrand factor | #802 |
| randomized patients | #804 |
| subclinical | #804 |
| microvesicles | #805 |
| anticoagulant agents | #805 |
| fibrillation blood | #806 |
| adverse outcomes patients | #806 |
| stroke risk factors | #807 |
| ventricular dysfunction | #808 |
| efficacy patients | #809 |
| hypertension cteph | #809 |
| activator inhibitor1 | #810 |
| 069 | #811 |
| model patients | #813 |
| primary aim | #814 |
| flights | #816 |
| factor vwf | #816 |
| 0·4 | #818 |
| vehicle control | #820 |
| irrespective | #820 |
| health predictive | #820 |
| abruptio | #821 |
| neuroradiologist | #822 |
| reduction mortality | #823 |
| prevention patients | #823 |
| coc | #824 |
| single administration | #824 |
| risk benefit | #825 |
| study incidence | #827 |
| gp | #828 |
| cardioembolic stroke | #828 |
| patients anticoagulants | #830 |
| cava filters | #832 |
| myers | #833 |
| 93 | #833 |
| antithrombotic treatment | #833 |
| abortion habitual | #835 |
| oral adult | #836 |
| plough | #836 |
| versus placebo | #837 |
| noac | #837 |
| 87 | #838 |
| 057 | #839 |
| genetic defect | #841 |
| risk scores | #844 |
| antithrombotic therapy | #846 |
| 49 | #846 |
| 072 | #847 |
| multidetector row | #847 |
| advise | #848 |
| recurrence risk | #849 |
| caesarean | #850 |
| patients diagnosis | #850 |
| area roc curve | #852 |
| 30 patients | #853 |
| reference method | #853 |
| pre‐eclampsia | #853 |
| advanced prostate | #854 |
| fibrin | #855 |
| clopidogrel aspirin | #855 |
| patients mutation | #859 |
| ultrafiltrate | #860 |
| dutch population | #861 |
| microg | #862 |
| cardiometabolic disease | #863 |
| 090 | #865 |
| placebo study | #866 |
| diagnostic methods | #868 |
| 1046 | #869 |
| 6 month | #870 |
| pyridones | #870 |
| longterm clinical outcomes | #872 |
| individual participant | #872 |
| favoring | #873 |
| tasman | #873 |
| targeted inhibition | #874 |
| thromboembolic pulmonary | #874 |
| imaging reproducibility | #874 |
| plasminogen activation | #875 |
| titles | #875 |
| n15 | #876 |
| cha2ds2 | #877 |
| dabigatran rivaroxaban | #878 |
| risk thromboembolic | #878 |
| anticoagulants atrial | #879 |
| 57 | #879 |
| oral | #881 |
| angiograms | #882 |
| control trial | #883 |
| 92 | #884 |
| imaging tests | #885 |
| prostate turp | #888 |
| handbook | #890 |
| 084 | #894 |
| male mexico | #894 |
| domiciliary | #894 |
| loading dose | #896 |
| p011 | #896 |
| repeatedly | #897 |
| uln | #901 |
| indefinite | #902 |
| bleedings | #904 |
| vkorc1 | #905 |
| wml | #906 |
| factor activity | #908 |
| 064 | #908 |
| subcutaneous administration | #909 |
| documented | #911 |
| patients clinical trials | #911 |
| haemostatic | #912 |
| initially | #912 |
| impedance | #913 |
| specificity sensitivity | #914 |
| haemodialysis patients | #916 |
| combined approach | #916 |
| 317 | #917 |
| thromboembolic events | #918 |
| 022 | #918 |
| chronic thromboembolic | #919 |
| antagonist oral | #920 |
| randomeffects model | #920 |
| standard patients | #920 |
| loss patients | #921 |
| ultrasound examination | #921 |
| optimal dose | #921 |
| estimate male | #923 |
| practise | #923 |
| study medication | #925 |
| multifactorial disease | #925 |
| total hip | #926 |
| safer | #928 |
| 902 | #928 |
| 004 | #929 |
| recurrent events | #930 |
| fxi | #931 |
| wording | #934 |
| treatment placebo | #934 |
| 84 | #936 |
| publication clinical trials | #937 |
| subgroup patients | #938 |
| 60 patients | #938 |
| rrr | #940 |
| families patients | #941 |
| teaching hospital | #943 |
| echocardiographically | #944 |
| stroke atrial | #944 |
| women preeclampsia | #944 |
| emboli | #945 |
| predictive values | #946 |
| ssc | #946 |
| anticoagulation treatment | #947 |
| knee replacement | #948 |
| extensive disease | #948 |
| diagnostic | #948 |
| previous diagnosis | #951 |
| adjudication | #954 |
| registro | #956 |
| dic | #956 |
| cancer humans | #956 |
| network metaanalysis | #956 |
| venous insufficiency | #957 |
| reassuring | #957 |
| day1 | #958 |
| efficacy | #958 |
| retropubic | #961 |
| combined oral | #961 |
| guidelines recommend | #962 |
| 3 months | #963 |
| blood product | #964 |
| travellers | #965 |
| reference lists | #966 |
| inhibitor1 | #966 |
| peaking | #969 |
| greater risk | #970 |
| allogeneic blood | #971 |
| risk allcause mortality | #973 |
| hoc | #973 |
| antiplatelet | #973 |
| prevalence characteristics | #973 |
| segmental | #974 |
| patients anticoagulation | #975 |
| female fibrinogen | #976 |
| vascular humans | #976 |
| fvii | #978 |
| false negative | #979 |
| 50 100 | #980 |
| 071 | #980 |
| onset aged aged | #980 |
| early gestation | #984 |
| 426 | #986 |
| randomised trials | #987 |
| prophylactic treatment | #987 |
| patients safety | #988 |
| vascular patency | #989 |
| study treatment | #990 |
| rises | #991 |
| missed | #991 |
| academic medical center | #992 |
| seminar | #992 |
| normal lung | #993 |
| counteracted | #993 |
| treatment bleeding | #994 |
| aged | #999 |
| 226 | #999 |
| justification | #1000 |
| thromboembolic risk | #1000 |
| lower extremity | #1000 |
| tissue type | #1001 |
| rivaroxaban apixaban | #1002 |
| parenteral administration | #1002 |
| eclamptic | #1003 |
| hyperprolactinaemia | #1005 |
| extended | #1005 |
| interleukin 6 | #1005 |
| pyridines | #1006 |
| 50 patients | #1007 |
| orthosis | #1007 |
| easier | #1007 |
| valsalva maneuver | #1009 |
| venous catheter | #1011 |
| individual participant data | #1012 |
| weighing | #1014 |
| pounds | #1018 |
| ticlopidine | #1018 |
| clotting time | #1019 |
| prostatic carcinoma | #1020 |
| 200 patients | #1022 |
| years risk | #1023 |
| cha2ds2 vasc | #1023 |
| humans randomized | #1024 |
| international prospective | #1024 |
| 076 | #1025 |
| diagnostic challenge | #1026 |
| prothrombin time | #1027 |
| firstdegree relatives | #1030 |
| decision analysis | #1030 |
| ixa | #1031 |
| prolactin | #1032 |
| relatives | #1033 |
| risk hemorrhage | #1033 |
| cardiovascular event | #1033 |
| 052 | #1035 |
| graft occlusion | #1037 |
| male netherlands | #1037 |
| 2 hours | #1039 |
| detect | #1040 |
| 025 | #1041 |
| 3 6 months | #1046 |
| vwf levels | #1047 |
| patients severe asthma | #1047 |
| examiner | #1050 |
| patients massive | #1050 |
| continuation | #1052 |
| patients analysis | #1053 |
| 221 | #1054 |
| mean±sd | #1054 |
| free triiodothyronine | #1056 |
| diseases liver | #1057 |
| coagulant | #1060 |
| 179 | #1060 |
| birth rate | #1060 |
| pad | #1061 |
| 610 | #1061 |
| published literature | #1062 |
| primary data | #1062 |
| false | #1064 |
| prekallikrein | #1065 |
| 150 | #1065 |
| 00008 | #1066 |
| live birth | #1066 |
| 101 | #1066 |
| lysosphingolipid | #1067 |
| cut | #1067 |
| pmol | #1068 |
| 95 increased risk | #1070 |
| register controlled | #1070 |
| observer variation | #1071 |
| specialties | #1072 |
| continued | #1073 |
| thorax | #1074 |
| laboratory diagnosis | #1074 |
| systematic search | #1078 |
| advocate | #1080 |
| 063 | #1080 |
| drawbacks | #1082 |
| f1 | #1087 |
| longterm therapy | #1087 |
| bandages | #1089 |
| stopping | #1095 |
| clarifications | #1095 |
| idarucizumab | #1096 |
| diagnostic utility | #1096 |
| mandated | #1096 |
| 1223 | #1099 |
| 083 | #1099 |
| 62 | #1102 |
| 96 | #1104 |
| fourfold | #1105 |
| blueprint | #1105 |
| clinical protocols | #1107 |
| peptide brain | #1107 |
| pending | #1111 |
| incidence pulmonary | #1112 |
| assigned | #1113 |
| diagnostic approach | #1115 |
| haemodialysis | #1116 |
| bypass grafts | #1116 |
| 252 | #1117 |
| qualified | #1118 |
| sensitivity specificity | #1119 |
| critical appraisal | #1120 |
| randomized controlled trials | #1122 |
| resistance factor | #1123 |
| probands | #1123 |
| new developments | #1124 |
| advised | #1125 |
| new perspectives | #1126 |
| 445 | #1126 |
| cip | #1127 |
| heparininduced thrombocytopenia | #1127 |
| patients pad | #1128 |
| judged | #1132 |
| discretion | #1132 |
| statistic | #1133 |
| ≤10 | #1133 |
| 95 confidence interval | #1134 |
| pulse rate | #1135 |
| gram negative | #1137 |
| 1043 | #1139 |
| disseminated | #1140 |
| 635 | #1141 |
| superior efficacy | #1141 |
| 86 | #1143 |
| 734 | #1145 |
| 844 | #1147 |
| refusal | #1150 |
| roc curve | #1150 |
| medical records | #1151 |
| medline | #1151 |
| embolectomy | #1153 |
| longterm complications | #1154 |
| risk recurrence | #1155 |
| blood loss | #1156 |
| patients influenza | #1156 |
| anticoagulation therapy | #1156 |
| prophylaxis treatment | #1157 |
| 3040 | #1158 |
| patients increased | #1159 |
| extension study | #1161 |
| cvc | #1162 |
| published guidelines | #1163 |
| bristol | #1163 |
| hyperhomocysteinemia | #1164 |
| stable angina | #1164 |
| viii | #1164 |
| safety concerns | #1164 |
| intermittent | #1164 |
| thromboembolism risk | #1165 |
| age 65 years | #1165 |
| angiogram | #1167 |
| perioperative bleeding | #1172 |
| atherosclerotic disease | #1172 |
| glucocorticoid treatment | #1172 |
| crossover design | #1172 |
| occlusive diseases | #1173 |
| practice guideline | #1173 |
| 5 years patients | #1176 |
| macroglobulin | #1176 |
| analysis studies | #1178 |
| findings patients | #1178 |
| 79 | #1179 |
| conceive | #1181 |
| concealed | #1181 |
| unaware | #1182 |
| hospitalized patients | #1182 |
| patients obesity | #1182 |
| combined therapy | #1186 |
| conclusive | #1186 |
| occult | #1189 |
| degree relatives | #1189 |
| adult analysis | #1191 |
| cus | #1194 |
| administration oral | #1195 |
| 21 patients | #1197 |
| international society | #1199 |
| cardiotonic agents | #1199 |
| mandate | #1199 |
| hypercortisolism | #1200 |
| 83 | #1203 |
| 015 | #1204 |
| categorized | #1204 |
| quantitative trait locus | #1204 |
| increase plasma | #1205 |
| 31 | #1207 |
| biomarkers blood | #1210 |
| 56 patients | #1212 |
| pph | #1214 |
| multicenter randomized | #1214 |
| 103 | #1218 |
| patient treatment | #1221 |
| scores patients | #1221 |
| warranted | #1221 |
| ultrasound screening | #1222 |
| 6months | #1223 |
| peak levels | #1224 |
| 64 patients | #1224 |
| vasc | #1225 |
| 16 patients | #1226 |
| blind | #1227 |
| sixfold | #1227 |
| consensus guidelines | #1228 |
| metabolic syndrome patients | #1228 |
| trial background | #1229 |
| peptide hydrolases | #1229 |
| radionuclide | #1229 |
| 65 patients | #1230 |
| rules | #1232 |
| doubles | #1232 |
| aspirin | #1234 |
| coronary angiography patients | #1238 |
| postoperative hemorrhage | #1238 |
| milliliter | #1238 |
| humans length | #1240 |
| clinical criteria | #1241 |
| patients fh | #1242 |
| vte prophylaxis | #1244 |
| neurohormone | #1245 |
| multinational | #1246 |
| thrombolytic | #1247 |
| knee arthroplasty | #1248 |
| intermediate risk | #1250 |
| matter lesions | #1252 |
| subgroups | #1252 |
| ml1 | #1252 |
| artery pulmonary | #1254 |
| oral vitamin | #1257 |
| search strategy | #1257 |
| extensive | #1257 |
| prospective cohort | #1258 |
| symptomatic patients | #1259 |
| major surgery | #1262 |
| visiting | #1266 |
| entity | #1266 |
| troponins | #1266 |
| macroglobulins | #1267 |
| 172 | #1270 |
| amputations | #1273 |
| equally | #1274 |
| intensive patients | #1274 |
| design study | #1276 |
| antiplatelet agents | #1278 |
| proportionally | #1279 |
| statin users | #1281 |
| routine screening | #1281 |
| 75 years | #1281 |
| factors ultrasonography | #1285 |
| thyroxine | #1287 |
| 050 | #1288 |
| blockers | #1290 |
| dermatan sulfate | #1292 |
| janssen | #1295 |
| perfusion defects | #1295 |
| scan | #1295 |
| predictive | #1297 |
| hemofiltration | #1297 |
| insufficiently | #1298 |
| cardiovascular complications | #1299 |
| low prevalence | #1299 |
| dutch | #1300 |
| prolong | #1302 |
| 61 | #1303 |
| pf4 | #1303 |
| pulmonary circulation | #1304 |
| scores | #1305 |
| 95 mortality | #1307 |
| 1st | #1312 |
| cyproterone | #1312 |
| apoa | #1312 |
| risk difference | #1312 |
| adamts13 activity | #1313 |
| 0·7 | #1314 |
| current strategies | #1314 |
| tests severity | #1314 |
| claudication | #1316 |
| atrial fibrillation | #1316 |
| carotid imt | #1317 |
| international guidelines | #1318 |
| replacement hip | #1320 |
| study time | #1321 |
| coagulation factor | #1322 |
| vienna | #1323 |
| increases risk | #1324 |
| glycoprotein gpiib | #1325 |
| lipoproteina | #1325 |
| patients coronavirus disease | #1326 |
| beneficial | #1329 |
| vascular diseases | #1329 |
| antibodies monoclonal antibodies | #1329 |
| thyroid disorders | #1330 |
| low moderate | #1330 |
| plasminogen activators | #1330 |
| coagulation cascade | #1331 |
| 77 | #1331 |
| 6 months patients | #1331 |
| 126 | #1332 |
| frequent complication | #1333 |
| adjusted age | #1335 |
| transurethral resection | #1336 |
| 91 | #1342 |
| likelihood ratio | #1342 |
| venous catheters | #1342 |
| blood sample | #1343 |
| daily patients | #1344 |
| antitrypsin | #1347 |
| surgical trauma | #1347 |
| patients relatives | #1351 |
| neurosurgery | #1355 |
| arthroplasty patients | #1356 |
| patients stable angina | #1357 |
| experimental model | #1359 |
| allcause mortality 95 | #1359 |
| 15 patients | #1359 |
| arsenal | #1363 |
| limb salvage | #1363 |
| vwf | #1363 |
| vtes | #1365 |
| 95 patients | #1366 |
| operatively | #1367 |
| 12 month | #1369 |
| heart valves | #1370 |
| starting | #1372 |
| ethinyl | #1373 |
| acetylsalicylic | #1375 |
| costeffectiveness analysis | #1376 |
| utmost | #1378 |
| consented | #1382 |
| management patients | #1383 |
| gps | #1384 |
| 224 | #1385 |
| noninferiority | #1385 |
| dl1 | #1385 |
| disorders blood | #1386 |
| ivt | #1389 |
| patients cvd | #1392 |
| substitute | #1394 |
| screening tests | #1399 |
| patients control subjects | #1400 |
| record linkage | #1400 |
| 82 | #1402 |
| antisense oligonucleotide | #1402 |
| equipoise | #1402 |
| mandatory | #1403 |
| clinical challenges | #1404 |
| patients advanced cancer | #1405 |
| 1886 | #1405 |
| obese patients | #1406 |
| pregnancy loss | #1406 |
| 515 | #1408 |
| categories | #1408 |
| 994 | #1409 |
| reflected | #1410 |
| inception | #1411 |
| tranexamic | #1413 |
| adamts13 | #1417 |
| 0·1 | #1418 |
| thrombotic complications | #1419 |
| 3 6 | #1419 |
| 7 weeks | #1419 |
| 6 weeks | #1419 |
| total knee | #1420 |
| 95 0 | #1421 |
| followup data | #1422 |
| university hospitals | #1422 |
| 061 | #1424 |
| daily | #1424 |
| ≥55 | #1424 |
| eightfold | #1425 |
| randomised controlled trials | #1427 |
| 080 | #1427 |
| rgs | #1430 |
| casecontrol study | #1430 |
| outcome pregnancy | #1438 |
| 096 | #1439 |
| imaging radiopharmaceuticals | #1439 |
| 78 | #1443 |
| principal | #1443 |
| 1123 | #1445 |
| drug levels | #1446 |
| weight bmi | #1446 |
| outcome studies | #1446 |
| underreporting | #1451 |
| support systems | #1452 |
| confusion | #1454 |
| population patients | #1454 |
| platelet factor | #1455 |
| aged blood | #1455 |
| dip | #1456 |
| mbe | #1457 |
| conclusions patients | #1459 |
| prospectively | #1460 |
| multicenter studies | #1461 |
| humans | #1463 |
| inaccuracy | #1464 |
| actual | #1466 |
| funded | #1466 |
| 0·9 | #1468 |
| avoided | #1468 |
| 26 patients | #1469 |
| heart failure hf | #1469 |
| groin | #1471 |
| risk factors mortality | #1472 |
| prevalences | #1473 |
| 1215 | #1473 |
| centrally | #1474 |
| probability | #1477 |
| systemic infection | #1477 |
| lowest tertile | #1478 |
| remained | #1480 |
| atherothrombotic | #1481 |
| undetermined | #1482 |
| dysfunction patients | #1483 |
| cushing syndrome | #1485 |
| analysis randomized | #1485 |
| methodologic | #1486 |
| phase iii trials | #1486 |
| general practice | #1491 |
| patients control | #1495 |
| procoagulant activity | #1495 |
| randomly | #1496 |
| 64 | #1498 |
| aged natriuretic | #1499 |
| exposing | #1501 |
| imt | #1507 |
| fracture surgery | #1510 |
| specificity 100 | #1512 |
| odds ratio 95 | #1513 |
| growing body | #1514 |
| adverse outcome | #1514 |
| proximal | #1516 |
| pregnancy postpartum | #1520 |
| patients 10 | #1520 |
| ganz | #1520 |
| subgroup | #1521 |
| factor deficiency | #1522 |
| gsk | #1524 |
| chills | #1526 |
| thrombotic events | #1527 |
| contraindicated | #1527 |
| score | #1529 |
| time study | #1529 |
| oral contraceptive | #1534 |
| mechanical compression | #1536 |
| immobilisation | #1539 |
| comparator | #1540 |
| patients life | #1541 |
| humans neoplasm | #1542 |
| hemostatics humans | #1545 |
| 089 | #1548 |
| tsh levels | #1551 |
| patients severe sepsis | #1552 |
| live births | #1552 |
| 23 | #1554 |
| vascular thrombosis | #1555 |
| fees | #1556 |
| neonatal period | #1558 |
| patients year | #1559 |
| discriminatory | #1562 |
| hypothyroidism | #1563 |
| pfa | #1564 |
| enfermedad | #1564 |
| iii topic | #1565 |
| treatment prevention | #1566 |
| topic | #1566 |
| 95ci | #1568 |
| hyperlipoproteinemia type | #1568 |
| cushings syndrome | #1568 |
| deficient | #1568 |
| aged biomarkers | #1571 |
| plasminogen activator | #1575 |
| 36 | #1575 |
| humans platelet | #1576 |
| 012 | #1577 |
| hyperlipoproteinemia | #1580 |
| risk myocardial infarction | #1584 |
| study entry | #1586 |
| thyroid dysfunction | #1586 |
| activation markers | #1586 |
| cocs | #1586 |
| studies association | #1587 |
| adjusted hazard ratio | #1589 |
| volunteers | #1591 |
| 1·1 | #1594 |
| total mortality | #1594 |
| translates | #1597 |
| noncancer | #1598 |
| placebo | #1598 |
| exclude | #1599 |
| lmw | #1601 |
| figures | #1604 |
| paroxetine | #1606 |
| abdominal surgery | #1607 |
| complement pathway | #1609 |
| curability | #1610 |
| general surgery | #1613 |
| 162 | #1613 |
| ethinylestradiol | #1614 |
| recommending | #1615 |
| tests reproducibility | #1616 |
| prospective cohort studies | #1616 |
| postpartum period | #1616 |
| factors tomography | #1616 |
| positive effects | #1616 |
| perinatal outcome | #1618 |
| 155 | #1618 |
| imaging tomography | #1619 |
| female hemostasis | #1619 |
| cvd patients | #1619 |
| proportion | #1620 |
| 12month followup | #1621 |
| uncertain | #1621 |
| 079 | #1623 |
| competing risk | #1628 |
| isis | #1630 |
| major | #1631 |
| incidentally | #1632 |
| pa patients | #1632 |
| venous disease | #1632 |
| clinical patients | #1633 |
| fresh frozen plasma | #1633 |
| double | #1639 |
| study outcomes | #1639 |
| 029 | #1642 |
| 181 | #1643 |
| stroke prevention | #1644 |
| ctni | #1644 |
| patients hospitalized | #1647 |
| mismatched | #1648 |
| 997 | #1651 |
| dorsiflexion | #1651 |
| 35 years | #1652 |
| ≤4 | #1652 |
| thrombin activity | #1653 |
| studies data | #1653 |
| clotting | #1656 |
| remaining | #1660 |
| plasma concentration | #1661 |
| outcome data | #1663 |
| spiral | #1669 |
| disease adult | #1670 |
| homocysteine levels | #1670 |
| thrombi | #1674 |
| inpatient treatment | #1676 |
| daily dosing | #1676 |
| plasma level | #1677 |
| deficiency | #1677 |
| warfarin dose | #1680 |
| arthroscopy | #1684 |
| unreliable | #1686 |
| steroidal anti | #1686 |
| patients acs | #1687 |
| thrombin | #1690 |
| severe renal | #1694 |
| patients brain metastases | #1695 |
| prospective | #1702 |
| necrosis factor | #1705 |
| highest risk | #1707 |
| cancer screening | #1708 |
| awaiting | #1710 |
| yielded | #1712 |
| 033 | #1712 |
| intravenous | #1715 |
| hemorheology | #1715 |
| bronchospasm | #1720 |
| hematologic malignancies | #1720 |
| mb | #1721 |
| diagnostic evaluation | #1721 |
| female femoral | #1721 |
| cardioembolic | #1722 |
| cumulative incidence | #1723 |
| laser doppler | #1724 |
| conference | #1726 |
| 107 | #1726 |
| derived microparticles | #1729 |
| volunteer | #1730 |
| 021 | #1730 |
| 161 | #1733 |
| percentage patients | #1734 |
| east asian | #1735 |
| clinical scores | #1735 |
| patients icu | #1736 |
| rico | #1737 |
| 500 | #1738 |
| minor | #1739 |
| revised | #1744 |
| table | #1745 |
| 691 | #1745 |
| patients ventricular | #1745 |
| profession | #1746 |
| risk cardiovascular events | #1747 |
| hyperinsulinaemia | #1747 |
| apc | #1749 |
| turp | #1749 |
| pselectin | #1750 |
| replacement | #1750 |
| homozygosity | #1750 |
| 128 | #1752 |
| 133 | #1753 |
| intracranial hemorrhages | #1753 |
| 3 studies | #1755 |
| spontaneous | #1756 |
| arterial occlusive | #1758 |
| patients randomized | #1759 |
| audiometry | #1760 |
| treatment recommendations | #1760 |
| assessor | #1760 |
| current treatment | #1761 |
| primary setting | #1762 |
| long‐term | #1763 |
| human insulin | #1764 |
| fx | #1764 |
| duplicate | #1769 |
| hemorrhage | #1770 |
| initial management | #1770 |
| arteriosclerosis | #1770 |
| allcause death | #1774 |
| 2 6 | #1774 |
| 28 weeks | #1781 |
| hemostasis humans | #1782 |
| trough levels | #1785 |
| infusions | #1787 |
| ethinyl estradiol | #1789 |
| clinical consequences | #1790 |
| selfmanagement | #1790 |
| microparticle | #1793 |
| reid | #1793 |
| cardiac troponin | #1794 |
| vascular surgical | #1794 |
| healthy male volunteers | #1799 |
| 042 | #1800 |
| 020 | #1802 |
| aggregation inhibitors | #1802 |
| retrospective analysis | #1805 |
| hemophilia humans | #1808 |
| unpublished | #1810 |
| slc6a4 | #1812 |
| tumor necrosis | #1812 |
| 95 specificity | #1812 |
| overlapped | #1814 |
| 51 | #1815 |
| 078 | #1818 |
| conjoint | #1819 |
| economic evaluation | #1819 |
| interobserver | #1823 |
| awareness | #1824 |
| screening middle | #1825 |
| preference | #1825 |
| 303 | #1828 |
| placebo 95 | #1832 |
| undergoing coronary | #1834 |
| compressibility | #1837 |
| definite | #1837 |
| kaplanmeier estimate | #1838 |
| cushing | #1838 |
| severe sepsis | #1839 |
| central venous | #1842 |
| 1 week | #1842 |
| workup | #1848 |
| orthopaedic | #1849 |
| explanations | #1852 |
| hydroxyethyl starch | #1852 |
| 160 | #1854 |
| fibrinopeptide | #1862 |
| cancer therapies | #1865 |
| alpha 2 | #1867 |
| gramnegative | #1869 |
| serially | #1870 |
| humans pregnancy | #1874 |
| separately | #1876 |
| oral anticoagulation | #1880 |
| diagnostic techniques | #1892 |
| shrs | #1892 |
| thromboses | #1892 |
| lower incidence | #1893 |
| stable patients | #1895 |
| 5 10 | #1897 |
| 067 | #1897 |
| contraindications | #1900 |
| diagnostic testing | #1901 |
| tnf | #1901 |
| extremity | #1901 |
| clt | #1905 |
| plaster | #1906 |
| hazard ratio | #1906 |
| induced thrombocytopenia | #1906 |
| differential effects | #1907 |
| 95 year | #1909 |
| referral | #1910 |
| efficacy treatment | #1910 |
| random | #1911 |
| plato | #1913 |
| experimental mice mice | #1916 |
| 238 | #1918 |
| randomized | #1919 |
| 793 | #1920 |
| 13 patients | #1920 |
| administration | #1921 |
| pregnancy treatment | #1922 |
| 868 | #1923 |
| stroke 95 | #1923 |
| 55 years | #1924 |
| biotin | #1924 |
| trials patients | #1926 |
| venous pressure | #1926 |
| μg | #1927 |
| intracranial hemorrhage | #1927 |
| coronary syndromes | #1928 |
| 272 | #1929 |
| cardiovascular events patients | #1930 |
| chimpanzee | #1931 |
| adjusted | #1932 |
| nonfatal | #1934 |
| glucocorticoid | #1934 |
| relative risks | #1935 |
| 3months | #1935 |
| acute | #1936 |
| 17 | #1936 |
| thrombolytic treatment | #1937 |
| 27 | #1938 |
| randomized placebo | #1947 |
| femoral vein | #1950 |
| safety effectiveness | #1950 |
| 0·5 | #1952 |
| medical illness | #1954 |
| overtreatment | #1955 |
| prolongation | #1958 |
| intravascular | #1959 |
| major risk | #1960 |
| advanced age | #1961 |
| investigators | #1962 |
| observer | #1962 |
| 1050 | #1965 |
| permanent | #1966 |
| 80 female | #1967 |
| hyperglycaemia | #1970 |
| coronary angioplasty | #1971 |
| 48 hours | #1973 |
| surgical blood | #1973 |
| fibrin clot | #1973 |
| renewed | #1976 |
| potent inhibitor | #1976 |
| topic clinical trials | #1978 |
| hyperaldosteronism | #1981 |
| 771 | #1981 |
| specificity ultrasonography | #1981 |
| computerised | #1982 |
| patients pancreatic | #1985 |
| 1·0 | #1986 |
| treatment cancer | #1986 |
| randomized controlled | #1988 |
| coumarins | #1990 |
| 177 | #1991 |
| prospero | #1992 |
| 018 | #1992 |
| drug drug therapy | #1994 |
| cmax | #1994 |
| computerized | #1995 |
| cvt | #1995 |
| hemorrhage patients | #1996 |
| ors | #1998 |
| 602 | #1999 |
| 3 months patients | #2000 |
| transient increase | #2000 |
| clinical severity | #2000 |
| autopsy | #2000 |
| 53 | #2003 |
| pneumonia patients | #2006 |
| 7 patients | #2006 |
| pih | #2011 |
| mantel | #2013 |
| catheterization central | #2014 |
| mongrel | #2017 |
| angina unstable | #2017 |
| poc | #2019 |
| 225 | #2020 |
| type plasminogen | #2023 |
| pathophysiologic | #2024 |
| 35 | #2025 |
| patients statins | #2026 |
| annual | #2028 |
| 15th | #2031 |
| atheroma | #2032 |
| patients lung | #2033 |
| 097 | #2033 |
| pertechnetate | #2036 |
| medical record | #2041 |
| costs cost | #2041 |
| undergoing major | #2042 |
| abstracts | #2042 |
| questioned | #2043 |
| thrice | #2045 |
| prediction rule | #2045 |
| dichotomous | #2046 |
| normal | #2048 |
| superior vena cava | #2051 |
| quartiles | #2051 |
| inadequately | #2052 |
| pregnancy trimester | #2053 |
| 277 | #2053 |
| controversial | #2055 |
| adherence guidelines | #2056 |
| stent implantation | #2056 |
| hospitalized | #2057 |
| randomized comparison | #2060 |
| outpatient | #2061 |
| interobserver variability | #2062 |
| varies | #2063 |
| requested | #2063 |
| clinical indications | #2064 |
| biological neoplasms | #2064 |
| hemostatics | #2070 |
| mcnemar | #2074 |
| national institute | #2074 |
| 188 | #2074 |
| familial hypercholesterolemia | #2077 |
| unavailable | #2079 |
| searched | #2082 |
| disseminate | #2083 |
| ristocetin | #2086 |
| bypasses | #2087 |
| media thickness | #2087 |
| 03 | #2089 |
| versions | #2091 |
| 114 | #2092 |
| square distribution | #2092 |
| tissue plasminogen | #2093 |
| reference range | #2099 |
| preformed | #2099 |
| 038 | #2100 |
| lifetime risk | #2101 |
| desmopressin | #2101 |
| 59 | #2101 |
| placebos | #2102 |
| concealment | #2104 |
| hospital treatment | #2106 |
| fibrin deposition | #2107 |
| argatroban | #2108 |
| 031 | #2109 |
| 1966 | #2109 |
| substantial | #2109 |
| aged 80 | #2111 |
| debated | #2116 |
| jugular vein | #2117 |
| unnecessary | #2118 |
| independently | #2118 |
| initial | #2119 |
| exists | #2119 |
| development validation | #2120 |
| coronary stent | #2122 |
| clinicaltrialsgov | #2122 |
| 11 | #2122 |
| acl reconstruction | #2125 |
| original | #2125 |
| patients cardiovascular disease | #2127 |
| topic surveys | #2127 |
| chose | #2129 |
| controlled | #2129 |
| current recommendations | #2131 |
| odds ratios | #2132 |
| protamines | #2134 |
| congress | #2134 |
| 190 | #2136 |
| 788 | #2137 |
| hip arthroplasty | #2139 |
| heterozygous | #2141 |
| antagonists | #2142 |
| live | #2145 |
| clot | #2145 |
| professionals | #2146 |
| bodyweight | #2146 |
| pancreatic cancer patients | #2157 |
| committee | #2160 |
| oestrogens | #2160 |
| lowdose aspirin | #2163 |
| academic medical | #2167 |
| drains | #2170 |
| embase | #2171 |
| fibrinogen | #2175 |
| 1998 | #2178 |
| trimesters | #2179 |
| reproductive age | #2182 |
| 674 | #2183 |
| advanced cancer | #2183 |
| giant cell arteritis | #2185 |
| 2 × | #2185 |
| fifty | #2185 |
| patients diagnosed | #2187 |
| 631 | #2188 |
| controlled study | #2192 |
| superficial | #2194 |
| difference incidence | #2198 |
| adjust | #2202 |
| diagnostic performance | #2204 |
| pravastatin | #2205 |
| increased patients | #2205 |
| antagonist | #2206 |
| clinical implications | #2208 |
| lower limbs | #2209 |
| diagnosis differential | #2212 |
| neutrophil elastase | #2212 |
| doubled | #2213 |
| pao2 | #2219 |
| 364 | #2219 |
| insufficient | #2221 |
| comparing | #2222 |
| 94 | #2225 |
| differential female | #2225 |
| lung perfusion | #2226 |
| italian society | #2227 |
| 76 | #2233 |
| takeda | #2236 |
| nationwide cohort study | #2245 |
| clot formation | #2247 |
| congenital heart disease | #2252 |
| hemorrhages | #2253 |
| clots | #2257 |
| hivinfected patients | #2257 |
| kilogram | #2259 |
| aprotinin | #2261 |
| 8000 | #2264 |
| stroke aged | #2265 |
| hyperthyroidism | #2265 |
| 12 | #2266 |
| 6 months | #2267 |
| metaanalysis | #2267 |
| reverses | #2273 |
| patients developed | #2273 |
| arterial | #2274 |
| intrinsic pathway | #2275 |
| famine | #2278 |
| 656 | #2279 |
| ultrasonographic | #2281 |
| setting | #2284 |
| based case | #2284 |
| 14 patients | #2286 |
| ft3 | #2288 |
| case control | #2291 |
| patients heart failure | #2293 |
| aged molecular | #2295 |
| daily dose | #2296 |
| sole | #2298 |
| strategy | #2303 |
| 88 | #2308 |
| 0047 | #2310 |
| normalised | #2312 |
| tests | #2314 |
| metaanalysis studies | #2314 |
| initial therapy | #2316 |
| nephelometry | #2316 |
| obstetrics | #2317 |
| adjustments | #2319 |
| humans myocardial | #2324 |
| method female | #2324 |
| methodological | #2325 |
| 60 | #2327 |
| normalized | #2329 |
| brachial | #2332 |
| gradually | #2335 |
| random sample | #2336 |
| positive predictive | #2337 |
| transfusion requirements | #2340 |
| ultrasonography doppler | #2341 |
| 543 | #2343 |
| inhibitor | #2344 |
| lacked | #2344 |
| prescribe | #2347 |
| illness severity | #2350 |
| 20 weeks | #2351 |
| thr | #2353 |
| prefer | #2354 |
| cancer progression | #2364 |
| 053 | #2371 |
| 118 | #2372 |
| receiving | #2374 |
| 099 | #2375 |
| risk bias | #2375 |
| patients active | #2376 |
| hemostasis | #2377 |
| predictable | #2377 |
| enrolling | #2379 |
| acute coronary syndromes | #2379 |
| 187 | #2381 |
| anticardiolipin | #2382 |
| dosing regimen | #2382 |
| 145 | #2387 |
| scintigraphy | #2389 |
| 140 | #2391 |
| 244 | #2393 |
| complication rate | #2400 |
| 757 | #2401 |
| patients liver cirrhosis | #2401 |
| 086 | #2402 |
| letters | #2405 |
| curable | #2406 |
| postinjection | #2413 |
| protein | #2413 |
| periodicals | #2413 |
| risk estimates | #2414 |
| sphingosine1 | #2415 |
| 22 | #2415 |
| study drug | #2424 |
| internal medicine | #2424 |
| 32 | #2425 |
| sensitivity 100 | #2426 |
| guidelines | #2426 |
| 002 | #2430 |
| coagulants | #2430 |
| legs | #2430 |
| 0048 | #2430 |
| patients adult | #2431 |
| ci95 | #2432 |
| normal range | #2433 |
| prolonging | #2434 |
| ptca | #2434 |
| aminoglycoside | #2435 |
| cindex | #2437 |
| 030 | #2438 |
| cumulative | #2439 |
| 166 | #2441 |
| endogenous | #2445 |
| microplate | #2446 |
| turbidimetry | #2448 |
| 719 | #2448 |
| administration schedule | #2449 |
| transmigration | #2453 |
| homocysteine | #2454 |
| anticoagulant activity | #2455 |
| ≥75 | #2459 |
| extensively | #2463 |
| prognostic patients | #2464 |
| watchful | #2464 |
| potential benefits | #2466 |
| nephrotoxic | #2468 |
| therapy acute | #2468 |
| 477 | #2469 |
| comprised | #2469 |
| pharmacologic | #2473 |
| consisted | #2474 |
| current review | #2476 |
| cancer population | #2476 |
| 05 | #2481 |
| 50 | #2482 |
| 648 | #2485 |
| pathway inhibitor | #2485 |
| treatment efficacy | #2489 |
| 1015 | #2490 |
| 829 | #2490 |
| duration | #2493 |
| chest | #2493 |
| 25 | #2495 |
| 616 | #2503 |
| illness tomography | #2503 |
| bnp | #2504 |
| subsequent pregnancies | #2505 |
| 522 | #2507 |
| movie | #2508 |
| recurrence retrospective | #2509 |
| unstable angina | #2510 |
| presentation | #2512 |
| superinfection | #2513 |
| comprising | #2515 |
| drug female humans | #2516 |
| 479 | #2516 |
| sulfates | #2519 |
| 750 | #2520 |
| neutrophil extracellular traps | #2521 |
| 463 | #2521 |
| accurate diagnosis | #2523 |
| 152 | #2523 |
| treatment arms | #2524 |
| scientific | #2529 |
| establish | #2534 |
| 164 | #2537 |
| 0046 | #2537 |
| 874 | #2537 |
| nematode | #2540 |
| 67 | #2542 |
| pyrazoles | #2547 |
| arrive | #2549 |
| decided | #2552 |
| effectiveness analysis | #2553 |
| hours | #2560 |
| haematology | #2560 |
| hydroxyethyl | #2560 |
| 928 | #2565 |
| radiologist | #2566 |
| roc | #2568 |
| biologic | #2569 |
| clinical settings | #2570 |
| infrequent | #2572 |
| kits | #2574 |
| 73 | #2574 |
| humans logistic | #2574 |
| prevalence | #2575 |
| pill | #2575 |
| translate | #2577 |
| patients total | #2577 |
| 973 | #2578 |
| specificity | #2580 |
| cancer chemotherapy | #2581 |
| 374 | #2582 |
| 591 | #2585 |
| efficacious | #2585 |
| pivotal | #2588 |
| analysed | #2589 |
| bolus | #2595 |
| 657 | #2596 |
| multiple organ failure | #2599 |
| hypercholesterolaemia | #2600 |
| doppler duplex | #2602 |
| laboratory investigation | #2603 |
| burden disease | #2605 |
| manifest | #2605 |
| parenteral | #2606 |
| metaregression | #2606 |
| fatal outcome | #2608 |
| patients 2 | #2608 |
| 098 | #2610 |
| p0001 patients | #2613 |
| died | #2615 |
| 886 | #2618 |
| percent | #2619 |
| aviation | #2620 |
| cost analysis | #2620 |
| concentrate | #2621 |
| occlusive | #2622 |
| presenting | #2625 |
| assess | #2626 |
| prescribed | #2631 |
| agents steroidal | #2633 |
| trials rcts | #2635 |
| coincided | #2635 |
| chondroitin | #2635 |
| 10 day | #2637 |
| 345 | #2641 |
| attractive | #2641 |
| mutation patients | #2642 |
| greatest risk | #2643 |
| 23 patients | #2645 |
| decision | #2649 |
| risk cardiovascular disease | #2656 |
| 134 | #2659 |
| recurrence | #2660 |
| hamilton | #2661 |
| benzimidazoles | #2662 |
| c677 | #2662 |
| 679 | #2663 |
| shr | #2667 |
| quartile | #2674 |
| receive | #2675 |
| 439 | #2677 |
| valsalva | #2680 |
| trials | #2682 |
| outcome ultrasonography | #2683 |
| 516 | #2683 |
| iii | #2685 |
| initial dose | #2685 |
| inconclusive | #2686 |
| tmax | #2687 |
| mortality 95 | #2688 |
| tissue plasminogen activator | #2690 |
| aso | #2691 |
| 594 | #2691 |
| bleed | #2692 |
| schedule female | #2694 |
| stillbirth | #2698 |
| patients risk factors | #2702 |
| early discharge | #2703 |
| 14 | #2706 |
| previous stroke | #2720 |
| prematurely | #2725 |
| 897 | #2727 |
| txb2 | #2729 |
| dose low | #2732 |
| management strategies | #2732 |
| cart | #2736 |
| 595 | #2737 |
| classifications | #2739 |
| 427 | #2739 |
| therapeutic options | #2744 |
| risk ratio | #2745 |
| 848 | #2746 |
| predetermined | #2746 |
| patients asthma | #2747 |
| baseline characteristics | #2747 |
| direct comparison | #2752 |
| pan | #2755 |
| nephrotoxicity | #2758 |
| randomised trial | #2764 |
| contusions | #2765 |
| 143 | #2768 |
| management acute | #2768 |
| confounded | #2769 |
| antithyroid | #2772 |
| alpha animals | #2772 |
| expert consensus | #2772 |
| active control | #2775 |
| thrombomodulin | #2776 |
| inpatient | #2776 |
| 563 | #2777 |
| compression | #2778 |
| dosages | #2779 |
| leukocyte count | #2781 |
| mass screening | #2782 |
| 466 | #2783 |
| hemostatic | #2784 |
| primary outcomes | #2785 |
| percentiles | #2788 |
| 90th | #2789 |
| nadph2 | #2791 |
| consecutive series | #2802 |
| 402 | #2802 |
| cirrhosis patients | #2805 |
| reaching | #2805 |
| international | #2809 |
| secondary | #2811 |
| standardized | #2811 |
| embolic | #2812 |
| follow studies | #2813 |
| 406 | #2813 |
| prevalence risk factors | #2814 |
| httlpr | #2816 |
| discriminant analysis | #2817 |
| selectins | #2819 |
| consisting | #2823 |
| equivalency | #2825 |
| antiplatelet drugs | #2826 |
| bid | #2826 |
| genetic variations | #2830 |
| 557 | #2833 |
| male mass | #2834 |
| recurrence rate | #2835 |
| contacting | #2835 |
| helminth | #2836 |
| ketoprostaglandin | #2836 |
| kruskal | #2839 |
| crossover | #2839 |
| 554 | #2843 |
| partum | #2847 |
| anterior cruciate ligament | #2850 |
| carboxypeptidase | #2851 |
| doppler ultrasonography | #2852 |
| iii trials | #2852 |
| ≤2 | #2853 |
| postoperative patients | #2854 |
| post discharge | #2857 |
| new treatment | #2857 |
| specialised | #2858 |
| methods prospective | #2862 |
| 497 | #2870 |
| discontinuation | #2871 |
| 264 | #2876 |
| 628 | #2877 |
| 52 | #2879 |
| excessive | #2880 |
| trimester pregnancy | #2880 |
| hit | #2884 |
| mdct | #2885 |
| balloon angioplasty | #2886 |
| anterior cruciate | #2887 |
| 670 | #2895 |
| eligibility | #2896 |
| 21 | #2897 |
| systematic review metaanalysis | #2897 |
| central venous catheters | #2900 |
| statin | #2902 |
| slight | #2903 |
| feasible | #2903 |
| severe asthma | #2903 |
| 12 patients | #2908 |
| concomitantly | #2910 |
| supposed | #2911 |
| insulin receptors | #2914 |
| leading death | #2917 |
| lowrisk patients | #2917 |
| 39 | #2919 |
| routine clinical practice | #2920 |
| referrals | #2921 |
| older children | #2922 |
| proportions | #2928 |
| 993 | #2928 |
| clear | #2932 |
| 2400 | #2934 |
| risk stratification patients | #2934 |
| aggregation platelet | #2941 |
| control subjects patients | #2945 |
| meier estimate | #2946 |
| addison | #2952 |
| portal | #2954 |
| 100 | #2956 |
| returned | #2957 |
| 010 | #2960 |
| 270 | #2960 |
| 20 | #2961 |
| followup | #2962 |
| exercise therapy | #2962 |
| transabdominal | #2963 |
| 132 | #2974 |
| echocardiography patients | #2975 |
| 123 | #2978 |
| risk myocardial | #2981 |
| declare | #2984 |
| lecture | #2984 |
| eclampsia pregnancy | #2986 |
| glucose levels | #2987 |
| preoperatively | #2988 |
| adult blood | #2990 |
| point | #2991 |
| pneumatic | #2991 |
| n4 | #2992 |
| undefined | #2993 |
| treatable | #2996 |
| cvr | #2997 |
| microvessels | #2998 |
| 499 | #3004 |
| prostacyclin | #3012 |
| dipyridamole | #3013 |
| factors surveys | #3015 |
| antigen levels | #3015 |
| 2 patients | #3016 |
| 081 | #3019 |
| double‐blind | #3022 |
| 35 patients | #3023 |
| early recognition | #3025 |
| nested case | #3025 |
| comorbidity | #3026 |
| contraindication | #3028 |
| intention | #3035 |
| extremities | #3038 |
| 419 | #3040 |
| 50 years | #3040 |
| patients hf | #3041 |
| lymphopenia | #3043 |
| relevant articles | #3044 |
| 095 | #3045 |
| prenatal exposure | #3047 |
| summarize | #3050 |
| respondents | #3052 |
| respects | #3060 |
| subcutaneous injection | #3062 |
| 80 | #3063 |
| nomogram | #3063 |
| fourteen | #3065 |
| 95 p0001 | #3066 |
| patients data | #3067 |
| study prevalence | #3071 |
| subsequently | #3076 |
| 2 4 | #3076 |
| disease aged | #3077 |
| 524 | #3082 |
| 342 | #3083 |
| angioplasty | #3088 |
| chronic renal failure | #3088 |
| independent risk factors | #3089 |
| healthy | #3090 |
| clinical risk factors | #3098 |
| lancet | #3102 |
| reviewer | #3104 |
| practice guidelines | #3109 |
| benchmark | #3110 |
| trimester | #3110 |
| npv | #3115 |
| pregnant woman | #3119 |
| neutrophil activation | #3120 |
| wallis | #3122 |
| lifelong | #3122 |
| oac | #3122 |
| inadequacy | #3123 |
| intravenously | #3129 |
| claimed | #3132 |
| 136 | #3134 |
| 12 months | #3134 |
| meta‐analysis | #3137 |
| 082 | #3142 |
| levels risk | #3142 |
| placentae | #3143 |
| randomized clinical trial | #3145 |
| time interval | #3147 |
| arthroscopic | #3149 |
| idiopathic | #3153 |
| 507 | #3153 |
| marathon | #3155 |
| mega | #3156 |
| avoiding | #3158 |
| radiologists | #3165 |
| initial presentation | #3172 |
| seventh | #3173 |
| cornerstone | #3182 |
| test | #3184 |
| 494 | #3188 |
| revascularisation | #3191 |
| 409 | #3193 |
| pregnancy women | #3194 |
| diethylstilbestrol | #3194 |
| pacientes | #3197 |
| 945 | #3198 |
| plasmin | #3198 |
| therapy risk | #3199 |
| tenth | #3199 |
| gold standard | #3200 |
| vivo model | #3205 |
| res | #3207 |
| patient preference | #3211 |
| catheter | #3212 |
| cancer types | #3219 |
| suggested | #3219 |
| intravenous infusion | #3223 |
| 153 | #3223 |
| 72 hours | #3225 |
| 605 | #3227 |
| methodological quality | #3238 |
| observers | #3239 |
| recombinant | #3241 |
| meetings | #3241 |
| intravenous administration | #3242 |
| risk stroke | #3246 |
| alternative | #3249 |
| bivalirudin | #3251 |
| 198 | #3251 |
| hypothyroid | #3253 |
| 29 | #3253 |
| scoring | #3255 |
| judgement | #3255 |
| normotensive | #3256 |
| 054 | #3257 |
| patient preferences | #3261 |
| glargine | #3265 |
| validated | #3266 |
| patients evidence | #3267 |
| 116 | #3268 |
| immunoassay | #3271 |
| 414 | #3275 |
| 6 | #3277 |
| tranexamic acid | #3279 |
| gbd | #3280 |
| contraceptive | #3281 |
| inclusion | #3284 |
| arthroplasty replacement | #3288 |
| coumarin | #3289 |
| tumor markers | #3289 |
| replace | #3290 |
| 65 years | #3291 |
| swan | #3292 |
| recurrence rates | #3294 |
| efficacy outcomes | #3299 |
| 812 | #3314 |
| rtpa | #3315 |
| reversibility | #3316 |
| anticardiolipin antibodies | #3319 |
| discriminant | #3321 |
| vascular risk | #3322 |
| 104 | #3325 |
| hemophilia | #3328 |
| 972 | #3329 |
| reduces | #3330 |
| 465 | #3330 |
| cruciate ligament | #3331 |
| patients symptoms | #3334 |
| 74 | #3337 |
| meta | #3338 |
| acute coronary syndrome | #3339 |
| cerebrovascular disease | #3344 |
| inpatients | #3344 |
| evaluating | #3349 |
| 362 | #3349 |
| spontaneous abortion | #3354 |
| diagnosing | #3354 |
| 273 | #3355 |
| diagnosis cancer | #3356 |
| common complication | #3356 |
| 15 | #3357 |
| lysate | #3358 |
| 581 | #3359 |
| 092 | #3361 |
| miscarriages | #3365 |
| prevalent | #3371 |
| thrombolysis | #3376 |
| treatment modalities | #3377 |
| 363 | #3378 |
| 301 | #3379 |
| concluded | #3379 |
| humans lower | #3379 |
| intima media | #3380 |
| computed tomography | #3382 |
| hematomas | #3387 |
| calf | #3389 |
| function patients | #3389 |
| contraception | #3390 |
| repeated | #3394 |
| 413 | #3395 |
| p0002 | #3397 |
| cava | #3399 |
| 311 | #3400 |
| acute treatment | #3403 |
| tunica | #3403 |
| 553 | #3403 |
| humans kaplan | #3408 |
| saved | #3415 |
| differs | #3418 |
| preventive | #3419 |
| randomisation | #3419 |
| surgical patients | #3420 |
| hypothesised | #3420 |
| study risk | #3420 |
| thrombocythemia | #3422 |
| odds | #3424 |
| confirm | #3425 |
| testimony | #3430 |
| competing | #3434 |
| natriuretic | #3437 |
| 70 | #3439 |
| ease | #3443 |
| asian patients | #3444 |
| 124 | #3445 |
| 519 | #3447 |
| 487 | #3451 |
| prevalence incidence | #3452 |
| 168 | #3452 |
| evening | #3458 |
| covid19 infection | #3464 |
| differ | #3470 |
| 34 | #3470 |
| intensive chemotherapy | #3471 |
| patients receive | #3472 |
| pregnancy complications | #3472 |
| worsened | #3476 |
| induced platelet | #3479 |
| undiagnosed | #3482 |
| antiphospholipid | #3485 |
| cancer metastasis | #3485 |
| increased morbidity | #3486 |
| lower leg | #3487 |
| asymptomatic | #3487 |
| paradox | #3490 |
| personyears | #3490 |
| pacemaker | #3493 |
| statistical methods | #3494 |
| convergent validity | #3496 |
| failure hf | #3497 |
| 201 | #3504 |
| hemorrhagic complications | #3506 |
| treat | #3506 |
| inhibitors | #3506 |
| 938 | #3513 |
| tomography angiography | #3521 |
| confirmed | #3522 |
| discusses | #3522 |
| 291 | #3527 |
| quintiles | #3529 |
| 95 confidence intervals | #3530 |
| lupus | #3533 |
| human cytomegalovirus | #3533 |
| areas covered | #3537 |
| societies | #3541 |
| guidance | #3541 |
| 113 | #3544 |
| gastro | #3551 |
| current practice | #3551 |
| 10 | #3552 |
| stroke risk | #3559 |
| baboons | #3560 |
| 344 | #3562 |
| benefits risks | #3564 |
| neutralize | #3565 |
| nsaids | #3566 |
| bibliographic | #3567 |
| depends | #3571 |
| patients recurrence | #3573 |
| inconsistent | #3575 |
| safety profiles | #3580 |
| 508 | #3584 |
| evaluates | #3592 |
| necessity | #3596 |
| prognosis prospective | #3596 |
| patient management | #3598 |
| prognostic significance | #3604 |
| vitamin | #3605 |
| risk stratification | #3606 |
| consensus document | #3617 |
| platelet function | #3619 |
| treated | #3619 |
| interval | #3622 |
| platelet activation | #3622 |
| mutation | #3624 |
| lipid profiles | #3626 |
| q3 | #3629 |
| kappa | #3629 |
| organ damage | #3635 |
| analysis performed | #3640 |
| 75 | #3641 |
| homozygote | #3642 |
| undergo | #3642 |
| bypass surgery | #3642 |
| externally | #3645 |
| p006 | #3645 |
| occlusions | #3646 |
| 1960 | #3649 |
| 30 | #3649 |
| fibrillation | #3651 |
| interindividual variability | #3651 |
| coronary events | #3656 |
| atherogenic | #3658 |
| newer | #3662 |
| patients 95 | #3667 |
| outcome administration | #3671 |
| optimal management | #3671 |
| endovascular treatment | #3678 |
| blinding | #3679 |
| treatment complications | #3680 |
| limited data | #3683 |
| 68 | #3684 |
| clopidogrel | #3685 |
| mammography | #3693 |
| myalgia | #3703 |
| 478 | #3706 |
| rationale | #3707 |
| 813 | #3708 |
| rebound | #3720 |
| diagnostic process | #3721 |
| drug monitoring | #3721 |
| pharmacodynamics | #3725 |
| inhibitors humans | #3725 |
| 130 | #3729 |
| unknown | #3731 |
| patient population | #3733 |
| serine proteases | #3736 |
| 349 | #3738 |
| humans intracranial | #3739 |
| effective | #3739 |
| factor 4 | #3741 |
| 585 | #3743 |
| 299 | #3744 |
| network meta | #3746 |
| homozygous | #3747 |
| 495 | #3750 |
| practitioner | #3752 |
| deterioration | #3754 |
| randomised | #3754 |
| objectives | #3759 |
| 8 patients | #3762 |
| subgroup analyses | #3762 |
| 00001 | #3765 |
| host defense | #3769 |
| statin therapy | #3772 |
| scarce | #3773 |
| computed ultrasonography | #3774 |
| clinicians patients | #3774 |
| inherited | #3775 |
| 517 | #3778 |
| interpretable | #3778 |
| 483 | #3782 |
| aminoglycosides | #3789 |
| total knee arthroplasty | #3789 |
| thyroid hormones | #3789 |
| 525 | #3791 |
| 412 | #3795 |
| 441 | #3797 |
| life illness | #3801 |
| 333 | #3802 |
| versus | #3803 |
| compelling | #3804 |
| vessel wall | #3804 |
| preexisting | #3808 |
| outcome measure | #3814 |
| patients lung cancer | #3815 |
| 330 | #3815 |
| valid | #3816 |
| iu | #3818 |
| 55 patients | #3821 |
| fv | #3823 |
| stasis | #3824 |
| lost | #3825 |
| compares | #3830 |
| itching | #3831 |
| proved | #3834 |
| osmolar | #3837 |
| elective | #3838 |
| hydrolases | #3839 |
| patient education | #3843 |
| 197 | #3849 |
| meeting | #3856 |
| irs | #3856 |
| anaesthesia | #3857 |
| 4 patients | #3858 |
| congresses | #3859 |
| acquired resistance | #3860 |
| review data | #3860 |
| male neoplasms | #3862 |
| preferred | #3864 |
| occurring | #3867 |
| death | #3880 |
| optimisation | #3884 |
| cancer survival | #3884 |
| record | #3885 |
| sensitivity | #3885 |
| avoids | #3887 |
| calculated | #3888 |
| difference | #3890 |
| 351 | #3890 |
| 184 | #3890 |
| 10000 | #3902 |
| halflives | #3903 |
| methylamines | #3903 |
| methimazole | #3904 |
| patients time | #3905 |
| incidence prevalence | #3908 |
| angiography | #3915 |
| specificity tomography | #3915 |
| coronary thrombosis | #3918 |
| decide | #3927 |
| 474 | #3931 |
| ankle | #3932 |
| 955 | #3935 |
| 458 | #3938 |
| jak2 | #3939 |
| extravasation | #3945 |
| case fatality | #3946 |
| 405 | #3946 |
| preeclampsia | #3952 |
| neurology | #3953 |
| 56 | #3956 |
| dichotomy | #3961 |
| p004 | #3961 |
| randomized clinical trials | #3963 |
| women | #3964 |
| carboxypeptidases | #3965 |
| postoperatively | #3966 |
| clinical effectiveness | #3968 |
| uncontrolled | #3970 |
| risk cancer | #3970 |
| behalf | #3971 |
| austrian | #3971 |
| cardiovascular events | #3972 |
| data studies | #3975 |
| 2nd | #3975 |
| quality assurance | #3980 |
| pregnancy | #3982 |
| 986 | #3982 |
| continuous infusion | #3983 |
| unstable | #3986 |
| flying | #3986 |
| month | #3987 |
| 488 | #3990 |
| systematic analysis | #3994 |
| sequentially | #4006 |
| calculate | #4010 |
| lower risk | #4011 |
| limited evidence | #4014 |
| patients evaluated | #4016 |
| scored | #4023 |
| secondary prevention | #4026 |
| 538 | #4028 |
| equivalence | #4029 |
| gln | #4031 |
| meyer | #4032 |
| cerebral venous | #4041 |
| 296 | #4045 |
| introduction | #4045 |
| 423 | #4047 |
| 262 | #4051 |
| ended | #4052 |
| validating | #4058 |
| received | #4062 |
| recurrent disease | #4066 |
| cruciate | #4073 |
| elevated | #4074 |
| compare | #4075 |
| bariatric | #4077 |
| pcc | #4077 |
| avoid | #4080 |
| 429 | #4081 |
| 326 | #4083 |
| hour | #4088 |
| oligosaccharides | #4089 |
| natriuretic peptide | #4089 |
| angioplasty balloon | #4091 |
| maneuver | #4092 |
| 3000 | #4093 |
| 16 | #4098 |
| activation | #4099 |
| indications | #4099 |
| cutoff | #4099 |
| contact | #4102 |
| pharmacological | #4106 |
| infusion rate | #4109 |
| 392 | #4113 |
| 335 | #4117 |
| 6 months treatment | #4119 |
| ptm | #4120 |
| completing | #4125 |
| patients low risk | #4133 |
| 008 | #4137 |
| withdrawn | #4137 |
| 41 | #4138 |
| bms | #4146 |
| patients died | #4149 |
| medical students | #4152 |
| haemorrhagic | #4154 |
| continue | #4158 |
| study control | #4161 |
| nulliparous | #4167 |
| patients prostate cancer | #4171 |
| 2030 | #4171 |
| antitumour | #4177 |
| steroidal | #4178 |
| multidisciplinary approach | #4189 |
| direct | #4192 |
| therapy combination | #4198 |
| casts | #4200 |
| 485 | #4212 |
| 411 | #4212 |
| medical center | #4214 |
| 408 | #4215 |
| weighted | #4221 |
| additional | #4222 |
| 452 | #4223 |
| 289 | #4226 |
| 121 | #4226 |
| trough | #4229 |
| crosssectional analysis | #4230 |
| p0005 | #4230 |
| hormonal | #4234 |
| veins | #4235 |
| cox regression | #4242 |
| patients mortality | #4242 |
| 178 | #4246 |
| nsaid | #4261 |
| 263 | #4263 |
| abbreviated | #4267 |
| encountered | #4268 |
| atrial fibrillation patients | #4274 |
| fab | #4279 |
| late pregnancy | #4285 |
| pai1 | #4286 |
| rise | #4287 |
| oral aged | #4294 |
| q4 | #4296 |
| 228 | #4303 |
| share | #4304 |
| 10 patients | #4306 |
| 105 | #4310 |
| rehospitalization | #4314 |
| patients increased risk | #4315 |
| 185 | #4316 |
| tat | #4319 |
| separate | #4322 |
| concentrates | #4328 |
| intima | #4329 |
| devised | #4331 |
| 294 | #4339 |
| 455 | #4340 |
| 102 | #4340 |
| pronounced | #4342 |
| incidental findings | #4345 |
| managed | #4350 |
| potential risk factors | #4350 |
| detrimental | #4356 |
| 253 | #4359 |
| agreed | #4360 |
| young age | #4363 |
| specialist | #4379 |
| minutes | #4383 |
| rapid | #4383 |
| retrospective studies | #4384 |
| 447 | #4385 |
| cd11b | #4387 |
| 288 | #4391 |
| 170 | #4392 |
| slice | #4394 |
| concurrently | #4394 |
| risk cardiovascular | #4396 |
| steadily | #4402 |
| 239 | #4406 |
| negative | #4407 |
| 71 | #4407 |
| general | #4407 |
| bowel diseases | #4407 |
| guideline recommendations | #4408 |
| postoperative day | #4409 |
| ventilation | #4413 |
| splanchnic | #4417 |
| lacking | #4417 |
| dose aspirin | #4419 |
| immunoassays | #4419 |
| recombinant proteins | #4423 |
| 3 patients | #4426 |
| author | #4427 |
| 148 | #4428 |
| 281 | #4429 |
| primary myelofibrosis | #4430 |
| appropriateness | #4433 |
| profoundly | #4436 |
| completed | #4438 |
| platelet | #4440 |
| cellulitis | #4441 |
| sixteen | #4442 |
| concomitant | #4445 |
| assays | #4453 |
| 334 | #4458 |
| vascular surgery | #4459 |
| 192 | #4459 |
| cytomegalovirus infection | #4461 |
| proband | #4461 |
| total costs | #4474 |
| 377 | #4479 |
| 443 | #4482 |
| clinical manifestations | #4486 |
| cd18 | #4486 |
| pancreatic cancer | #4487 |
| inadequate | #4487 |
| coronavirus disease covid19 | #4489 |
| smr | #4492 |
| risk prediction | #4493 |
| bus | #4497 |
| current management | #4498 |
| 476 | #4499 |
| doubling | #4500 |
| infected patients | #4502 |
| comprises | #4503 |
| activation platelet | #4503 |
| 54 | #4513 |
| primary diagnosis | #4515 |
| alpha2 | #4516 |
| therapeutic | #4532 |
| septic | #4534 |
| 3 groups | #4535 |
| male pulmonary | #4541 |
| 526 | #4542 |
| elastase | #4544 |
| hitherto | #4546 |
| fairly | #4552 |
| cardiovascular death | #4559 |
| 985 | #4564 |
| 1250 | #4567 |
| cerebrovascular disorders | #4571 |
| calculating | #4571 |
| multicenter trial | #4574 |
| 2c | #4585 |
| debate | #4586 |
| disadvantage | #4588 |
| plasma concentrations | #4591 |
| 283 | #4592 |
| attenuating | #4594 |
| preserves | #4594 |
| gradual | #4595 |
| eventually | #4595 |
| simplified | #4596 |
| 204 | #4596 |
| 4 | #4601 |
| 4000 | #4601 |
| encouraged | #4603 |
| icer | #4610 |
| frequently | #4611 |
| acetylsalicylic acid | #4613 |
| vii | #4613 |
| vaginal | #4614 |
| 917 | #4619 |
| assay | #4634 |
| subclinical atherosclerosis | #4636 |
| risks benefits | #4640 |
| hospital costs | #4640 |
| 242 | #4642 |
| genetic risk factors | #4644 |
| escalating | #4648 |
| priori | #4654 |
| 003 | #4658 |
| habitual | #4658 |
| survey | #4659 |
| transurethral | #4663 |
| myelofibrosis | #4670 |
| 171 | #4670 |
| thyroid hormone | #4673 |
| 40 | #4675 |
| 407 | #4679 |
| day | #4680 |
| fh | #4680 |
| recurrent stroke | #4681 |
| wheezing | #4693 |
| unchanged | #4698 |
| ranging | #4698 |
| 5 patients | #4701 |
| complicated | #4703 |
| truncated | #4709 |
| therapeutic intervention | #4715 |
| differential humans | #4719 |
| immobilization | #4725 |
| 129 | #4727 |
| orthopedic | #4735 |
| cardiovascular morbidity | #4738 |
| current guidelines | #4739 |
| therapeutic strategies | #4744 |
| ranged | #4769 |
| 027 | #4774 |
| chronic renal | #4775 |
| baseline patients | #4775 |
| acute coronary | #4784 |
| 44 | #4785 |
| scheduled | #4785 |
| molecular | #4792 |
| knee | #4800 |
| insulin glargine | #4801 |
| prophylactic | #4802 |
| arthroplasty | #4803 |
| alternatively | #4810 |
| extracranial | #4813 |
| courses | #4819 |
| diagnostic imaging | #4825 |
| therapy humans | #4836 |
| echocardiography | #4846 |
| 174 | #4848 |
| cholesterol levels | #4853 |
| definition | #4861 |
| acl | #4861 |
| efficiency | #4869 |
| gpiib | #4870 |
| nonvalvular atrial fibrillation | #4870 |
| increased plasma | #4875 |
| unexposed | #4876 |
| gynecological | #4880 |
| antiphospholipid syndrome | #4881 |
| screening tool | #4884 |
| 322 | #4886 |
| total | #4891 |
| antiplatelet therapy | #4891 |
| treating | #4896 |
| abstracted | #4897 |
| doses | #4902 |
| ischemic heart disease | #4905 |
| tests prognosis | #4906 |
| preparations | #4906 |
| served | #4910 |
| chlamydophila | #4913 |
| fmd | #4913 |
| 560 | #4914 |
| recommendation | #4918 |
| geriatrics | #4920 |
| acute ischemic | #4923 |
| renal dysfunction | #4929 |
| 556 | #4932 |
| 154 | #4933 |
| 870 | #4934 |
| cpb | #4939 |
| 325 | #4951 |
| 26 | #4952 |
| satisfied | #4957 |
| appeared | #4959 |
| fund | #4972 |
| dose | #4976 |
| manufacturers | #4976 |
| albeit | #4982 |
| orthopedics | #4982 |
| recommended | #4987 |
| cardiology | #5000 |
| references | #5006 |
| 389 | #5006 |
| reminder | #5009 |
| epoprostenol | #5009 |
| probnp | #5014 |
| point mutation | #5018 |
| risk women | #5023 |
| syndrome patients | #5033 |
| 156 | #5040 |
| screening test | #5040 |
| proposal | #5042 |
| global burden | #5044 |
| primary health | #5045 |
| analytic | #5047 |
| obstetrical | #5048 |
| lasted | #5049 |
| patients sepsis | #5051 |
| limitations | #5055 |
| diagnosis management | #5058 |
| patients myocardial infarction | #5062 |
| spinal surgery | #5065 |
| 255 | #5068 |
| conflicting | #5070 |
| saphenous | #5075 |
| inaccessible | #5078 |
| 1a | #5079 |
| switched | #5084 |
| evaluable | #5089 |
| regarded | #5089 |
| relation | #5090 |
| hip fractures | #5090 |
| transluminal | #5093 |
| menstrual | #5094 |
| fashion | #5098 |
| amputation | #5102 |
| external validation | #5103 |
| arteritis | #5107 |
| inflammatory responses | #5109 |
| oxadiazoles | #5110 |
| dalys | #5112 |
| tailor | #5115 |
| admission patients | #5118 |
| composite | #5120 |
| discriminative | #5123 |
| vivo studies | #5124 |
| bay | #5124 |
| 108 | #5125 |
| 282 | #5129 |
| ischaemic stroke | #5130 |
| 0018 | #5130 |
| 131 | #5131 |
| female | #5131 |
| transfused | #5134 |
| balancing | #5136 |
| contrast media | #5136 |
| fetal death | #5138 |
| activator | #5139 |
| scans | #5143 |
| 341 | #5146 |
| n6 | #5150 |
| kg1 | #5151 |
| disagreement | #5157 |
| shortly | #5157 |
| preclinical studies | #5160 |
| doppler | #5165 |
| 11 patients | #5170 |
| predispose | #5170 |
| hazard | #5171 |
| readers | #5173 |
| prescriptions | #5174 |
| graft failure | #5178 |
| weaknesses | #5185 |
| renal impairment | #5186 |
| 70 patients | #5190 |
| infarctions | #5191 |
| screening | #5193 |
| threefold | #5198 |
| highest | #5202 |
| extracellular vesicles | #5204 |
| acs | #5205 |
| 144 | #5206 |
| hospital patients | #5208 |
| remains | #5209 |
| excess mortality | #5210 |
| doppler color | #5221 |
| polysaccharides | #5223 |
| heparan | #5229 |
| emergencies | #5233 |
| articles | #5233 |
| indwelling | #5241 |
| flowmetry | #5242 |
| gram | #5244 |
| 3 | #5248 |
| platelet aggregation | #5252 |
| considerably | #5253 |
| comparison | #5262 |
| testing | #5264 |
| plasma levels | #5265 |
| estimate | #5288 |
| pooling | #5289 |
| 365 | #5289 |
| aware | #5300 |
| thrombus | #5301 |
| 36 patients | #5301 |
| urokinase | #5302 |
| atherogenesis | #5302 |
| triage | #5303 |
| case reports | #5305 |
| benefit | #5308 |
| reversal | #5310 |
| stroke treatment | #5314 |
| contrasted | #5316 |
| orthomyxoviridae | #5319 |
| openlabel | #5320 |
| 70 years | #5325 |
| aged postoperative | #5330 |
| animal drug evaluation | #5332 |
| dizziness | #5334 |
| absent | #5335 |
| factor humans | #5336 |
| stratify | #5340 |
| reagent | #5341 |
| acute ischemic stroke | #5341 |
| blood vessel | #5343 |
| ultrasound imaging | #5344 |
| fatality | #5347 |
| contrast agents | #5355 |
| arose | #5361 |
| schedule drug | #5363 |
| male | #5363 |
| based guidelines | #5370 |
| hyper | #5372 |
| obstetric | #5376 |
| accepted | #5383 |
| thyrotropin | #5401 |
| informed consent | #5402 |
| blood products | #5405 |
| selected patients | #5406 |
| adult | #5407 |
| heart valve | #5409 |
| intracranial | #5411 |
| questionnaire | #5414 |
| register | #5415 |
| summarized | #5416 |
| 19 | #5417 |
| noninvasive | #5421 |
| clinical risk | #5424 |
| nonsignificant | #5429 |
| protein levels | #5430 |
| concerns | #5439 |
| charts | #5440 |
| hyperprolactinemia | #5441 |
| familiarity | #5442 |
| 37 | #5445 |
| 630 | #5448 |
| retrieved | #5450 |
| cancer growth | #5455 |
| presently | #5456 |
| congenital heart | #5465 |
| registered | #5470 |
| recombinant human | #5474 |
| intermediate | #5475 |
| 340 | #5476 |
| 395 | #5484 |
| allocation | #5488 |
| 247 | #5490 |
| occurrences | #5490 |
| moyamoya disease | #5491 |
| ntprobnp | #5493 |
| kaplan meier | #5496 |
| patient risk | #5497 |
| 260 | #5497 |
| continuing | #5499 |
| discomfort | #5499 |
| 9 patients | #5500 |
| postal | #5503 |
| ssris | #5515 |
| correctly | #5517 |
| weight | #5524 |
| 309 | #5530 |
| period | #5533 |
| erythema | #5539 |
| limitation | #5539 |
| suggestions | #5541 |
| survival benefit | #5542 |
| imputed | #5545 |
| receptor1 | #5563 |
| established | #5563 |
| 175 | #5565 |
| 545 | #5566 |
| management | #5569 |
| 46 | #5573 |
| reduce risk | #5573 |
| 324 | #5595 |
| excludes | #5597 |
| circulating levels | #5598 |
| equivalent | #5598 |
| categorical | #5600 |
| stm | #5607 |
| grounds | #5617 |
| expert | #5620 |
| 02 | #5624 |
| microgram | #5626 |
| minus | #5627 |
| premenopausal women | #5629 |
| retrieve | #5633 |
| food preferences | #5637 |
| drug administration | #5641 |
| platelet count | #5643 |
| 80 years | #5644 |
| reclassification | #5644 |
| 65 | #5651 |
| trial | #5653 |
| 087 | #5667 |
| published data | #5671 |
| 48 | #5676 |
| seventy | #5684 |
| 214 | #5689 |
| latex | #5690 |
| platelet glycoprotein | #5692 |
| reproducible | #5696 |
| 1997 | #5698 |
| meier | #5714 |
| 370 | #5718 |
| return | #5721 |
| 40 years | #5729 |
| atherosclerotic | #5730 |
| 89 | #5732 |
| perform | #5734 |
| 995 | #5748 |
| 091 | #5755 |
| stand | #5756 |
| 0014 | #5761 |
| metabolic effects | #5764 |
| milder | #5771 |
| semiquantitative | #5771 |
| 241 | #5777 |
| recurrence patients | #5781 |
| varied | #5784 |
| creatinine clearance | #5788 |
| 3rd | #5791 |
| incidence rates | #5804 |
| mpo | #5804 |
| 95 women | #5809 |
| orthopedic procedures | #5810 |
| male middle aged | #5811 |
| url | #5812 |
| 1000 | #5819 |
| aircraft | #5819 |
| income countries | #5828 |
| diagnosed | #5840 |
| undergoing surgery | #5843 |
| true | #5852 |
| atrial | #5852 |
| 088 | #5854 |
| attending | #5856 |
| 290 | #5857 |
| women pregnancy | #5857 |
| hip | #5866 |
| advantageous | #5875 |
| complete resolution | #5878 |
| reliable | #5894 |
| occurrence | #5894 |
| excluded | #5899 |
| aged models | #5919 |
| adding | #5923 |
| safety patients | #5927 |
| aged platelet | #5928 |
| 22 patients | #5928 |
| graded | #5934 |
| premenopause | #5938 |
| revision | #5938 |
| 353 | #5945 |
| prodrugs | #5946 |
| rrs | #5949 |
| 141 | #5952 |
| gastrointestinal hemorrhage | #5954 |
| janus kinase | #5959 |
| rcts | #5962 |
| 43 | #5962 |
| families | #5967 |
| 328 | #5971 |
| deemed | #5977 |
| savings | #5980 |
| counseling | #5985 |
| blood platelets | #5987 |
| blood | #5990 |
| receiver operating | #5996 |
| guideline | #5998 |
| cancer incidence | #6006 |
| current standard | #6013 |
| therapeutic interventions | #6028 |
| nadir | #6034 |
| registries risk | #6039 |
| patients experience | #6042 |
| allocated | #6044 |
| ≥3 | #6052 |
| wash | #6059 |
| advance | #6062 |
| quarter | #6065 |
| spect | #6068 |
| glycosaminoglycans | #6069 |
| decompensated | #6074 |
| 24 | #6076 |
| bacteremia | #6090 |
| topics | #6101 |
| type iii | #6101 |
| suggestive | #6105 |
| emerging evidence | #6113 |
| prevent | #6117 |
| safety data | #6120 |
| directly | #6133 |
| 72 | #6135 |
| 267 | #6136 |
| lipid profile | #6140 |
| ≥2 | #6144 |
| normalization | #6151 |
| centuries | #6153 |
| 47 | #6157 |
| generation | #6160 |
| ffa | #6160 |
| lobar | #6161 |
| agents blood | #6164 |
| 292 | #6165 |
| informed | #6173 |
| pharmacodynamic | #6188 |
| lung male | #6190 |
| updating | #6192 |
| advantages disadvantages | #6194 |
| lower | #6195 |
| bilateral | #6198 |
| cyclosporine | #6208 |
| tumour growth | #6212 |
| pathogenetic | #6221 |
| femoral artery | #6224 |
| terminated | #6228 |
| mortality morbidity | #6228 |
| new drugs | #6229 |
| 312 | #6230 |
| evidence base | #6232 |
| vitro studies | #6234 |
| crp | #6235 |
| discontinued | #6236 |
| 111 | #6240 |
| abdomen | #6248 |
| denmark | #6254 |
| proportional | #6268 |
| colleagues | #6273 |
| practitioners | #6273 |
| administered | #6277 |
| 1978 | #6283 |
| screened | #6293 |
| infused | #6297 |
| 840 | #6318 |
| prostatectomy | #6330 |
| 017 | #6334 |
| saphenous vein | #6339 |
| 63 | #6340 |
| 135 | #6340 |
| percentile | #6344 |
| higher doses | #6345 |
| adequacy | #6347 |
| divided | #6348 |
| apache | #6351 |
| screen | #6357 |
| opinions | #6360 |
| opposed | #6362 |
| percentage | #6370 |
| longterm followup | #6372 |
| risk mortality | #6386 |
| dyslipidemias | #6390 |
| kaplan | #6391 |
| consensus | #6392 |
| 208 | #6397 |
| potential mechanisms | #6404 |
| roche | #6405 |
| factor gene | #6405 |
| initiated | #6408 |
| compensated | #6411 |
| investigating | #6427 |
| ultrasound | #6441 |
| restenosis | #6442 |
| bootstrap | #6452 |
| collection | #6457 |
| post operative | #6464 |
| enzyme linked | #6467 |
| bariatric surgery | #6468 |
| coronary syndrome | #6469 |
| decreased risk | #6471 |
| 218 | #6472 |
| perfusion | #6475 |
| imbalance | #6484 |
| angina pectoris | #6493 |
| calendar | #6498 |
| peripheral artery disease | #6501 |
| accuracy | #6501 |
| incidence risk | #6502 |
| cancer cell | #6502 |
| complement activation | #6505 |
| pregnancies | #6519 |
| surgical procedure | #6520 |
| supervised | #6521 |
| models male | #6522 |
| 138 | #6523 |
| triiodothyronine | #6524 |
| 318 | #6524 |
| washout | #6524 |
| peripheral | #6525 |
| vena | #6527 |
| cochrane | #6532 |
| highrisk patients | #6532 |
| increased incidence | #6532 |
| placebo patients | #6536 |
| replaced | #6537 |
| bowel | #6538 |
| exogenous | #6538 |
| thirteen | #6540 |
| aspirin patients | #6540 |
| year | #6546 |
| superior | #6549 |
| clinical assessment | #6550 |
| cohorts | #6555 |
| dilemma | #6560 |
| crt | #6561 |
| dosing | #6576 |
| tertile | #6581 |
| 231 | #6586 |
| limited | #6589 |
| md | #6592 |
| prediction | #6596 |
| treatment choice | #6600 |
| pooled | #6601 |
| occurs | #6610 |
| 510 | #6611 |
| belgium | #6620 |
| crude | #6621 |
| injections | #6638 |
| genetic testing | #6641 |
| pancreatic neoplasms | #6641 |
| individual | #6650 |
| complications | #6650 |
| complaints | #6652 |
| degranulation | #6663 |
| methylenetetrahydrofolate | #6665 |
| liver diseases | #6674 |
| patents | #6680 |
| smoking cessation | #6696 |
| 17 patients | #6704 |
| routinely | #6706 |
| tumour progression | #6708 |
| saline | #6709 |
| 194 | #6713 |
| approval | #6727 |
| hazard ratios | #6729 |
| recognised | #6729 |
| thromboxane | #6734 |
| allcause mortality | #6744 |
| multicenter | #6747 |
| appropriately | #6748 |
| increasing age | #6751 |
| body temperature | #6766 |
| 385 | #6766 |
| q1 | #6768 |
| clinical signs | #6771 |
| age patients | #6774 |
| defined | #6780 |
| 2 groups | #6780 |
| expense | #6781 |
| 42 patients | #6791 |
| train | #6796 |
| hyperglycemia | #6801 |
| premedication | #6803 |
| reached | #6803 |
| plasma proteins | #6807 |
| response relationship | #6807 |
| benefits | #6810 |
| cardiovascular risk | #6821 |
| 256 | #6831 |
| 280 | #6838 |
| iqr | #6839 |
| glucocorticoids | #6840 |
| summary | #6850 |
| 279 | #6854 |
| cancer diagnosis | #6856 |
| systematic | #6870 |
| points | #6877 |
| ambulatory | #6883 |
| weekly | #6884 |
| reviews | #6891 |
| physicians | #6893 |
| fibrillation patients | #6898 |
| disturbances | #6912 |
| adverse event | #6912 |
| sought | #6918 |
| 112 | #6923 |
| 251 | #6940 |
| complications patients | #6948 |
| vasopressin | #6957 |
| failure | #6965 |
| subsequent | #6971 |
| hematologic | #6974 |
| 246 | #6976 |
| intensity | #6976 |
| humans hydroxymethylglutaryl | #6982 |
| papers | #6983 |
| tpa | #6986 |
| intervals | #6987 |
| addressed | #6989 |
| 259 | #6992 |
| 222 | #6995 |
| shock septic | #6995 |
| adapted | #6998 |
| disclosed | #7001 |
| incidence risk factors | #7008 |
| hazards models | #7015 |
| cardiovascular disease | #7019 |
| myeloperoxidase | #7020 |
| lung cancer patients | #7023 |
| stenting | #7024 |
| responded | #7026 |
| cohort | #7037 |
| 1 patient | #7038 |
| unacceptable | #7039 |
| interleukin8 | #7042 |
| reductases | #7045 |
| preventing | #7056 |
| curve | #7058 |
| patients baseline | #7065 |
| animal doseresponse relationship | #7071 |
| reduced risk | #7075 |
| written | #7080 |
| applicability | #7084 |
| asymptomatic patients | #7086 |
| monoclonal antibody | #7098 |
| hospitalization humans | #7101 |
| betacoronavirus covid19 | #7104 |
| computed | #7104 |
| novartis | #7108 |
| complications pregnancy | #7111 |
| infarction stroke | #7114 |
| superiority | #7116 |
| interquartile range | #7120 |
| select | #7122 |
| carotid intima | #7141 |
| internationality | #7146 |
| surveys questionnaires | #7160 |
| 163 | #7166 |
| pharmacy | #7167 |
| patients renal | #7171 |
| physicians patients | #7177 |
| randomization | #7184 |
| liver cirrhosis | #7187 |
| 211 | #7188 |
| brain metastases | #7190 |
| oral animals | #7192 |
| walking | #7195 |
| drawn | #7196 |
| combination | #7197 |
| 5year | #7204 |
| withdrawal | #7204 |
| cardiovascular disease cvd | #7210 |
| acting | #7210 |
| disposition | #7212 |
| paucity | #7218 |
| humans lung | #7221 |
| 20 patients | #7225 |
| sulfate | #7240 |
| operating characteristic | #7244 |
| treatment children | #7250 |
| vldl | #7250 |
| hematocrit | #7255 |
| retrospective cohort study | #7257 |
| 199 | #7257 |
| alongside | #7258 |
| clinical benefit | #7265 |
| controls | #7267 |
| diagnostics | #7270 |
| option | #7273 |
| grouped | #7275 |
| young women | #7278 |
| products | #7282 |
| likelihood | #7284 |
| modest | #7290 |
| sensitivity analysis | #7290 |
| atrium | #7291 |
| 360 | #7303 |
| types | #7304 |
| factors stroke | #7305 |
| undergoing | #7327 |
| partial | #7330 |
| patients isolated | #7332 |
| ischemic stroke | #7338 |
| pectoris | #7338 |
| 1c | #7352 |
| interleukin6 | #7352 |
| standardised | #7356 |
| p0001 | #7356 |
| myocardial infarction | #7356 |
| betacoronavirus | #7357 |
| simple | #7360 |
| radiology | #7379 |
| pap | #7392 |
| patients aspirin | #7400 |
| angiopathies | #7401 |
| regimens | #7405 |
| 109 | #7409 |
| bias | #7411 |
| peptide fragments | #7413 |
| iiia | #7424 |
| intravenous injection | #7429 |
| 420 | #7431 |
| propranolol | #7438 |
| favourable | #7440 |
| hypercholesterolemia | #7441 |
| respective | #7444 |
| dose dependent | #7447 |
| infusion | #7448 |
| clinical setting | #7454 |
| ways | #7465 |
| risk adverse | #7497 |
| il6 | #7510 |
| mortality rates | #7515 |
| 209 | #7516 |
| considerations | #7517 |
| exclusions | #7518 |
| patient safety | #7520 |
| angina | #7522 |
| urgently | #7522 |
| cmv infection | #7541 |
| phase iii | #7555 |
| 257 | #7558 |
| € | #7559 |
| interim | #7561 |
| injection | #7564 |
| cinahl | #7578 |
| 191 | #7578 |
| comorbid | #7578 |
| pheochromocytoma | #7585 |
| ischaemic | #7598 |
| antibodies monoclonal | #7601 |
| reasons | #7602 |
| tended | #7608 |
| pooled analysis | #7609 |
| azathioprine | #7615 |
| 13 | #7616 |
| predictor | #7620 |
| femoral | #7640 |
| random allocation | #7646 |
| 29 patients | #7647 |
| epidemiological studies | #7647 |
| abrupt | #7655 |
| derivation | #7662 |
| interquartile | #7675 |
| manifestation | #7676 |
| temporary | #7679 |
| positive patients | #7687 |
| 18 | #7705 |
| medical conditions | #7705 |
| seventeen | #7710 |
| 304 | #7719 |
| ligament | #7732 |
| consent | #7733 |
| study association | #7735 |
| cytomegalovirus | #7736 |
| severe | #7742 |
| adverse outcomes | #7745 |
| costs | #7753 |
| cardiac surgical | #7760 |
| 189 | #7770 |
| cochrane library | #7771 |
| pregnancy outcome | #7787 |
| manufacturer | #7802 |
| 110 | #7802 |
| ≤ | #7803 |
| 9 | #7811 |
| oxygenases | #7813 |
| male gender | #7815 |
| interleukin | #7816 |
| pts | #7819 |
| label | #7828 |
| hormone replacement | #7828 |
| 31 patients | #7828 |
| cpr | #7829 |
| 5 | #7833 |
| abortion | #7838 |
| influenza | #7845 |
| radiation exposure | #7850 |
| regular | #7877 |
| tramadol | #7878 |
| academic | #7878 |
| septic patients | #7880 |
| 95 confidence | #7884 |
| replacing | #7886 |
| patients chemotherapy | #7888 |
| iib | #7908 |
| journals | #7922 |
| strict | #7927 |
| expertise | #7928 |
| bioavailability | #7930 |
| adoption | #7934 |
| urogenital | #7939 |
| highrisk | #7939 |
| diseased | #7944 |
| increasing evidence | #7947 |
| disadvantages | #7949 |
| 243 | #7965 |
| patients 1 | #7972 |
| human blood | #7973 |
| fragment | #7975 |
| new class | #7976 |
| 28 | #7989 |
| individualized | #7990 |
| aim | #7992 |
| premenopausal | #7995 |
| advice | #8016 |
| qol | #8022 |
| malignant disease | #8026 |
| pulmonary disease | #8031 |
| 99mtc | #8034 |
| oligonucleotides | #8040 |
| vascular disease | #8049 |
| 600 | #8051 |
| preventable | #8051 |
| medical | #8051 |
| list | #8059 |
| selective | #8062 |
| routine clinical | #8068 |
| fact | #8078 |
| lasting | #8080 |
| helpful | #8084 |
| 36 months | #8086 |
| outcome acute | #8092 |
| extracorporeal | #8095 |
| 248 | #8113 |
| 90 | #8114 |
| training | #8120 |
| patients heart | #8120 |
| 2004 | #8122 |
| initiating | #8123 |
| tsh | #8125 |
| cholesterol ldl | #8138 |
| sensorineural | #8140 |
| investigational | #8141 |
| imaging studies | #8141 |
| mild | #8156 |
| nosocomial | #8164 |
| multiple organ | #8175 |
| stroke | #8176 |
| 237 | #8183 |
| 158 | #8184 |
| arteries | #8190 |
| confidence | #8204 |
| parenteral nutrition | #8204 |
| renal dialysis | #8209 |
| 33 | #8223 |
| impairment | #8228 |
| renal function | #8228 |
| 81 | #8233 |
| therapy | #8235 |
| quantitative | #8240 |
| smoking | #8243 |
| lowest | #8250 |
| lists | #8250 |
| version | #8260 |
| activated | #8264 |
| 125i | #8264 |
| minimum | #8270 |
| mortality | #8280 |
| leukopenia | #8281 |
| 0008 | #8284 |
| agents | #8286 |
| 119 | #8290 |
| utilisation | #8298 |
| practice | #8310 |
| suffered | #8316 |
| schedule | #8320 |
| thrombectomy | #8322 |
| postulated | #8338 |
| endothelium vascular | #8338 |
| immunosorbent assay | #8339 |
| elimination | #8341 |
| linked immunosorbent | #8345 |
| hematology | #8351 |
| 2 years | #8382 |
| absence presence | #8382 |
| cell derived | #8384 |
| 229 | #8394 |
| draw | #8405 |
| 28 patients | #8415 |
| occur | #8415 |
| ≥50 | #8416 |
| reports | #8427 |
| 137 | #8433 |
| mentioned | #8436 |
| covid19 coronavirus | #8447 |
| 265 | #8452 |
| glucuronidase | #8458 |
| patient characteristics | #8459 |
| procedures operative | #8463 |
| transient ischemic | #8463 |
| 295 | #8466 |
| exceed | #8486 |
| knowledge | #8493 |
| 27 patients | #8496 |
| evaluate | #8501 |
| covariate | #8501 |
| criterion | #8504 |
| inborn | #8519 |
| validate | #8528 |
| rabbits | #8537 |
| atherosclerosis | #8557 |
| large cohort | #8558 |
| menstrual cycle | #8563 |
| 193 | #8565 |
| 250 | #8568 |
| adjusted life | #8574 |
| leukocytes | #8581 |
| adolescent | #8582 |
| 146 | #8582 |
| row | #8590 |
| carotid arteries | #8596 |
| thirty | #8596 |
| safety profile | #8602 |
| cox | #8604 |
| intensities | #8605 |
| risks | #8606 |
| fish oil | #8624 |
| 15 years | #8624 |
| attenuates | #8625 |
| entry | #8639 |
| thresholds | #8646 |
| presumed | #8652 |
| emissioncomputed | #8654 |
| 223 | #8655 |
| hydroxymethylglutaryl coa | #8656 |
| valves | #8658 |
| syndrome | #8664 |
| factors patients | #8666 |
| evaluations | #8679 |
| certainty | #8687 |
| markers | #8689 |
| renal failure | #8690 |
| biomarkers | #8693 |
| polytetrafluoroethylene | #8698 |
| publication aged aged | #8706 |
| portal vein | #8708 |
| hold | #8723 |
| 1 2 | #8723 |
| additional studies | #8726 |
| cardiotonic | #8729 |
| definitions | #8731 |
| address | #8733 |
| judgment | #8744 |
| platelet counts | #8754 |
| requiring | #8755 |
| practical | #8756 |
| cardiovascular | #8756 |
| endovascular | #8756 |
| vasoactive | #8762 |
| 236 | #8763 |
| interpret | #8766 |
| undetected | #8778 |
| subpopulation | #8789 |
| medical treatment | #8792 |
| illnesses | #8798 |
| cardiovascular mortality | #8802 |
| 249 | #8834 |
| internship | #8836 |
| hydroxymethylglutaryl | #8837 |
| convenient | #8837 |
| resolving | #8863 |
| representative | #8864 |
| 2 | #8872 |
| cesarean | #8876 |
| merits | #8887 |
| endarterectomy | #8896 |
| chronic liver disease | #8902 |
| mimics | #8903 |
| early treatment | #8910 |
| surgical intervention | #8911 |
| planned | #8914 |
| micrograms | #8914 |
| epoxide | #8916 |
| aged myocardial | #8919 |
| influenced | #8934 |
| normal subjects | #8936 |
| signs symptoms | #8945 |
| proportional hazards | #8945 |
| clinicians | #8956 |
| cessation | #8958 |
| experienced | #8960 |
| heparan sulfate | #8962 |
| leads | #8973 |
| 24 hours | #8977 |
| rct | #8980 |
| options | #9002 |
| patients placebo | #9002 |
| chemoprevention | #9005 |
| comprise | #9005 |
| societies medical | #9007 |
| clinical events | #9007 |
| reply | #9017 |
| receiver | #9026 |
| rank | #9043 |
| 7 | #9061 |
| databases factual | #9064 |
| early mortality | #9075 |
| mps | #9080 |
| diagnose | #9080 |
| frequency | #9083 |
| jan | #9088 |
| statins | #9090 |
| alpha1 | #9115 |
| blood proteins | #9116 |
| prone | #9142 |
| valve prosthesis | #9147 |
| time points | #9147 |
| patient patients | #9150 |
| pelvis | #9158 |
| square | #9165 |
| life threatening | #9170 |
| molecular mechanisms | #9179 |
| 75 patients | #9183 |
| advanced stage | #9184 |
| lysis | #9190 |
| editor | #9193 |
| consensus statement | #9209 |
| 361 | #9213 |
| considerable | #9225 |
| platelets | #9226 |
| 1 month | #9227 |
| dyspnea | #9230 |
| pci | #9230 |
| performs | #9233 |
| contrast | #9238 |
| 4 hours | #9259 |
| extrinsic | #9263 |
| illness surveys | #9264 |
| hazards | #9264 |
| experts | #9266 |
| uncomplicated | #9267 |
| mumol | #9278 |
| attenuation | #9283 |
| rabbit | #9286 |
| positive | #9286 |
| trial registration | #9297 |
| corresponded | #9298 |
| dialysis | #9319 |
| feasibility | #9320 |
| earlier | #9339 |
| suboptimal | #9342 |
| p0004 | #9355 |
| patients negative | #9355 |
| preceded | #9376 |
| loss | #9378 |
| higher incidence | #9380 |
| 014 | #9380 |
| purposes | #9383 |
| invited | #9384 |
| single center | #9385 |
| death patients | #9391 |
| radioactivity | #9394 |
| bacterial infections | #9401 |
| fourth | #9402 |
| 2b | #9412 |
| ascending | #9415 |
| haemorrhage | #9425 |
| 167 | #9436 |
| properly | #9442 |
| rheumatic | #9446 |
| hospitalised | #9448 |
| dysfunction | #9460 |
| belonged | #9480 |
| secondary analysis | #9483 |
| respiratory tract | #9486 |
| 169 | #9490 |
| 240 | #9493 |
| ipd | #9502 |
| factual | #9503 |
| valvular | #9505 |
| thyroid function | #9507 |
| selectin | #9509 |
| hrs | #9524 |
| inflammatory agents | #9529 |
| confirms | #9530 |
| designed | #9535 |
| cardiopulmonary bypass | #9540 |
| swelling | #9542 |
| 3 4 | #9544 |
| insight | #9557 |
| cooperation | #9561 |
| requirements | #9566 |
| hemoglobins | #9573 |
| rose | #9592 |
| il10 | #9597 |
| observational cohort | #9598 |
| lpa | #9600 |
| rates | #9617 |
| comparative effectiveness | #9630 |
| primary point | #9638 |
| kidney failure | #9638 |
| successful treatment | #9639 |
| laboratories | #9644 |
| cardiogenic | #9645 |
| optimal treatment | #9650 |
| 2008 | #9656 |
| hf | #9670 |
| published | #9674 |
| congestive | #9695 |
| pathophysiological | #9704 |
| patients hospital | #9713 |
| spontaneously | #9720 |
| modalities | #9721 |
| inappropriate | #9724 |
| reuptake | #9727 |
| acts | #9729 |
| identifier | #9730 |
| 2007 | #9732 |
| lactoferrin | #9734 |
| 42 | #9744 |
| substitutes | #9747 |
| hypothetical | #9754 |
| nested | #9764 |
| nonesterified | #9768 |
| 90 patients | #9777 |
| reproducibility | #9778 |
| sepsis | #9802 |
| 210 | #9803 |
| absence | #9813 |
| straightforward | #9814 |
| precise | #9817 |
| easily | #9817 |
| coa reductase | #9828 |
| nmol | #9828 |
| classification | #9836 |
| craniotomy | #9839 |
| 212 | #9839 |
| 0006 | #9849 |
| utility | #9855 |
| danish | #9857 |
| labile | #9865 |
| nonhuman primates | #9871 |
| heterozygotes | #9871 |
| discordant | #9908 |
| moderately | #9919 |
| cmv | #9930 |
| 60 years | #9933 |
| lower limb | #9936 |
| promise | #9937 |
| degradation | #9941 |
| 2003 | #9941 |
| tomography | #9944 |
| treatment strategy | #9951 |
| 216 | #9958 |
| low dose | #9971 |
| investigator | #9983 |
| detecting | #9992 |
| regimen | #9995 |
| pancreatic | #9997 |
| 12 hours | #9997 |
| casecontrol studies | #9997 |
| 213 | #10000 |
| neoplasm metastasis | #10001 |
| chance | #10008 |
| physician | #10015 |
| extending | #10027 |
| informative | #10028 |
| hereditary | #10041 |
| obstacles | #10045 |
| protective | #10045 |
| addressing | #10051 |
| medication adherence | #10052 |
| mthfr | #10079 |
| presentations | #10082 |
| familial | #10087 |
| higher prevalence | #10089 |
| chart | #10108 |
| recipients | #10113 |
| qualitative | #10117 |
| 1980 | #10134 |
| completely | #10145 |
| tested | #10150 |
| aged obesity | #10170 |
| 182 | #10176 |
| invasive | #10181 |
| abnormalities | #10186 |
| regularly | #10189 |
| cast | #10193 |
| multicentre | #10198 |
| investigations | #10199 |
| cell activation | #10199 |
| cardiovascular risk factors | #10209 |
| clinical data | #10213 |
| medical therapy | #10213 |
| tumor necrosis factoralpha | #10215 |
| replacement therapy | #10225 |
| routine | #10234 |
| syndrome humans | #10253 |
| heart failure | #10265 |
| 183 | #10280 |
| gaps | #10291 |
| hospitalization | #10293 |
| blood transfusion | #10293 |
| postpartum | #10305 |
| measuring | #10314 |
| aetiology | #10315 |
| 8 | #10318 |
| photon emission | #10329 |
| 032 | #10336 |
| dilution | #10336 |
| 667 | #10337 |
| worldwide | #10337 |
| greatly | #10352 |
| aorta | #10352 |
| indirectly | #10377 |
| restoration | #10378 |
| creatinine | #10381 |
| cardiopulmonary | #10385 |
| pneumonia viral | #10397 |
| medical management | #10404 |
| outcome measures | #10408 |
| p0003 | #10408 |
| tissue injury | #10411 |
| bidirectional | #10419 |
| circulation | #10432 |
| reductase inhibitors | #10432 |
| transfusion | #10435 |
| enrolment | #10446 |
| reflux | #10457 |
| patients age | #10461 |
| priority | #10461 |
| quality life | #10471 |
| phase 3 | #10481 |
| activity levels | #10489 |
| increased prevalence | #10489 |
| 1991 | #10491 |
| style | #10491 |
| 147 | #10501 |
| predictive factors | #10514 |
| sex age | #10526 |
| assessing | #10529 |
| necrosis | #10534 |
| matched | #10556 |
| lower rate | #10558 |
| portable | #10563 |
| ray | #10570 |
| patients moderate | #10570 |
| 125 | #10574 |
| p002 | #10576 |
| pulmonary artery | #10578 |
| inform | #10580 |
| recurrences | #10583 |
| antisense | #10583 |
| 293 | #10584 |
| 180 | #10598 |
| manifestations | #10601 |
| closer | #10602 |
| 159 | #10605 |
| microvascular | #10605 |
| vasoconstrictor | #10607 |
| hospitals | #10612 |
| medical oncology | #10615 |
| november | #10628 |
| percutaneous coronary | #10633 |
| persist | #10635 |
| fragments | #10637 |
| ascertained | #10641 |
| 1b | #10647 |
| publication administration | #10653 |
| postoperative | #10659 |
| held | #10674 |
| concerned | #10674 |
| pulmonary vascular | #10690 |
| term | #10697 |
| discriminate | #10697 |
| risk developing | #10704 |
| synergism | #10709 |
| multivariable analysis | #10713 |
| neutrophil | #10729 |
| consultation | #10735 |
| centres | #10751 |
| median duration | #10755 |
| decisions | #10759 |
| entire | #10774 |
| haemoglobin | #10797 |
| perioperative | #10798 |
| patients cirrhosis | #10804 |
| term mortality | #10829 |
| 300 | #10832 |
| 38 | #10849 |
| prospective observational | #10855 |
| sustained | #10865 |
| randomised controlled | #10867 |
| anatomical | #10873 |
| airways | #10903 |
| diagnoses | #10903 |
| neurosurgical | #10905 |
| monoclonal antibodies monoclonal | #10909 |
| coronavirus infections | #10921 |
| maximal | #10924 |
| threatening | #10963 |
| amniotic | #10987 |
| coronary intervention | #10989 |
| relative | #10990 |
| blocker | #10996 |
| needed | #11009 |
| obese | #11037 |
| neutropenia | #11057 |
| ischemic | #11057 |
| summarizes | #11062 |
| ethical | #11062 |
| attained | #11062 |
| treatment option | #11070 |
| balloon | #11071 |
| 12 weeks | #11074 |
| originally | #11083 |
| inability | #11108 |
| location | #11108 |
| catheters | #11143 |
| beta2 | #11159 |
| ischemic attack | #11165 |
| hematoma | #11189 |
| confirmation | #11199 |
| neoplasms risk | #11201 |
| metabolic syndrome | #11202 |
| iia | #11204 |
| strokes | #11217 |
| choice | #11228 |
| eligible patients | #11247 |
| risk groups | #11263 |
| 1992 | #11272 |
| cerebrovascular | #11281 |
| humans kidney | #11281 |
| waiting | #11282 |
| ≥1 | #11291 |
| endothelial function | #11297 |
| troponin | #11304 |
| determine | #11306 |
| 202 | #11308 |
| aged prevalence | #11331 |
| post | #11332 |
| adherent | #11338 |
| acute respiratory | #11345 |
| acute myocardial infarction | #11361 |
| event | #11363 |
| combination therapy | #11380 |
| glycoprotein | #11391 |
| factors smoking | #11395 |
| reconstructive | #11397 |
| apply | #11399 |
| developed | #11405 |
| 2005 | #11415 |
| competent | #11416 |
| medically | #11426 |
| treatment decisions | #11427 |
| prostaglandins | #11434 |
| diuretics | #11439 |
| hematological malignancies | #11443 |
| morbidity | #11445 |
| media | #11464 |
| protocol | #11487 |
| satisfying | #11502 |
| performances | #11525 |
| hospital admission | #11526 |
| placebo treatment | #11533 |
| occlusion | #11533 |
| outflow | #11542 |
| multicenter study | #11542 |
| enrolled | #11545 |
| humans intensive | #11570 |
| 55 | #11577 |
| chronic inflammation | #11600 |
| definitive | #11621 |
| younger patients | #11624 |
| baseline | #11624 |
| sct | #11638 |
| investigate | #11670 |
| normal controls | #11684 |
| contribution | #11687 |
| reference | #11694 |
| life qol | #11697 |
| lipopolysaccharides | #11699 |
| hypotension | #11715 |
| ascites | #11717 |
| myoglobin | #11741 |
| independent risk | #11745 |
| acute myocardial | #11753 |
| radiopharmaceuticals | #11783 |
| extent | #11786 |
| orally | #11790 |
| involving | #11792 |
| 2010 | #11802 |
| nonspecific | #11809 |
| vena cava | #11829 |
| distinction | #11841 |
| episodes | #11865 |
| eclampsia | #11872 |
| release | #11874 |
| woman | #11885 |
| 151 | #11891 |
| 006 | #11906 |
| elicited | #11912 |
| icu patients | #11915 |
| vasculitis | #11937 |
| activating | #11948 |
| age | #11953 |
| sulphate | #11955 |
| began | #11957 |
| lethality | #11967 |
| collectively | #11970 |
| inferior | #11978 |
| serum creatinine | #11979 |
| myocardial injury | #11980 |
| adp | #11981 |
| immunosorbent | #12006 |
| cardiovascular diseases | #12015 |
| mortality rate | #12041 |
| reduced | #12043 |
| dietary intake | #12057 |
| thirds | #12057 |
| minority | #12058 |
| monitored | #12061 |
| differently | #12066 |
| early pregnancy | #12076 |
| humanized | #12077 |
| wounds injuries | #12079 |
| fair | #12096 |
| thoracotomy | #12111 |
| evidenced | #12130 |
| 1995 | #12135 |
| elevated risk | #12140 |
| 085 | #12141 |
| profile | #12143 |
| prostate | #12153 |
| 149 | #12157 |
| 120 | #12170 |
| digoxin | #12177 |
| offset | #12179 |
| uncommon | #12187 |
| healthcare | #12202 |
| causality | #12208 |
| lung | #12208 |
| spent | #12219 |
| takes | #12233 |
| tendency | #12271 |
| pregnancy risk | #12276 |
| expectancy | #12281 |
| resolve | #12300 |
| flaps | #12302 |
| micromol | #12326 |
| mismatch | #12335 |
| favored | #12342 |
| births | #12351 |
| obstructive pulmonary | #12358 |
| epinephrine | #12365 |
| dependently | #12372 |
| prescription | #12394 |
| registration | #12398 |
| incremental | #12399 |
| inflammatory response | #12409 |
| switzerland | #12409 |
| consistent | #12418 |
| potential confounders | #12425 |
| echocardiographic | #12450 |
| fifty patients | #12451 |
| arginine | #12475 |
| patient discharge | #12480 |
| apparent | #12483 |
| prospective randomized | #12486 |
| sensitivity analyses | #12490 |
| 117 | #12494 |
| switch | #12513 |
| 10 years | #12521 |
| standards | #12524 |
| requires | #12540 |
| guide | #12540 |
| statistically | #12548 |
| prognostic | #12579 |
| chronic obstructive | #12584 |
| monoclonal | #12589 |
| rapidly | #12597 |
| tomography ray | #12611 |
| lipoprotein | #12619 |
| literature | #12637 |
| repeat | #12653 |
| single dose | #12673 |
| drug interactions | #12680 |
| hypertension pulmonary | #12684 |
| physiological | #12687 |
| pharmacogenetics | #12706 |
| 45 | #12708 |
| prostatic | #12708 |
| endocrine | #12709 |
| ifngamma | #12722 |
| minute | #12733 |
| dosage | #12736 |
| congestive heart failure | #12747 |
| cardiac surgery | #12756 |
| personal | #12770 |
| estrogens | #12778 |
| animal model | #12796 |
| thyroid | #12808 |
| settings | #12820 |
| malignancies | #12823 |
| infections | #12836 |
| burden | #12849 |
| intraoperative complications | #12862 |
| cancer patient | #12864 |
| reporting | #12866 |
| 196 | #12881 |
| 1999 | #12904 |
| cvd | #12906 |
| raised | #12910 |
| endpoints | #12912 |
| extracted | #12940 |
| confirming | #12947 |
| 18 years | #12976 |
| ray computed | #12983 |
| postoperative complications | #12990 |
| filters | #13009 |
| monotherapy | #13017 |
| transiently | #13024 |
| instance | #13041 |
| oral administration | #13041 |
| located | #13049 |
| tumor angiogenesis | #13067 |
| based cohort | #13094 |
| fold | #13100 |
| severity | #13106 |
| cancer risk | #13107 |
| escalation | #13107 |
| vomiting | #13112 |
| physical | #13112 |
| latin | #13125 |
| sexes | #13143 |
| drug therapy | #13144 |
| 0 | #13145 |
| ratio | #13159 |
| focused | #13189 |
| appearance | #13195 |
| compliance | #13199 |
| pregnant women | #13202 |
| optimal | #13213 |
| expensive | #13226 |
| support | #13231 |
| exist | #13235 |
| 142 | #13236 |
| lack | #13240 |
| narcotic | #13261 |
| formal | #13262 |
| commercially | #13265 |
| participant | #13273 |
| median follow | #13286 |
| indirect | #13288 |
| emission computed | #13352 |
| mediator | #13366 |
| maintain | #13391 |
| electronic databases | #13394 |
| hypothesized | #13395 |
| advantage | #13432 |
| admitted | #13437 |
| p00001 | #13442 |
| anti | #13455 |
| reliably | #13459 |
| surveys | #13463 |
| endothelial dysfunction | #13466 |
| transient | #13478 |
| patients experienced | #13481 |
| provided | #13489 |
| crosssectional study | #13491 |
| patients patient | #13494 |
| surrogate | #13537 |
| vivo | #13545 |
| retrospectively | #13548 |
| maintained | #13555 |
| 195 | #13556 |
| pulmonary hypertension | #13563 |
| accurate | #13563 |
| longterm outcomes | #13585 |
| monitoring | #13620 |
| laboratory | #13629 |
| elucidated | #13643 |
| abdominal | #13652 |
| whilst | #13665 |
| mitral | #13682 |
| north america | #13705 |
| marker | #13707 |
| vascular | #13708 |
| competence | #13708 |
| 45 years | #13716 |
| 2009 | #13734 |
| icu | #13748 |
| drug effects | #13753 |
| medicine | #13755 |
| healthy individuals | #13758 |
| inhibitory effects | #13763 |
| establishing | #13766 |
| pelvic | #13773 |
| explanation | #13773 |
| participating | #13774 |
| phospholipid | #13776 |
| heart diseases | #13789 |
| women risk | #13816 |
| conservative | #13820 |
| circulating | #13824 |
| condition | #13859 |
| kidney diseases | #13860 |
| systematically | #13868 |
| tissue | #13876 |
| coronary angiography | #13889 |
| internal | #13916 |
| techniques | #13923 |
| microparticles | #13927 |
| dissemination | #13928 |
| 1993 | #13939 |
| 176 | #13979 |
| require | #13986 |
| castration | #13998 |
| radioisotopes | #14011 |
| 48 patients | #14013 |
| insufficiency | #14022 |
| algorithms | #14029 |
| members | #14033 |
| risk death | #14033 |
| requirement | #14046 |
| independent predictors | #14058 |
| continuous | #14060 |
| organ failure | #14072 |
| situations | #14084 |
| focus | #14084 |
| vasoconstriction | #14119 |
| offer | #14137 |
| supporting | #14164 |
| activates | #14188 |
| cardiac output | #14194 |
| leukocyte | #14204 |
| mitral valve | #14205 |
| sensitivities | #14216 |
| document | #14242 |
| primary prevention | #14248 |
| newborns | #14256 |
| nausea | #14276 |
| making | #14285 |
| effectiveness | #14304 |
| independent | #14342 |
| inhibition | #14357 |
| 4 years | #14367 |
| meaningful | #14371 |
| pathologic | #14372 |
| female fetal | #14377 |
| acquired | #14378 |
| 6 patients | #14391 |
| min1 | #14391 |
| amniotic fluid | #14403 |
| substances | #14409 |
| pregnant | #14423 |
| disease chronic | #14460 |
| interleukin1 | #14489 |
| infarction | #14491 |
| influence | #14509 |
| interventions | #14510 |
| costeffectiveness | #14535 |
| locations | #14586 |
| participated | #14592 |
| similarities | #14608 |
| 205 | #14632 |
| statistics | #14637 |
| renal insufficiency | #14637 |
| reasonable | #14646 |
| comparative | #14648 |
| natural | #14667 |
| blood samples | #14672 |
| surgery patients | #14696 |
| entered | #14698 |
| pandemics | #14707 |
| classify | #14715 |
| institutes | #14736 |
| surveyed | #14741 |
| 39 patients | #14742 |
| sampled | #14749 |
| 2017 | #14783 |
| arms | #14785 |
| validity | #14787 |
| independent predictor | #14787 |
| databases | #14808 |
| heart association | #14814 |
| white matter | #14816 |
| complete | #14819 |
| stable | #14828 |
| cox proportional | #14835 |
| pge2 | #14844 |
| duplex | #14845 |
| population | #14872 |
| contribute | #14928 |
| retest | #14931 |
| criteria | #14938 |
| premature | #14952 |
| critical illness | #15004 |
| phospholipids | #15030 |
| european society | #15041 |
| cardiac catheterization | #15042 |
| prostheses | #15059 |
| questionnaires | #15082 |
| treatment failure | #15087 |
| sf36 | #15089 |
| elective surgical | #15107 |
| controlled clinical | #15109 |
| flight | #15110 |
| ldl | #15120 |
| relate | #15127 |
| health costs | #15128 |
| initiation | #15140 |
| obstruction | #15142 |
| obstructive | #15146 |
| stratification | #15164 |
| proper | #15177 |
| selection | #15187 |
| registries | #15197 |
| decrease | #15201 |
| copd | #15201 |
| randomized controlled trial | #15210 |
| unilateral | #15223 |
| ongoing | #15230 |
| induces | #15231 |
| individuals | #15239 |
| young patients | #15247 |
| previous | #15250 |
| methods retrospective | #15255 |
| disorders | #15278 |
| drug | #15278 |
| myocardial | #15279 |
| 4 weeks | #15296 |
| quantitation | #15298 |
| fewer | #15300 |
| hospital discharge | #15328 |
| quantify | #15340 |
| activators | #15356 |
| neonates | #15370 |
| consequence | #15405 |
| locally | #15441 |
| impaired | #15446 |
| pedigree | #15471 |
| randomised controlled trial | #15474 |
| women age | #15474 |
| grafts | #15484 |
| zealand | #15509 |
| asthma | #15511 |
| undetectable | #15512 |
| current literature | #15513 |
| records | #15520 |
| 1994 | #15522 |
| aggregation | #15535 |
| thrombocytopenia | #15537 |
| implementation | #15538 |
| pa | #15540 |
| intended | #15567 |
| reviewed | #15577 |
| surgery | #15590 |
| updated | #15592 |
| discharged | #15616 |
| immunoenzyme | #15617 |
| purpose | #15634 |
| heterozygosity | #15660 |
| centre | #15666 |
| standard | #15679 |
| patients admitted | #15702 |
| perinatal | #15711 |
| explain | #15726 |
| view | #15729 |
| unexpected | #15737 |
| detection | #15766 |
| start | #15808 |
| examination | #15813 |
| effectively | #15813 |
| prescribing | #15823 |
| vary | #15829 |
| febrile | #15847 |
| confer | #15849 |
| serologic | #15853 |
| reach | #15876 |
| interpretation | #15881 |
| janus | #15892 |
| numerous | #15899 |
| inter | #15907 |
| quality adjusted | #15919 |
| dyslipidemia | #15942 |
| prominent | #15961 |
| blocked | #15985 |
| severely | #15997 |
| discuss | #15997 |
| alanine | #15998 |
| external | #16007 |
| causal | #16021 |
| hepatectomy | #16025 |
| complication | #16054 |
| compared controls | #16057 |
| rarely | #16076 |
| systemic inflammation | #16077 |
| fever | #16082 |
| metabolic | #16112 |
| demonstrates | #16117 |
| insensitive | #16125 |
| affect | #16135 |
| conditional | #16136 |
| basis | #16144 |
| carotid | #16168 |
| bypass | #16221 |
| early | #16262 |
| antiretroviral | #16271 |
| neoplasms | #16294 |
| hospital | #16314 |
| special | #16336 |
| signs | #16384 |
| cost | #16418 |
| recommendations | #16420 |
| aimed | #16432 |
| area | #16442 |
| syndromes | #16485 |
| unable | #16508 |
| prevented | #16513 |
| develop | #16513 |
| cancer treatment | #16516 |
| 106 | #16543 |
| radiography | #16545 |
| calibrated | #16568 |
| multivariable | #16576 |
| 2021 | #16583 |
| descriptive | #16618 |
| alternatives | #16629 |
| integrins | #16641 |
| creactive protein | #16645 |
| gained | #16652 |
| consists | #16666 |
| weeks | #16674 |
| downregulation | #16681 |
| residual | #16708 |
| prior | #16725 |
| explained | #16763 |
| fat | #16775 |
| electrocardiography | #16807 |
| epidemiology | #16821 |
| potent | #16848 |
| thought | #16868 |
| genetic risk | #16876 |
| survival | #16892 |
| 093 | #16911 |
| humans liver | #16932 |
| constitute | #16939 |
| gestational age | #16946 |
| vasodilator | #16950 |
| driven | #16958 |
| critically patients | #16965 |
| enable | #16976 |
| verify | #16984 |
| smokers | #16998 |
| inherent | #17023 |
| carotid artery | #17040 |
| apolipoproteins | #17063 |
| individual patients | #17078 |
| markedly | #17097 |
| units | #17139 |
| estimates | #17144 |
| assayed | #17145 |
| elderly patients | #17150 |
| regard | #17197 |
| critically | #17220 |
| adjustment | #17237 |
| cooperative | #17262 |
| lung neoplasms | #17262 |
| estimated | #17274 |
| acute phase | #17288 |
| largest | #17288 |
| 400 | #17295 |
| clinician | #17339 |
| desirable | #17347 |
| 2019 | #17393 |
| limb | #17439 |
| dilated | #17443 |
| disease cvd | #17451 |
| synthetic | #17459 |
| increasingly | #17488 |
| kinds | #17510 |
| antibodies | #17538 |
| prompt | #17565 |
| demographics | #17584 |
| cirrhosis | #17586 |
| 0002 | #17604 |
| finding | #17620 |
| applicable | #17636 |
| obtaining | #17637 |
| coronary | #17653 |
| sex factors | #17688 |
| prosthesis | #17710 |
| independent risk factor | #17712 |
| distal | #17714 |
| multivariate analysis | #17792 |
| gastrointestinal | #17804 |
| selecting | #17815 |
| 3 years | #17833 |
| 2006 | #17840 |
| illustrated | #17852 |
| 1 | #17853 |
| hemorrhagic | #17855 |
| drugs | #17878 |
| current evidence | #17881 |
| undergone | #17883 |
| marked | #17903 |
| epidemiologic | #17920 |
| hospitalizations | #17922 |
| nationwide | #17924 |
| global | #17933 |
| percutaneous | #17942 |
| essential | #17964 |
| corticosteroids | #17975 |
| distant | #18007 |
| intensive | #18031 |
| reductase | #18047 |
| verified | #18052 |
| peptide | #18060 |
| defects | #18070 |
| 000 | #18092 |
| operated | #18111 |
| trend | #18115 |
| centers | #18134 |
| protein crp | #18152 |
| clinical significance | #18164 |
| consistently | #18169 |
| quality | #18175 |
| chemotherapy | #18203 |
| prenatal | #18250 |
| participate | #18252 |
| deaths | #18263 |
| year follow | #18286 |
| ventricular function | #18296 |
| metastases | #18296 |
| inflammatory bowel | #18314 |
| gestation | #18344 |
| tolerated | #18425 |
| attributable | #18434 |
| and or | #18480 |
| coa | #18497 |
| larger | #18513 |
| mutations | #18533 |
| humans hypertension | #18543 |
| stratified | #18569 |
| heart disease | #18579 |
| commercial | #18589 |
| bayes | #18675 |
| ≥ | #18700 |
| extra | #18726 |
| mechanisms | #18742 |
| questions | #18760 |
| plasma | #18797 |
| conventional | #18799 |
| monoclonal antibodies | #18844 |
| increases | #18850 |
| life | #18851 |
| vessel | #18855 |
| oligopeptides | #18887 |
| clearance | #18903 |
| validation | #18907 |
| classical | #18919 |
| hormone | #18938 |
| molecular basis | #19034 |
| single | #19069 |
| worse | #19094 |
| statistical | #19103 |
| soluble | #19124 |
| simultaneously | #19131 |
| tailored | #19134 |
| real | #19158 |
| 5 years | #19189 |
| variable | #19205 |
| moderate | #19239 |
| contributes | #19241 |
| decade | #19291 |
| infarct | #19308 |
| ages | #19312 |
| pubmed | #19345 |
| 0005 | #19412 |
| essentially | #19469 |
| ventricular | #19481 |
| investigates | #19493 |
| 2 3 | #19507 |
| therapies | #19511 |
| called | #19515 |
| partially | #19535 |
| explore | #19544 |
| endothelium | #19553 |
| systemic | #19561 |
| january | #19567 |
| uterine | #19582 |
| reversed | #19601 |
| procedures | #19611 |
| tka | #19675 |
| etiology | #19677 |
| operating | #19692 |
| guided | #19709 |
| histology | #19727 |
| characterised | #19753 |
| inflammation | #19779 |
| median followup | #19863 |
| exclusively | #19881 |
| autologous | #19886 |
| graft | #19904 |
| endothelial cell | #19986 |
| controlled trial | #20019 |
| comorbidities | #20045 |
| gestational | #20050 |
| 2002 | #20050 |
| additionally | #20057 |
| cytokines | #20058 |
| salvage | #20102 |
| inversely | #20149 |
| concentration | #20153 |
| predisposition disease | #20162 |
| diastolic | #20170 |
| small | #20201 |
| alterations | #20228 |
| body | #20230 |
| alpha | #20261 |
| polymorphism genetic | #20264 |
| variables | #20277 |
| subjects | #20283 |
| combine | #20369 |
| adjusting | #20377 |
| catheterization | #20391 |
| introduced | #20458 |
| 1 3 | #20492 |
| younger | #20499 |
| hormones | #20508 |
| length | #20512 |
| theoretically | #20515 |
| ability | #20536 |
| analyses | #20553 |
| clarify | #20561 |
| persistent | #20562 |
| elisa | #20562 |
| improves | #20570 |
| september | #20598 |
| persons | #20696 |
| humans models | #20753 |
| active | #20756 |
| observational | #20823 |
| incorporated | #20843 |
| prognosis | #20934 |
| fetal | #20955 |
| reduce | #21005 |
| measure | #21033 |
| auc | #21046 |
| report | #21048 |
| intrinsic | #21055 |
| responsible | #21081 |
| constructed | #21098 |
| innate | #21135 |
| operative | #21137 |
| attenuated | #21137 |
| 1 year | #21144 |
| designated | #21167 |
| october | #21177 |
| performing | #21185 |
| × | #21191 |
| upper | #21226 |
| reflecting | #21230 |
| selected | #21264 |
| depending | #21267 |
| preschool female | #21270 |
| 005 | #21324 |
| hemodynamics humans | #21403 |
| symptoms | #21425 |
| center | #21469 |
| differed | #21501 |
| 1990 | #21507 |
| 0004 | #21546 |
| logistic | #21639 |
| explored | #21757 |
| animals antibodies | #21767 |
| young | #21860 |
| 139 | #21894 |
| majority | #21894 |
| observe | #21969 |
| facilitate | #21994 |
| decreased | #22047 |
| progression | #22078 |
| genotype | #22116 |
| imaging | #22125 |
| coronary disease | #22178 |
| tract | #22180 |
| neoadjuvant | #22207 |
| generally | #22291 |
| regression | #22321 |
| surgical procedures | #22327 |
| authors | #22330 |
| demonstrated | #22352 |
| inhibiting | #22426 |
| newborn male | #22473 |
| varying | #22556 |
| significance | #22586 |
| represented | #22593 |
| slower | #22607 |
| allogeneic | #22614 |
| grade | #22615 |
| phase | #22698 |
| older | #22831 |
| differential | #22835 |
| july | #22843 |
| modified | #22851 |
| march | #22907 |
| application | #22920 |
| combining | #22961 |
| ratios | #22986 |
| 2012 | #23037 |
| anti inflammatory | #23123 |
| offered | #23214 |
| protocols | #23283 |
| 2016 | #23284 |
| challenging | #23285 |
| yielding | #23334 |
| prevents | #23432 |
| resting | #23488 |
| includes | #23496 |
| renal | #23566 |
| median | #23599 |
| inhibits | #23686 |
| inbred c57bl mice | #23705 |
| increasing | #23723 |
| endopeptidases | #23727 |
| advanced | #23745 |
| adverse | #23767 |
| naive | #23767 |
| reactive protein | #23807 |
| minimal | #23827 |
| interestingly | #23831 |
| showing | #23885 |
| longer | #23967 |
| surgical | #24020 |
| vascular endothelial | #24085 |
| prolonged | #24478 |
| generate | #24487 |
| count | #24514 |
| december | #24569 |
| unrelated | #24572 |
| determining | #24577 |
| activity | #24581 |
| changed | #24651 |
| implies | #24682 |
| underlying | #24749 |
| suggests | #24813 |
| august | #24821 |
| linearly | #24940 |
| february | #24945 |
| frequent | #25109 |
| june | #25175 |
| representing | #25214 |
| acceptable | #25300 |
| carried | #25310 |
| illness | #25373 |
| suitable | #25501 |
| enhance | #25503 |
| 0003 | #25598 |
| linked | #25616 |
| local | #25663 |
| mm | #25732 |
| fully | #25888 |
| reducing | #25912 |
| describes | #25923 |
| difficult | #26054 |
| supported | #26091 |
| scanning | #26181 |
| differentiate | #26212 |
| respect | #26378 |
| promising | #26384 |
| asked | #26410 |
| define | #26421 |
| defective | #26510 |
| female heart | #26685 |
| dependent | #26722 |
| leading | #26774 |
| improving | #27057 |
| contained | #27059 |
| national | #27215 |
| strongest | #27229 |
| quantitatively | #27333 |
| recognized | #27386 |
| mass bmi | #27411 |
| commonly | #27411 |
| implicated | #27484 |
| caused | #27495 |
| remain | #27689 |
| correlate | #27710 |
| artery | #27999 |
| cross | #28142 |
| recorded | #28182 |
| detected | #28405 |
| inflammatory | #28439 |
| multivariate | #28454 |
| examine | #28475 |
| beta | #28655 |
| allowed | #28793 |
| hypothesis | #28801 |
| improved | #28920 |
| required | #29047 |
| large | #29116 |
| chemically | #29137 |
| short | #29272 |
| patients chronic | #29316 |
| genetic predisposition | #29434 |
| bmi | #29470 |
| female health | #29531 |
| achieved | #29589 |
| 001 | #29634 |
| underwent | #29797 |
| 2011 | #30149 |
| indicating | #30233 |
| approved | #30511 |
| declined | #30756 |
| participants | #30828 |
| predisposition | #30981 |
| genotype humans | #31051 |
| aims | #31216 |
| measured | #31265 |
| antineoplastic agents | #31706 |
| expected | #31791 |
| specific | #31901 |
| endothelial | #32294 |
| modality | #32386 |
| inhibit | #32629 |
| conducted | #32675 |
| predicted | #32889 |
| inhibited | #33631 |
| agreement | #33673 |
| sensitive | #34362 |
| antineoplastic | #34560 |
| correlated | #34744 |
| greater | #34856 |
| poor | #35078 |
| neoplasms male | #35230 |
| humans magnetic | #35433 |
| 0001 | #35646 |
| free | #35793 |
| sectional | #35852 |
| include | #39773 |
| collected | #40746 |
| examined | #41010 |
| mediated | #41310 |
| neoplasm | #47468 |
Bericht ausführen | |
Schlüsselpersonen für Pulmonary Embolism
Top -Kols der Welt
Wählen Sie einen Suchphrase aus pulmonary embolism , pulmonary embolism patients , pulmonary embolism 95 , pulmonary embolism diagnosis , pulmonary embolism treatment
Harry Roger Büller:Expertenwirkung
Konzepte für welcheHarry Roger Büllerhat direkten Einfluss:Pulmonary embolism, Venous thromboembolism, Venous thrombosis, Major bleeding, Deep vein thrombosis, Atrial fibrillation, Vein thrombosis.
Harry Roger Büller:KOL -Auswirkungen
Konzepte im Zusammenhang mit der Arbeit anderer Autoren, für diefor which Harry Roger Büller hat Einfluss:Venous thromboembolism, Pulmonary embolism, Atrial fibrillation, Deep vein thrombosis, Oral anticoagulants, Major bleeding, Vte patients.
Tools
Ist das dein Profil? Fordern Sie Ihr Profil an URL kopieren Einbetten Sie den Link zu Ihrem Profil ein |